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 Our understanding of the central dogma of biology has changed greatly 
since the discovery of non-protein coding RNAs that play key regulatory roles in 
protein expression. The research presented in this thesis is an investigation of a 
highly conserved type of regulatory RNA, small interfering RNA (siRNA), which 
regulates gene expression at the post-transcriptional level through the RNA 
interference (RNAi) pathway. RNAi is a conserved gene regulatory mechanism 
employed by most eukaryotes as a key component of their innate immune 
response to viruses and retrotransposons, wherein exogenous long dsRNAs are 
cleaved (diced) into ~21-28nt long siRNA duplexes with characteristic 5′-
phosphate and 3′-dinucleotide termini that are subsequently loaded into the 
effector RNA Induced Silencing Complex (RISC). The mature duplex siRNA is 
then unwound and activated in a strand-specific and ATP-dependent manner. 
Upon recognition of a target mRNA, the siRNA guides RISC to initiate sequence 
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specific mRNA cleavage (slicing) by the Argonaut (Ago) protein, thus inhibiting 
the production of a specific protein. 
 As a countermeasure to RNAi, many viruses have evolved viral RNA 
silencing suppressors (RSS) that tightly, and presumably quantitatively, bind 
siRNAs to thwart RNAi-mediated degradation. Viral RSS proteins also act across 
kingdoms as potential immunosuppressors in gene therapeutic applications. 
Here we report fluorescence quenching and electrophoretic mobility shift assays 
that probe siRNA binding by the dimeric RSS p19 from Carnation Italian Ringspot 
Virus, as well as by human Dicer and RISC assembly complexes. We find that 
the siRNA:p19 interaction is readily reversible and p19 efficiently competes with 
recombinant Dicer and inhibits the formation of RISC-related assembly 
complexes found in human cell extract. Computational modeling based on these 
results provides evidence for the transient formation of a ternary complex 
between siRNA, human Dicer, and p19. An expanded model of RNA silencing 
indicates that multiple turnover by reversible binding of siRNAs potentiates the 
efficiency of the RSS protein.  
 siRNAs have yielded powerful insights into biological function through 
reverse genetic approaches and have given birth to a new field of gene 
therapeutics. A number of questions are outstanding concerning the potency of 
siRNAs, necessitating an understanding of how short double-stranded RNAs are 
processed by the cell. Recent work suggests that unmodified siRNAs are 
protected in the intracellular environment, although the mechanism of protection 
still remains unclear. We have developed a set of doubly-fluorophore labeled 
RNAs (more precisely, RNA/DNA chimeras) to probe in real-time the stability of 
siRNAs and related molecules by fluorescence resonance energy transfer 
(FRET). We found that these RNA probes are substrates for relevant cellular 
degradative processes, including the RNase H1 mediated degradation of an 
DNA/RNA hybrid and Dicer-mediated cleavage of a 24-nucleotide (per strand) 
double-stranded RNA. In addition, we found that 21- and 24-nucleotide double-
stranded RNAs are relatively protected in human cytosolic cell extract, but less 
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so in blood serum, whereas an 18-nucleotide double-stranded RNA is less 
protected in both fluids. These results suggest that RNAi effector RNAs are 
specifically protected in the cellular environment and may provide an explanation 
for recent results showing that unmodified siRNAs in cells persist intact for 
extended periods of time. 
 Despite the vast application of RNAi in functional genomics and 
therapeutics, there still are also several outstanding questions about the 
composition of siRISC. Although it is known that the minimal RISC is composed 
of Dcr, TRBP and Ago2, the roles played by other Ago2 and RISC associated 
proteins are still under debate. Much of the complexity associated with assigning 
specific roles to the pathways components arises from the inherent complexity of 
the pathway itself and from the inability to develop a comprehensive system of 
study for RNAi. Our results demonstrate that the two systems we and others 
have employed, i.e., the HeLa whole cell extract and the HeLa S100 cytoplasmic 
extract, utilize siRNA duplexes versus single-stranded antisense siRNA with 
differential efficiency in cleaving a target mRNA, despite their uniform ability to 
perform slicing. We have shown that the ability of HeLa cytoplasmic extract to 
utilize siRNA duplexes better than single-stranded antisense siRNA may be due 
to elevated concentrations of two RNA helicases, MOV10 and RHA. Additionally, 
we have shown that ATP has an inhibitory effect on the target cleavage mediated 
by HeLa cytoplasmic extract. Our results suggest a potential role for MOV10 and 
RHA in siRNA duplex loading of RISC. We also hypothesize that ATP may be 
mediating some yet-to-be-identified allosteric and/or structural change in RISC 
that has an inhibitory effect on its target mRNA cleavage activity. Taken together, 
the work presented in this thesis has furthered our understanding of how siRNAs 












 The advances in molecular biology since the early 1900s have been 
staggering and have enticed scientists from all over the world to work towards 
understanding life at its most fundamental level. The breadth of research 
conducted thus far in this field has gone to prove the existence of ever more 
complex molecular processes in increasingly complex organisms. 
 The beginning of the golden era of molecular biology was marked by the 
demonstration of a linear relationship between genes (DNA) and proteins by 
George Beadle and Edward Tatum in 19401, followed by the discovery of DNA as 
the genetic material by the famous Avery-MacLeod-McCarty transformation 
experiment in 19442, and the Hershey-Chase hereditary experiment in 19523. 
The seminal work by Rosalind Franklin influenced the work of James D. Watson 
and Francis Crick, leading to the recognition of DNA as a double helix in 19534. 
This discovery, followed by the influential presentation by Crick in 19575 that the 
Central Dogma of Biology is a sequential relationship between DNA, RNA and 




 The Central Dogma of Biology describes the flow of genetic information to 
be sequential residue- by-residue and unidirectional, i.e., the genetic information 
stored in the double-stranded DNA molecule is translated via single-stranded 
ribonucleic acid (RNA, specifically messenger RNA, mRNA) molecules with the 
help of ribosomes to proteins6. It was believed that the main role of RNAs within 
a cell was to code for proteins and hence most research done by molecular 
biologists was focused on understanding the structure, function and interactions 
between the two macromolecules: Deoxyribonucleic acids (DNA) and Proteins.  
 Ever since, our understanding of this dogma and the role of RNA within 
the cell have evolved significantly, owing to the seminal discovery of ribozymes 
(RNAs with catalytic properties) by Thomas Cech and Sidney Altman in the 
1980s7, 8 as well as the discovery, made during the Human Genome Project in 
20009, 10, that approximately 98.5% of the human genome does not code for 
protein11.  Additionally, it has been noted that the number of non-protein coding 
RNAs, but not as much the number of protein coding mRNAs, increases with 
increasing complexity of the organism (Fig. 1.1) 12, 13.  Since then a number of 
non-coding RNA classes have been discovered that play either a structural, 
catalytic or regulatory role, such as transfer RNA (tRNA), ribosomal RNA (rRNA), 
short interfering RNA (siRNA), microRNA (miRNA), Piwi-interacting RNA 
(piRNA), small nuclear RNA (snRNA), small nucleolar (snoRNA) and others11. 
These non-coding RNAs have critical impact on several diseases such as 
cancer, diabetes, Alzheimer's, autism etc14.  Despite the fact that non-coding 
RNAs have been studied extensively over the last decade, as evident from the 
exponential increase in the number of PubMed entries for research articles on 
non coding RNAs, (Fig. 1.2) the mechanism of action of most of them still needs 
to be brought to light. My research in the Walter Lab at the Department of 
Chemistry, University of Michigan, has focused on monitoring key steps in the 
mechanism of action of one such type of regulatory non-coding RNA called small 




1.2 Non coding RNAs: The face of the current era of Molecular Biology 
 Non-coding RNAs (ncRNAs) are ribonucleic acids that are transcribed 
from DNA and predominantly do not code for proteins. While the initial 
assumption was that DNA that was transcribed into RNA is always translated into 
protein and DNA not coding for protein was considered evolutionary 'junk', recent 
findings suggest that the majority of the human genome is in fact transcribed into 
non-protein coding RNAs or ncRNAs that contain information or have a 
function12. ncRNAs can be either transcribed as their own genes (RNA genes), or 
can be derived from mRNA introns, appended to an mRNA as untranslated 
regions (UTRs), alternatively spliced and/or processed into smaller products11.   
 ncRNAs predominantly are single-stranded stretches of nucleotides that 
may contain self-complementary sequences enabling them to form highly 
complex structures15. Like proteins, ncRNAs can assume specific secondary 
structures such as short helices, hairpin loops, bulges and internal loops16. These 
secondary and tertiary structures are stabilized by metal ions such as Mg2+ 17 that 
help ncRNAs achieve functional forms similar to proteins18, 19. Over a decade, 
ncRNAs have been found to be involved in a plethora of cellular processes that 
include protein synthesis (transfer RNA, ribosomal RNA), gene regulation (short 
interfering RNA, microRNA), RNA processing (ribozymes), to name a few19, 20. 
These ncRNAs have been grouped into diverse classes of RNA molecules with 
structural, catalytic, or regulatory functions, ranging in size from alternatively 
spliced transcripts of many kilo-bases (kb) in length to 22-nucleotide small 
RNAs11. Additionally, several other ncRNAs exist whose functions within the cell 
still remain unknown. 
 Structural ncRNAs that have been known for a while now include transfer 
RNAs (tRNAs) and ribosomal RNAs (rRNAs) that play a role in mRNA 
translation, small nuclear RNAs (snRNAs) or spliceosomal uRNAs that are 
involved in splicing, and the common small nucleolar RNAs (snoRNAs) that are 







Figure 1.1. The fraction of non-protein-coding DNA increases with the 
increasing complexity of the organism. Plot illustrating the percent ncDNA per 
sequenced genome across phyla. The prokaryote and bacterial genomes are 
depicted in black. Single-celled organisms are shown in gray, organisms known 
to be both single and multi-cellular depending on lifecycle are light blue, basal 
multi-cellular organisms are blue, plants are green, nematodes are purple, 
arthropods are orange, chordates are yellow, and vertebrates are red. Reprinted 








































Figure 1.2. Increase in amount of research on non-coding RNAs. Graph 
depicting the exponential increase in the number of publications on non-coding 






























role in catalytic process in addition to sequence specific recognition of RNA 
substrates21, 22, 23, 24, 25. Two major rRNAs constitute about 60% of the total weight 
of ribosome, which is composed of a large and a small subunit made of proteins 
and RNAs.  The rRNAs have a structural role, acting as a scaffold defining the 
positions of the ribosomal proteins and aiding in the binding of the two ribosomal 
subunits. The 40S small ribosomal subunit contains one 18S rRNA and 33 
proteins, whereas the three rRNAs (5S, 5.8S and 28S) that comprise the catalytic 
core26, 27, 28, 29 are present, along with 46 other proteins, in the 60S large subunit 
of the ribosome, which acts as a ribozyme and catalyzes peptide bond 
formation30, 31. The mRNA to be translated is sandwiched between the two 
subunits of the ribosome, where the small subunit binds the mRNA and monitors 
the interaction of the tRNA anticodon, whereas the mRNA codon and the large 
subunit houses the three binding sites, A, P and E, for tRNAs32. During 
translation, the A site is occupied by an aminoacyl-tRNA (a tRNA that contains a 
complementary anticodon on one end and is charged with an amino acid on the 
other end), which attacks the ester linkage of the peptidyl-tRNA present within 
the P site to form a new peptide bond by peptidyl transfer. Subsequently, the 
attacked tRNA, now uncharged, exits the ribosome through the E site. Based on 
a similar principle of ordered assembly, snRNAs (commonly referred to as U-
RNAs owing to their high uridine content) associate with several proteins to form 
the spliceosome33, which is the complex responsible for removal of introns from 
pre-mRNA within the nucleus, through the post-transcriptional process called 
splicing. Each snRNA (U1, U2, U4, U5 and U6) associates with a set of specific 
protein and is referred to as small nuclear ribonucleoproteins (snRNP) complex 
(often pronounced "snurps")34. In addition to being involved in the assembly of 
spliceosome, U1 snRNP is also responsible for initiating spliceosomal activity by 
base pairing with the pre-mRNA, which has also been shown to protect pre-
mRNA from polyadenylation as well as premature cleavage35. Besides splicing, 
U1 snRNA has also been implicated in regulation of transcription initiation by 
RNA polymerase II through interaction with the transcription initiation factor TFIIH 
and possibly in cell cycle regulation36, 37.  
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 Several other ncRNAs, for example, ribozymes and riboswitches exist that 
have functional roles in various cellular processes. Ribozymes or RNA enzymes 
are small ncRNA molecules with the ability to catalyze a specific biochemical 
reaction, similar to protein enzymes. The first ribozymes discovered in 1980s by 
Thomas R. Cech and Sidney Altman were the self-splicing Group I intron of an 
RNA transcript in Tetrahymena thermophila38 and the RNA component of the 
bacterial enzyme RNase P that is involved in the maturation of pre-tRNAs39, 
respectively. Since then, ribozymes have been found to be involved in a variety 
of cellular processes including protein synthesis as part of the large subunit 
rRNA, and in RNA processing such as RNA splicing, viral replication and tRNA 
biosynthesis. Examples of small ribozymes include the hammerhead ribozyme, 
the hepatitis delta virus (HDV) ribozyme, the Varkud satellite (VS) ribozyme and 
the glmS ribozyme130. The group of hammerhead ribozymes are ubiquitous 
catalytic RNAs40, 41 that catalyze site-specific reversible self-cleavage reactions 
within RNA molecules42. They occur in the intronic regions of a few specific 
genes and point to a conserved biological role during pre-mRNA biosynthesis43. 
Through a similar mechanism of self-cleavage within the RNA molecule, the HDV 
ribozyme achieves monomerization of longer RNA transcripts synthesized during 
the rolling circle replication of the viral HDV genome; it is thought to be the only 
catalytic RNA required for viability of a human pathogen44.   
 Riboswitches, regulatory segments mostly found upstream of the coding 
sequence in mRNA transcripts, bind small molecules (ligands) that control the 
expression of downstream genes, thereby facilitating the self-regulation of mRNA 
abundance. Riboswitches adopt various mechanisms to mediate gene 
regulation45, which includes ligand induced formation of terminator hairpins that 
lead to transcription termination (e.g., PreQ1-I riboswitch in Bacillus subtilis)
46, 
ligand mediated structural changes that inhibit translation by sequestering the 
ribosome-binding site (e.g., PreQ1-II riboswitch found in certain species of 
Streptococcus)47, ligand mediated alternate structure formation of pre-mRNA that 
affects splicing, thereby affecting the expression of downstream genes (e.g., 
thiamin pyrophosphate riboswitch)48, and ligand mediated ribozyme-like self-
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cleavage (e.g., by the glmS riboswitch)49 of mRNAs. The glucosamine-6-
phosphate dependent glmS riboswitch is an ncRNA that is both a ribozyme, 
catalyzing self-cleavage, and a riboswitch regulating genes in response to 
binding glucosamine-6-phosphate (GlcN6P)50. The glmS ribozyme is present in 
the 5' untranslated region (UTR) of the mRNA that codes for the glmS enzyme, 
which is responsible for GlcN6P biosynthesis in bacteria51. The ribozyme binds 
GlcN6P, which causes self-cleavage of the mRNA backbone leading to its 
degradation and, consequently, reduced synthesis of the glmS enzyme encoded 
by the mRNA. The ribozyme thus employs a negative feedback loop to regulate 
GlcN6P biosynthesis when it senses an already high level within the cell52, 53. 
Other examples of riboswitches include the flavin mononucleotide (FMN) 
riboswitch, the cobalamin riboswitch, the lysine riboswitch and the S-adenosyl 
methionine riboswitch that bind their respective metabolite to regulate its 
biosynthesis and transport, and the glycine riboswitch, the glutamine riboswitch 
and the purine riboswitch that regulate genes involved in the metabolism and 
transport of their respective metabolite binding partners45, 54, 55.  
 The expression of most genes is regulated by trans-acting ncRNAs, i.e., 
regulatory RNAs that function by base-pairing with complementary sequences in 
other RNAs and DNA, to form RNA:RNA or RNA:DNA duplexes, or cis-acting 
ncRNAs that form secondary structures upon binding of ligands and are 
recognized, and acted upon, by regulatory complexes. The 5`UTRs, 3`UTRs, and 
intronic regions in pre-mRNAs contain cis-acting regulatory ncRNAs, such as 
riboswitches, internal ribosome entry sites (IRES) and RNA leader sequences, 
that receive trans-acting signals by forming secondary structures that recruit 
regulatory proteins56, 57, 58. The UTRs also act as sensors of trans-acting 
regulatory ncRNAs, like miRNAs that act through partial sequence 
complementary to one or more messenger RNA (mRNA) molecules, generally in 
3' UTRs59, 60. Interestingly, it was noted that the average length of UTRs in 
mRNAs and the fraction of alternatively spliced genes increases with 
developmental complexity in animals, indicating the existence of increased and 
sophisticated mRNA regulation in the higher organisms61, 62. Another group of 
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regulatory ncRNAs includes siRNAs that are similar to miRNAs but use the RNA 
interference (RNAi) cellular pathway to control gene expression through a 
different, yet related mechanism63. siRNAs, miRNAs and RNAi are discussed in 
more detail in the subsequent sections.  
 In summary, the discovery of functional ncRNAs not only rectified the 
fundamental misconception of genetic programming in higher organisms but also 
brought to light the existence of an enormous repertoire of ncRNAs and a 
sophisticated RNA-based regulatory system. Recently a number of short and 
long ncRNAs have been discovered, which constitute another previously hidden 
layer of molecular genetic signals, helping us gain a better understanding of the 
complexities involved in human transcriptome expression and the tremendous 
diversity of characteristics among mammals and other complex organisms. The 
work presented in this thesis will outline how studies of the interaction of a class 
of ncRNAs (siRNA) with either viral RNA silencing suppressor (RSS) or RNA 
induced silencing complex (RISC) proteins, and of chemical modification of 
ncRNAs provide important insight into the function and applications of this 
important class of ncRNAs and the underlying RNAi pathway mechanisms. 
 
1.3 History and mechanism of RNA interference 
 RNA interference (RNAi) is a fundamentally important regulatory 
mechanism in which small RNAs enable specific regulation of gene expression at 
the RNA level. Found in fungi, plants, and animals, RNAi is thought to have 
evolved to combat viral infections and has had a tremendous impact on 
fundamental and applied research. RNAi is currently one of the most promising 
new approaches for disease therapy and RNA silencing by miRNAs has been 
shown to play a fundamental role in chromatin remodeling, genome 
rearrangement, developmental timing, brain morphogenesis, and stem cell 
maintenance64, 65, 66, 67, 68, 69, 70. 
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 RNAi was first observed in transgenic petunia plants71 as a phenomenon 
wherein small ncRNA fragments act as triggers to either repress or destroy 
complementary mRNA targets, which over time was collectively called post-
transcriptional gene silencing (PTGS). In 1998, Craig C. Mello and Andrew Fire 
were the first to identify double-stranded RNA as the causative agent for this 
phenomenon and termed it RNAi72. Since then a lot of research has been 
performed to elucidate the RNAi mechanism. It has been found that two types of 
small RNA molecules – exogenous siRNA and endogenous miRNA - are central 
to a pair of closely related pathways, RNAi and RNA silencing, respectively.  
 miRNAs involved in RNA silencing are trans-acting regulatory ncRNAs 
that are expressed endogenously from genomic DNA and processed into ~20-
30nt long ncRNAs that bind to short complementary seed sequences (6-8 nt) in 
the 3'UTRs of target mRNAs, thereby regulating mRNA gene expression at the 
post-transcriptional level73. It has been predicted computationally that over 50% 
of human genes are controlled by ~1,500 different miRNAs through an adaptive, 
complex, regulatory network where a single miRNA controls many different 
(>100) mRNAs and a single mRNA often has multiple binding sites for the same 
or different miRNAs74, 75. miRNA biosynthesis is tightly regulated74 wherein 
primary transcripts (pri-miRNAs) are transcribed by RNA polymerase II (Pol II) or 
Pol III containing either a single miRNA or a cluster of miRNAs with one or 
several stem-loop structures containing imperfectly base-paired stems76, 77. 
These pri-miRNAs are then cleaved into precursor-miRNAs (pre-miRNA), which 
are ~70 nt long and contain a single stem-loop with a 2-nt overhang on their 3’-
end, by a protein complex containing the RNase III-type endonuclease Drosha 
and the microprocessor DGCR8. These pre-miRNAs are then transported by 
Exportin-5 (Xpo-5) via the nuclear pore complex (NPC) to the cytoplasm, where 
they are cleaved by a Dicer containing complex into ~22 nt long mature miRNA 
duplexes with 2-nt overhangs on the 3’-end of each strand. As a part of the 
miRNA-induced silencing complex (miRISC), one strand of the mature miRNA 
duplex, i.e., the guide strand, base pairs with the partially complementary target 
mRNA to mediate its repression78 and the passenger strand is cleaved. In cases 
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where the miRNA is perfectly complementary to the mRNA target, there is 
complete knockdown of gene expression resulting from the endonucleolytic 
cleavage of the target mRNA, as expected for siRNAs79 (Fig. 1.3).  
 By contrast, exogenous long double-stranded RNAs (dsRNAs) that result 
from RNA virus replication, convergent transcription of cellular genes, mobile 
genetic elements, self-annealing transcripts, or experimental transfection, supply 
substrates for the siRNA mediated RNAi pathway80. siRNAs are another class of 
trans-acting regulatory ncRNAs that bind the target mRNA with complete 
complementarity, leading to its endonucleolytic cleavage, thereby regulating its 
gene expression at the post-transcriptional level. The exogenous long dsRNAs 
are cleaved into siRNA duplexes, ~21-28 base pairs (bp) in length, with 
characteristic 5′-Phosphate modification and 3′-dinucleotide overhang, by a 
complex that contains an endogenous RNase III-type enzyme called Dicer 
(Dcr)81, 82, 83, 84. These siRNA duplexes are thought to be subsequently loaded 
onto an effector RNA Induced Silencing Complex85 (RISC) that contains 
Argonaute (Ago), an RNase H-type protein. The siRNA duplexes are then 
unwound and activated in a strand-specific and ATP-dependent manner within 
RISC86. In humans, it has been proposed that the siRNA duplex is loaded first 
into the RISC-loading ternary complex, consisting of Argonaute, Dicer and TAR-
RNA binding protein (TRBP)87 that then further matures. Upon engagement of a 
target mRNA, the unwound single-stranded siRNA (namely the guide strand) 
guides siRISC to initiate sequence specific mRNA (slicing) and degradation88, 
thus stopping the production of a specific protein (Fig. 1.3).  
 During strand unwinding and strand selection of the siRNA duplex, the 
RNA strand with the thermodynamically less stable 5′-end is preferentially loaded 
into RISC as the guide strand89, 90 and the passenger strand is cleaved. 
Passenger strands are not always byproducts of siRNA biogenesis; they can also 
be loaded into siRISC to function as siRNAs91, 92. In Drosophila, strand selection 
is thought to be mediated by R2D2, which binds to the more stable end of 






Figure 1.3. A graphical representation of the siRNA and miRNA pathway. 
The biogenesis of siRNA and miRNAs and their mechanism of regulation of gene 




two dsRNA-binding domains (R2) and is associated with DCR-2 (D2). It has been 
shown that in addition to thermodynamic parameters, the processing polarity 
(i.e., the end from which the long dsRNA substrate is cleaved) of dsRNA by Dicer 
can also play a role in guide strand selection95. In the absence of thermodynamic 
instability, the RNA strand that has its 3’-end bound to Dicer has been shown to 
be preferentially incorporated as the guide strand95, thus making it equally likely 
for either strand of the siRNA duplex to affect RNAi in this context.  
 Despite our expanding knowledge in this field, the composition of the 
effector RISC still remains under debate.  Although active RISCs of varying sizes 
ranging from ~160-500 kDa have all been shown to cleave mRNA targets 86, 88, 96, 
it is still unknown if these complexes represent the complete active RISC or if 
they just contain the core proteins responsible for the RNAi activity. In vitro 
experiments with Drosophila embryo extracts resulted in a model for RISC 
assembly in which complexes were seen to form sequentially, containing Dicer 
both at the beginning and end, and ultimately causing target mRNA cleavage97. 
These findings suggest an extended role for Dicer beyond the initiation phase of 
RNAi, at least in the fruit fly. Human Dicer (hDcr) in complex with TRBP has been 
shown to interact with Ago proteins98, 99, where Dicer binds to the PIWI-box of 
Ago proteins through one of its RNase III domains100. Ago has been shown to be 
present at the heart of silencing effector complexes with single-stranded 
siRNA/miRNA101, 102 and in pre-miRNA processing complexes that transfer the 
miRNA into a target-mRNA cleaving complex103. Several proteins have been 
shown to be associated with Ago proteins either directly or through adaptor 
proteins that mediate strand selection, strand unwinding, passenger strand 
removal and repression either by stimulating mRNA decay or translational 
repression99, 103, 104. The work presented in Chapter 4 of this thesis will focus on 
identifying the functional role of a couple of previously identified Ago associated 





1.4 Viral suppressors of RNA silencing 
  RNAi is a conserved sequence-specific gene regulation mechanism that 
also functions as an adaptive inducible antiviral defense against invasive foreign 
nucleic acids105. In addition to exogenous virus derived siRNAs, it has been 
demonstrated that mammalian cells have endogenous cellular miRNAs that can 
sequester and degrade viral mRNAs through the related RNA silencing 
pathway106. Several endogenous anti-viral miRNAs exist, including miR-28, miR- 
125b, miR-150, miR-223, miR-382 and miRNA-29a, that target different regions 
of the human immunodeficiency virus-1 (HIV-1) mRNAs107; miR-199a and miR-
32 restrict Hepatitis C virus (HCV) and primate foamy virus type 1 (PFV-1) 
replication, respectively108, 109; and miR-100 and miR-101 function against human 
cytomegalovirus110.  
 Pathogenic viruses have developed, in turn, RNA silencing suppressor 
(RSS) mechanisms to counteract the host anti-viral defense. This phenomenon 
was first observed in plant viruses such as potato virus and cucumber mosaic 
virus111. In addition, it has been predicted that most mammalian viruses, i.e., HIV, 
influenza A virus, HCV, Vaccinia, Ebola virus and PFV-1, that elicit host anti-viral 
defenses contain viral RSS proteins that harbor dsRNA binding domains and 
GW/WG motifs in their sequences112, 113. RSS proteins of plant viruses have 
been well characterized and shown to target most steps of the RNAi pathway, 
including viral RNA recognition, dicing, RISC assembly, RNA targeting and 
amplification114(Fig. 1.4). Several viral RSS proteins have been identified that 
inhibit RNAi, including the p14 protein of Pothos latent aureusvirus and p38 of 
Turnip crinkle virus, which bind dsRNAs size-independently and inhibit their 
processing to siRNAs115; the p19 protein of Tombusviruses, the 2b protein of 
Tomato aspermy cucumovirus and the B2 protein of Flock house virus, which all 
sequester siRNAs by binding double-stranded siRNA with high affinity in a 
sequence non-specific, but size-specific manner116; and the 2b protein of 
Cucumber mosaic virus (CMV) that interacts with Ago to inhibit slicing activity 
and prevent the spread of the long-range silencing signal117. Thus, the viral RSS 
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proteins often target one or more conserved core components of the RNAi 
pathway such as siRNAs, Ago and Dcr proteins to suppress the pathway in host 
cells. 
 Understanding the activity of viral RSS proteins has important implications 
both in basic research that employs siRNA/miRNA to study viral infection and 
pathogenesis and in siRNA/miRNA/shRNA based gene therapy approaches. 
Deciphering the mechanism of RSS proteins will make them potential targets for 
future therapies and drug development. To better understand the mechanism of 
sequestration of siRNA, the research presented in Chapter 2 of this thesis 
focuses on understanding the siRNA binding and dissociation kinetics by one 
such viral RSS protein, p19, found in Carnation Italian Ringspot Virus (CIRV) and 
other tombusviruses. p19 is a 19 KDa protein that functions as a homodimer and 
binds siRNA duplex in a positively charged surface cleft. It has a pair of 
tryptophan residues that stack on both terminal base pairs of an siRNA and 
facilitates a sequence-independent, caliper-like size selection for siRNA 
duplexes118. p19 also has been shown to inhibit siRNA mediated target mRNA 
cleavage and RISC assembly in Drosophila embryo extracts116.   
 
1.5 RNAi therapeutics  
 RNAi based therapeutics has already had a transformational effect on 
modern medicine and offers significant potential for treatment against potentially 
any target disease. A lot of research is currently being performed to validate the 
use of siRNAs as therapeutic agents. Synthetic siRNAs or short hairpin RNAs 
(shRNAs) leverage the host RNAi machinery to reduce expression of any 
pathological molecular RNA target with high selectivity, which is impractical to 
achieve with pharmaceutical approaches involving small molecules. The major 
challenges that concern the use of siRNA duplexes for therapeutic applications 
are their delivery, stability, specificity and potency119. siRNAs are extremely 







Figure 1.4. A model illustrating the steps of the RNA silencing pathway and 
their suppression by various RSS proteins. The Viral-silencing suppressor 
proteins can inhibit the RNAi at multiple points in the pathway, thereby preventing 
the anti-viral host response. The model represents the various steps at which the 
RSS proteins (i.e. P14, P38, V2, 2b, P19, HC-Pro, P21, P0 and P1) interact with 




highly susceptible to degradation by serum nucleases120.  However, it has been 
demonstrated by several research groups that introducing specific chemical 
modifications to synthetic siRNAs renders them both stable and of increased in 
vitro potency, depending on the environment of the siRNA121, 122, 123. Such 
modifications include a 3′-phosphorothioate backbone linkage for exonuclease 
resistance and 2′-O-methyl, 2'-O-methoxyethyl and 2′-fluoro modifications (2′-
OMe, 2′-O-MOE and 2′-F, respectively) for endonuclease resistance123. It was 
also observed that modifications at the 5'-end of the guide strand was less well 
tolerated than those at the 3'-end; that 2′-F modification on the sugar is well 
tolerated on the guide strand compared to 2′-O-MOE modification; and that the 
incorporation of 2′-O-Me or 2′-O-MOE in the passenger strand does not affect the 
activity of the siRNA124. Another modification that was tolerated on both strands 
in moderation was a 4′-thioribose modification125, which adopts conformations 
very similar to the C3′-endo pucker observed for unmodified sugars and 
increases the potency of siRNAs when used both individually and in combination 
with 2′-O-Me and 2′-O-MOE modifications126. Off-target effects due to partial 
homology with the siRNAs were shown to be considerably reduced by 
introducing a 2′-O-Me modification at a single nucleotide position (position 2) of 
the guide strand127. Although chemical modifications have been shown to clearly 
stabilize siRNAs and improve their potency, the work presented in Chapter 3 of 
this thesis along with a few pieces of evidence in the literature suggest that 
siRNAs are relatively protected within the cell and chemical modification may not 
be imperative after all128, 129.  This protection of siRNA may be due to binding of 
the siRNA by RISC or other RNAi components, which keeps it largely hidden 
from nucleolytic decay either as the base-paired siRNA duplex or as the single 
guide strand processed into active RISC. 
 
1.6 Conclusion 
 RNAi and for that matter siRNAs have found tremendous application in 
various areas of biomedicine, ranging from research based applications for gene 
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knock down, functional genomics and genome-scale RNAi screens to 
biotechnology and medical application as therapeutics. This extensive application 
of siRNAs in several arenas only bolsters the need for a better understanding of 
the RNAi pathway and its components. The research presented in this thesis 
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Viral RNAi suppressor reversibly binds siRNA to outcompete Dicer and 




 Over the past decade, RNA interference (RNAi) has become recognized 
as a benchmark laboratory and potential clinical tool to control gene expression, 
as well as a highly conserved eukaryotic immune response against viral 
pathogens or transposons.1-4 During viral infection, plant and invertebrate cells 
are known to activate RNAi where viral RNA is specifically recognized by the 
cytoplasmic RNase III-type endonuclease Dicer and degraded by an RNA-
induced silencing complex (RISC). Dicer cleaves exposed stretches of double-
stranded RNA into small interfering RNAs (siRNAs) 21-24 nucleotides in length 
(depending on species). Dicer then delivers the double-stranded siRNA via the 
RISC-loading complex5 to RISC,6,7 where the passenger strand of the duplex is 
cleaved and released while the guide strand is retained to guide specific 
cleavage of complementary viral RNA genomes or transcripts.8,9 Dicer is thus 
thought to play a critical dual role in RNAi by both generating virus-specific 
siRNA duplexes and assembling them with the necessary protein 
                                                          
1
 Rawlings, R. A., Krishnan, V. and Walter, N. G. (2011). Viral RNAi suppressor reversibly binds 
siRNA to outcompete Dicer and RISC via multiple turnover. Journal of  Molecular Biology 408(2), 
262-276. Reprinted with permission from Elsevier. 
2
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Vishalakshi Krishnan performed RISC assembly complex formation, Western Blot Analyses 
assisted with Electrophoretic mobility shift assays (Fig 2.2, Fig 2.5 a-g, Fig 2.6, Fig 2.7). Renata 
A. Rawlings performed Steady-state fluorescence spectroscopy, Electrophoretic mobility shift 
assays, Time-resolved FRET and Modeling p19 in the context of RNAi (Fig 2.1, Fig 2.3, Fig 2.4, 
Fig 2.5 d-g, Fig 2.7).  
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components into active RISC.10 In mammalian including human cells, artificial 
siRNAs have been shown to confer antiviral immunity,11 but only very recently 
evidence has emerged to suggest that small RNAs including siRNAs are also 
directly generated from infecting viruses.12 
 To subvert the host RNAi response many viruses have evolved small 
proteins that act as RNA silencing suppressors (RSSs).13,14 One of the best 
characterized RSSs is exemplified in the plant pathogen Carnation Italian 
Ringspot Virus (CIRV), which encodes a 19 kDa protein termed p19, an 
important pathogenicity factor that is highly conserved among all 
tombusviruses.14 Crystal structures15,16 and recent molecular dynamics 
simulations17 show that homodimers of p19 bind a single siRNA duplex in a 
positively charged surface cleft (Fig. 2.1a). Pairs of tryptophan residues stack on 
both terminal base pairs to establish a sequence-independent, caliper-like size 
selection for siRNA duplexes with 19 base pairs and 2-nucleotide long 3´-
overhangs. Sequestration and binding of Dicer-generated siRNAs by p19 has 
been observed to correlate with reduced viral RNA degradation, systemic 
symptom spread, and sustainability of the viral phenotype after infection.18-21 
Previous electrophoretic mobility shift assays (EMSAs) have suggested that the 
affinity of dimeric p19 for siRNA is high with an apparent equilibrium dissociation 
constant of KP = 0.17 ± 0.02 nM.
15 Such tight binding is consistent with a widely 
accepted sequestration model wherein the p19 dimer near-quantitatively binds 
siRNA duplexes to suppress RNAi.14,18 Binding of double-stranded RNA is 
considered to be the most common RSS mechanism,22,23 yet measurements of 
siRNA binding and dissociation kinetics to better understand sequestration have 
not been reported to date for any RSS protein. 
 Here we develop solution-based fluorescence quenching assays that 
observe siRNA:p19 (SP) binding to be readily reversible with not only a rapid 
binding rate constant ((1.69  0.07)108 M-1s-1), but also a dissociation rate 
constant (koff = 0.062  0.002 s
-1) markedly faster than those of slow-release 
nucleic acid binding proteins.24,25 Our results are consistent, within error, with the 
high apparent affinity measured in EMSAs, yet expand on the sequestration 
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model. If binding were completely irreversible, it would require the virus to 
generate sufficient quantities of p19 dimer to quantitatively bind all small RNAs 
produced enzymatically by either Dicer cleavage or the amplification effected in a 
plant cell through RNA-dependent RNA polymerase.2 By contrast, facile 
reversibility of SP complex formation opens the possibility that multiple-turnover 
may potentiate p19’s efficacy as RSS. In particular, if p19 were to disrupt the 
siRNA:Dicer (SD) interaction via multiple-turnover, it would potently interfere with 
the role of Dicer as obligatory RISC assembly factor. 
 Consistent with such a mechanism of p19 action, we observe the efficient 
competition of p19 for siRNA binding with active recombinant human Dicer in the 
absence of other known RISC components, as well as the prominent disruption 
of RISC assembly complexes observed in human HeLa cell extract containing 
the three core RISC-loading complex components Dicer, TRBP, and Ago2.5 
Mathematical modeling demonstrates that the Dicer competition data are only 
accurately reproduced assuming the formation of a transient ternary complex, 
siRNA:Dicer:p19 (SDP). Taken together, a multiple-turnover “catch and release” 
mechanism emerges wherein p19 repeatedly promotes dissociation of SD 
complexes to efficiently suppress Dicer-mediated RISC assembly.  
 
2.2 Materials and Methods 
Sources of p19, Dicer, HeLa cell extract, and RNA. Purified p19 protein was 
prepared as previously described,15 and its dimer concentration was measured 
by Bradford assay. Recombinant human Dicer was prepared by Genlantis using 
the Baculovirus system with a commercially available protocol from Invitrogen. 
The His-tagged Dicer was purified on a Ni2+ column and the His tag removed by 
Tev protease cleavage, which should remove any contaminating factors that do 
not remain bound to the recombinant Dicer. S100 cytosolic HeLa cell extract was 
obtained from Jena Biosciences and the integrity of Dicer in both samples was 
tested by Western blot analysis (Fig. 2.2a). Additionally, we demonstrated 
biological activity of the recombinant Dicer through cleavage assays using long 
double-stranded RNA substrates (Fig. 2.2b). An estimate of Dicer concentration 
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in the partially purified preparation was derived from Bradford assays to measure 
the total protein concentration in combination with the 5% purity quoted by 
Genlantis and verified by Coomassie staining of a denaturing SDS-PAGE gel 
(Fig. 2.2c). This estimate is conservative as higher relative purities would only 
imply that even higher concentrations of Dicer are needed to efficiently compete 
with p19 for siRNA binding. All RNAs were synthesized by the HHMI 
Biopolymer/Keck Foundation Biotechnology Resource Laboratory at the Yale 
University School of Medicine, then deprotected and purified as previously 
described.27,56 siRNA sequences were derived from the firefly luciferase gene26 
and were as follows: Sense strand 5´-P-CGU ACG CGG AAU ACU UCG AAA-3´; 
antisense strand 5´-P-UCG AAG (Fluorescein-dT)AU UCC GCG (Amino C6-
dT)AC GUG-3´, where P denotes a 5´-phosphate, and Fluorescein-dT and Amino 
C6-dT denote the phosphoramidites of the same name from Glen Research; the 
antisense strand was also synthesized with only one or no modification wherein 
U replaced the modified dT. Where needed, tetramethylrhodamine was coupled 
to the Amino C6 linker and the RNA purified as described.56 miRNA sequences 
were derived from the human wild-type let-7a miRNA and were as follows: Let-7a 
antisense strand 5´-P-UGA GGU AGU AGG UUG UAU AGU U-3´; Let-7a sense 
strand 5´-P-CUA UAC AAU CUA CUG UCU UUC C-3´. 
Steady-state fluorescence spectroscopy. Standard fluorescence 
measurements were performed on an Aminco Bowman spectrofluorometer 
(Thermo Scientific) at 37 oC. siRNA duplexes were formed by mixing an excess 
of 100 nM of unlabeled sense strand with 50 nM labeled sense strand in near-
physiologic standard buffer (50 mM Tris-Acetate, pH 7.4, 80 mM KCl, 20 mM 
NaCl, 1 mM MgCl2, 1 mM DTT, 0.02% (v/v) Tween 20), heat annealing for 2 min 
at 70 oC, and cooling to room temperature over 5 min. 
Fluorescein/tetramethylrhodamine doubly-labeled siRNAs were excited at 490 
nm (4 nm slit width) and emission alternately detected at 520 nm (for fluorescein, 
F) and 585 nm (8 nm slit width, for tetramethylrhodamine, T) to calculate the T/F 
ratio; F or T singly-labeled siRNAs were excited/detected at 490/520 nm or 
565/585nm, respectively. In a typical experiment, p19 was added to 50 nM 
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labeled siRNA and mixed manually to a final concentration of 500 nM unless 
otherwise indicated. For a chase experiment, unmodified siRNA duplex (formed 
through annealing the unlabeled composite sense and antisense RNA strands in 
a 2:1 ratio in standard buffer) was added to a final concentration of 3 µM. 
Saturation by the chase was ensured by triplicate trials using 500 nM, 750 nM, 
1.5 µM, and 3 µM (Appendix A, Fig. A.1). 
 To observe fast SP complex formation, siRNA samples were prepared as 
above in standard buffer to a final concentration of 40 nM. In standard buffer p19 
was added to varying (at least 8-fold) final excess concentrations (0.32 – 1.76 
µM) at 37 oC in a KinTek PMA23B stopped-flow spectrofluorometer while exciting 
at 520 nm and detecting emission at 585 nm. All time course were fit with single-
exponential increase or decrease functions in Origin (OriginLab) as described.57  
Electrophoretic mobility shift assays. For radioactive EMSAs the non-
phosphorylated antisense strand was first 5´-32P labeled with T4 polynucleotide 
kinase (PNK) and -32P-ATP at an RNA concentration of 800 nM. PNK was 
inactivated by heating to 90 C for 10 min, then the 5´ phosphorylated 
complementary strand was added in 2-fold molar excess and the reaction slowly 
cooled to room temperature to anneal the two strands. The siRNA duplex was 
further purified by nondenaturing, 20% (w/v) polyacrylamide gel electrophoresis. 
The duplex siRNA was cut out, eluted overnight into 1 mM EDTA at 4 oC, ethanol 
precipitated, and dissolved in RNase-free water. Scintillation counting was done 
on a Beckman LS6500 Multipurpose Scintillation Counter. EMSAs were 
performed as described previously15 on 10-cm non-denaturing 12% (w/v) 
polyacrylamide gels in 0.5x TBE (44.5 mM Tris-Borate, 1 mM EDTA) and run at 
500 V and 4 oC for 2 h. Dicer and p19 at varying final concentrations were added 
to radiolabeled siRNA duplex (50,000 cpm, < 400 pM of 5´-32P labeled duplex) in 
10 µL standard buffer and incubated for 0.5 hrs. Next, 10 µL non-denaturing 
loading buffer (10% glycerol, 0.5x TBE, 0.025% bromophenol blue, and 0.025% 
xylene cyanol) was added and each sample loaded into a well of the EMSA gel. 
Competition experiments were performed by preincubating < 400 pM siRNA 
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duplex (prepared as above) in standard buffer either with 140 nM Dicer and 
increasing concentrations of p19, or with 0.17 nM or 2.5 nM p19 and increasing 
concentrations of Dicer. Gel chase experiments were done in standard buffer 
with 70 and 10 nM of Dicer or p19 respectively to < 400pM 5´-32P labeled siRNA 
and addition of 750 nM unlabeled siRNA chase for 0, 10, 30, 60 and 120 min. 
Gels were wrapped in plastic wrap and exposed to phosphor screens, which 
were scanned on a Storm 840 PhosphorImager and quantified using Image 
Quant software (Molecular Dynamics). The relative fraction f of relevant protein 
complexes was fit with the following hyperbolic binding isotherm to extract 










RISC assembly complex formation. To observe RISC assembly complexes 15, 
50, or 75% (v/v) cytosolic HeLa cell extract was incubated with < 400 pM siRNA 
duplex (prepared as above) in a final volume of 10 µl HeLa buffer [8% (v/v) Lysis 
Buffer (23.7 mM HEPES, pH 7.5, 79 mM potassium acetate, 1.58 mM 
magnesium acetate, 5 mM DTT, and 1 mg/ml Perabloc SC (Roche)), 
supplemented with 20% (v/v) 5x RNAi mix (125 mM creatine phosphate, 5 mM 
ATP, 25 mM DTT), 2% (w/v) creatine kinase, and 20% (v/v) RNA guard RNase 
Inhibitor (GE Bioscience)] for 2 h at 4 oC, unless otherwise specified. For 
competition experiments, p19 was added in increasing concentrations to the 
HeLa cell extract/siRNA mixture either immediately or after a 2 h preincubation. 
Time courses were stopped by direct loading onto a running nondenaturing 4% 
(w/v) polyacrylamide gel in 0.5x TBE (44.5 mM Tris-Borate, 1 mM EDTA), run at 
~50 mW/cm2 and 4 oC. For comparison with a previous assay, 50 and 75% (v/v) 
HeLa cell extract was incubated with siRNA as described in28 for 1 h at 4 oC to 37 
oC and analyzed by EMSA, yielding similar results (Appendix A, Fig. A.3). 15% 
(v/v) extract was preferred for most of our work due to the better pH control 
afforded by this lower concentration and to conserve material. For antibody 
supershift EMSA, cytosolic HeLa cell extract (24 µg total protein) was pre-
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incubated with 0.8 µg or 1.6 µg of anti-Dicer rabbit polyclonal antibody (Santa 
Cruz Biotechnology, Inc.) and 0.8 µg or 1.6 µg of unrelated control antibodies, 
either anti-DsRed rabbit polyclonal antibody (Clontech Laboratories, Inc.) or anti-
β actin mouse monoclonal antibody (Sigma-Aldrich, Inc.), for 2 h at 4 oC prior to 
the RISC assembly assay. The final volume was 60 µl per lane. Nondenaturing 
4% (w/v) polyacrylamide gel electrophoresis was used to resolve these 
complexes as described above. Time courses and titration curves were fit as 
above. 
Time-resolved FRET. Time-resolved donor (fluorescein, F) fluorescence decays 
were collected in the presence and absence of acceptor (tetramethylrhodamine, 
T) using time-correlated single-photon counting, as previously described.58,59 As 
before, the donor decay in the presence of acceptor was modeled as a weighted 
average of the decays for each donor-acceptor distance in the ensemble of 
molecules assuming a three-dimensional Gaussian distance distribution with a 
Förster distance of 54 Å between F and T.58,59  
Western Blots for Dicer Detection. For denaturing Western blots, the cytosolic 
HeLa cell extract, the recombinant Dicer enzyme preparation, and recombinant 
TRBP (Abcam) and Ago2 (Abnova) proteins were run on a NuPAGE Novex 4-
12% gradient Bis-Tris Gel in the presence of a molecular weight marker (ECL 
Plex Rainbow marker). The gel was then electroblotted in Tris-Glycine buffer (25 
mM Tris, 192 mM Glycine, and 20% (v/v) Methanol) onto a Polyvinylidene 
Fluoride (PVDF) membrane (Immobilon-P Membrane, Millipore) over 75 min at 
300 mA, using a Bio-Rad Trans-Blot SD semi-dry transfer cell per the 
manufacturer’s instructions. After transfer the membrane was probed with either 
rabbit anti-Dicer (Santa Cruz Biotechnology), mouse anti-TRBP or mouse anti-
Ago2 (both Abnova) followed by goat anti-Rabbit-Cy5 and goat anti-mouse-Cy3 
(both Amersham), respectively. The probed blots in Fig. 2.2a,d,e were visualized 
on a Typhoon 9410 Variable Mode Imager (GE Healthcare Life Sciences). 
 For non-denaturing Westerns blots, RISC assembly complexes were 
formed as described above but reactions were scaled up by 6-fold. Gels were 
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soaked in 0.1% (w/v) SDS for 15 min and then electroblotted in Tris-Glycine 
transfer buffer (25 mM Tris, 25 mM Glycine) onto a PVDF membrane 
(Immobilon-P Membrane, Millipore) over 75 min at 300 mA, using a Bio-Rad 
Trans-Blot SD semi-dry transfer cell per the manufacturer’s instructions. After 
transfer, the proteins were fixed to the membrane by incubating in 5-10% (v/v) 
acetic acid, rinsing with deionized water, and air drying. The membrane was 
probed with a rabbit primary antibody against Dicer (Santa Cruz Biotechnology), 
followed by a goat anti-rabbit secondary antibody, conjugated with horseradish 
peroxidase (Zymed, Invitrogen). The blot was developed using a 
peroxide/enhancer solution (ECL-Plus detection, Amersham), and visualized on 
a Typhoon 9410 Variable Mode Imager (Fig. 2.6). 
Modeling p19 in the context of RNAi. For the model described schematically in 
(Fig. 2.7a), changes in viral protein expression levels were monitored at steady-
state in the absence and presence of the RSS p19. Changes in free p19 protein 
over time depend on terms representing the natural rates of production (rx rt / 
rdm), degradation (rdp [p19]), the extent of siRNA binding (kon [siRNA] [P]), and the 
siRNA:p19 complex dissociation (koff [SP]). Production of p19 is governed by its 
transcription rate (rx), its messenger RNA degradation rate (rdm), and its 
translation rate (rt), which are assumed to have reached equilibrium on a 
timescale faster than that of repression. The p19 protein is degraded by the first-




 The amount of usable siRNA in the system, i.e., the fraction able to 
associate with RISC, is reduced by the amount of siRNA bound to p19. 
Production of siRNA is dependent on the catalytic rate constant of Dicer (kcatD), 
and siRNA is degraded with a first order rate constant (rds). The parameter n is 













 The time evolution of the viral protein of interest that serves as a reporter 





where (kcatR) is the catalytic rate constant for RISC-mediated cleavage of mRNA. 
The additional term in the denominator of Equation 3 is a quasi-steady state 
assumption used in previous work33,60 to describe RISC mediated degradation of 
viral messenger RNA (mRNA). It assumes that the active concentration of 
siRNA-loaded RISC is approaching its steady-state value with rate constant kcatR. 
This buildup of siRNA-loaded RISC contributes to the rate of degradation of the 
viral mRNA, as described by the concentrations of RISC and siRNA, as well as 
the dissociation constant KDR. The proteins not silenced by RNAi are represented 




 Equations 1-3 are rescaled as described by Marshall33 and solved at 













where y and β are the parameters previously described as the efficiency of the 
RNAi pathway and the RNAi settling time, respectively.33 The parameters a, v, 
and A are the fraction of siRNA-bound relative to total p19, the efficiency of p19, 
and the efficiency of Dicer in a particular cell line, respectively. The level of the 
viral protein at steady-state is dependent mostly on S. For example, in the 
absence of RNAi (i.e., in the absence of Dicer) S = 0, so that V = 1, that is, the 
viral protein level is not suppressed. Substituting Equation 6 into Equation 7 















 In the absence of p19 (i.e., P = 0), based on Equations 7 and 8, V reduces 




















 The enhancement of viral protein production due to either irreversible (Irr) 






Fluorescence assays to observe siRNA:p19 complex formation. We site-
specifically labeled the antisense (guide) strand of an established luciferase-
targeting siRNA duplex26,27 with either fluorescein or tetramethylrhodamine as 
fluorescence quenching probes in positions not expected to interfere with p19 
binding (Fig. 2.1a). We found that only the tetramethylrhodamine label was 
efficiently quenched upon p19 addition (Fig. 2.1b). Addition of buffer or other 
proteins such as recombinant Dicer caused no such quenching (Appendix A, 
Fig. A.1). To observe a robust quenching signal upon p19 addition, we 
proceeded to label with both fluorophores together, allowing us to monitor a 
normalized tetramethylrhodamine:fluorescein (T/F) fluorescence ratio that is 
insensitive to dilution effects and other perturbations of an otherwise relative 
fluorescence signal. Next, we tested by EMSA p19 binding of this doubly-labeled 
siRNA against that of the unlabeled siRNA and detected no interference from the 
fluorophores (KP = 0.17 ± 0.03 nM in both cases, consistent with earlier EMSA 









Figure 2.1.  Fluorescence assays to detect siRNA:p19 complex formation. 
(a) Crystal structure of p19 (blue) bound to an siRNA (grey). The nucleotides to 
which the fluorophores fluorescein (F) and tetramethylrhodamine (T) are 
attached are highlighted in green and red, respectively. (b) The T-only labeled 
siRNA (red) is quenched upon p19 addition, while the F-only labeled siRNA 
(green) is unaffected by p19. (c) EMSA analysis shows that the doubly-labeled ft-
siRNA (red) binds to p19 with the same affinity as the unlabeled siRNA (black). 
(d) Time-resolved FRET measures the F:distances for the single-stranded, 
protein-free double-stranded, and p19-bound double-stranded siRNA 35 Å, 43.4 







Figure 2.2. Characterization of recombinant (r)Dicer and HeLa cell extract. 
(a) Denaturing Western blot against Dicer showing the presence of full length 
Dicer p rotein (218 kDa) in both extracts. Lane 1 (from left, marked “L”): Full-
Range Rainbow Molecular Weight Marker (RPN800E). Lanes 2-5: Recombinant 
Dicer (Genlantis) – 3, 6, 9, and 12 µL, respectively. Lanes 6-9: Cytosolic HeLa 
cell extract – 3, 6, 9, and 12 µL, respectively. The multiple bands seen on the 
Western blot may result from degradation of Dicer or cross-reactivity of the 
antibody. (b) Cleavage assay measuring the activity of recombinant Dicer.  
Recombinant Dicer was incubated with radio-labeled double-stranded 32 
nucleotide RNA for 1, 3, 5, 7, 9, 12, and 24 h in the Genlantis supplied buffer 
(lanes 2-8 from left to right) and in the near-physiologic standard buffer (lanes 12-
18) used for the Dicer assays (50 mM Tris-Acetate, pH 7.4, 80 mM KCl, 20 mM 
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NaCl, 1 mM MgCl2, 1 mM DTT, 0.02% (v/v) Tween 20). In the company-supplied 
buffer, cleavage was observed over the recommended incubation time of 12 h. In 
the near-physiologic buffer, all RNA was 100% cleaved into mature siRNA as 
early as 1 h after incubation. (c)  Coomassie stained 4-12% SDS-PAGE gel. 
Lane 1 (from left, marked “L”): Full-Range Rainbow Molecular Weight Marker 
(RPN800E). Lane 2: Recombinant Dicer (Genlantis) – 5 µL. Lane 3: 
Recombinant Dicer (Genlantis) – 10 µL. Fraction of full length Dicer was 
calculated as 5 ± 2% (d)  Western blot of recombinant Dicer and HeLa cell 
extract against Ago2. (e) Western blot of recombinant Dicer and HeLa cell extract 
against TRBP. Reprinted with permission from Elsevier.  
  
 43 
 (trFRET) between the two fluorophores revealed only a small increase in 
fluorophore distance distribution upon p19 addition (with the mean distance 
increasing from 43.4 to 44.5 Å; Fig. 2.1d), indicating that formation of the SP 
complex leads to only a minor deformation of the siRNA duplex, as expected 
from X-ray crystallography.15 We conclude that the doubly-labeled siRNA duplex 
is a suitable reporter for formation of the siRNA:p19 interaction in solution.  
p19 binds siRNA rapidly and reversibly. Addition of increasing excess 
concentrations of p19 to the doubly-labeled siRNA led to an increase in the 
pseudo-first order rate constant of tetramethylrhodamine quenching as monitored 
by the T/F ratio, yielding a bimolecular binding rate constant of kon = (1.69 ± 0.07) 
 108 M-1s-1 (Fig. 2.3a,b). Next, dissociation of the preformed SP complex was 
monitored upon addition of a large excess of unlabeled siRNA (chase), yielding a 
dissociation rate constant of koff = 0.062  0.002 s
-1 (Fig. 2.3c and Appendix A, 
Fig. A.1). Together with the rapid kon, a solution-based dissociation equilibrium 
constant of koff/kon = KP,sol = 0.37 ± 0.08 nM is obtained, within 2-fold of the EMSA 
predicted value (0.17 nM), attesting to a high-affinity, yet also notably reversible 
siRNA:p19 binding mode.  
p19 efficiently competes with recombinant human Dicer for siRNA binding. 
The critical dual role of Dicer in RNAi as both the enzyme that produces siRNAs 
and as a RISC assembly factor10 suggests the siRNA:Dicer (SD) interaction as a 
particularly vulnerable step during RNA silencing. Previous studies in embryo 
extracts of the fruitfly Drosophila have shown that p19 suppresses RNA silencing 
by competing with the Dcr2-R2D2 complex.18,22 To determine whether p19 also 
competes with human Dicer for siRNA, we employed EMSA using radio-labeled 
siRNA duplexes and an active recombinant human Dicer preparation, devoid of 
other known RISC proteins (Fig. 2.2) (available as a relatively crude purification 
of heterologously overexpressed Dicer from Genlantis, see Materials and 
Methods). We measured the apparent equilibrium dissociation constant of the 
human SD complex as KD = 3.7 ± 0.4 nM (Fig. 2.4a and Appendix A, Fig. 
A.2a). The presence of a low concentration of p19 (0.17 nM), equivalent to the 







Figure 2.3.  Kinetics of formation and dissociation of the siRNA:p19 
complex. (a) Pseudo-first order kinetics of the binding of doubly-labeled siRNA 
(50 nM) to excess p19, measured through the T/F ratio during stopped-flow 
mixing. Scatter points denote raw data; lines denote single-exponential fits to 
extract rate constants. (b) Plot of the observed pseudo-first rate constants from 
panel A over the p19 concentration. The linear fit yields the indicated bimolecular 
binding rate constant, kon. (c) Fluorescence detection of the binding of doubly-
labeled siRNA (50 nM) to p19 (500 nM) and of complex dissociation upon 
addition of an unlabeled siRNA chase (3 μM). A single-exponential fit (red line) 








Figure 2.4.  Competition of p19 with human Dicer for siRNA binding as 
detected by EMSA. (a) The fraction of siRNA bound to Dicer over increasing 
Dicer concentrations in the absence of p19 (black squares), and presence of 
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0.17 nM (open red circles) or 2.5 nM p19 (blue dots). Solid lines, corresponding 
fits of hyperbolic binding isotherms. Dashed lines indicate the predicted curves 
based on a dissociative binding mechanism (siRNA has to first dissociate from 
Dicer to bind p19). (b) Fraction of siRNA bound to p19 over increasing p19 
concentrations in the absence (black squares) or presence of a saturating Dicer 
concentration of 140 nM (open green circles). Solid lines, corresponding fits of 
hyperbolic binding isotherms. The dashed-dotted line indicates the predicted 
curve based on a dissociative binding mechanism. (c) Schematic of the two 
competition models between Dicer and p19 for siRNA; the dashed box highlights 
the part unique to the ternary complex formation model. Reprinted with 






 ~100 nM (Fig. 2.4a and Appendix A, Fig. A.2b). The presence of a saturating 
concentration of p19 (2.5 nM) weakened the interaction still further by >270-fold 
to an estimated lower limit of ~1.0 µM (Fig. 2.4a and Appendix A, Fig. 
A.2c).These findings led us to hypothesize that p19 can function to inhibit RNAi 
in humans by interrupting the SD complex before Dicer can hand off siRNA to 
RISC. Reciprocal competition experiments showed that the presence of even 
saturating concentrations (140 nM) of Dicer lowered the apparent affinity of p19 
for siRNA only marginally (~4-fold from 0.17 ± 0.03 nM to 0.81 ± 0.06 nM; Fig. 
2.4b and Appendix A, Fig. A.2d,e), further supporting the hypothesis that strong 
competition with the SD complex is an important mode of action for p19 inhibition 
of RNAi in human cells.  
Human siRNA-containing complexes formed in cytosolic cell extract are 
vulnerable to p19 challenge. Previous studies with Drosophila extracts have 
shown that p19 inhibits RISC assembly while disrupting preassembled RISC to a 
lesser extent.22 Our result that p19 disrupts the complex of recombinant human 
Dicer with siRNA suggests that p19 may also be effective in suppressing RISC 
assembly in mammals. To test this hypothesis and probe p19’s effect on the 
formation of human RISC-related complexes, we used a modified in vitro RISC 
assembly assay.28,29 Specifically, we incubated radio-labeled siRNA duplex with 
15% (v/v) cytosolic HeLa cell extract, which we showed to contain the three core 
RISC-loading complex components Dicer, TRBP, and Ago2 (Figs. 2.2 and 2.6), 
and analyzed the products by EMSA and autoradiography (Fig. 2.5a,b). Three 
distinct siRNA-containing complexes were observed that correspond to those 
previously observed, including a slowly-migrating complex D that is thought to 
contain Dicer, as well as two faster migrating bands termed C1 and C218,30 (Fig. 
2.5b). The normalized fraction of complex C2 decreases over a 2-h period, 
whereas the complex C1 and D fractions increase (with estimated rate constants 
of 2  10-3 s-1, 0.8  10-3 s-1, and 0.4  10-3 s-1, respectively, Fig. 2.5a). To test for 
the presence of Dicer we performed supershift assays with anti-Dicer polyclonal 
antibody and found that only complex D specifically supershifts with this antibody 




Figure 2.5.  Competition of p19 with human siRNA-containing complexes 
found in cytosolic HeLa cell extract. (a) Normalized fraction of siRNA bound to 
complexes D (green), C2 (red), and C1 (black), where the highest point is 
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normalized to unity in each complex over time, as derived from the gel in panel 
B. The relative abundances of C1 and complex D increase over time with 
estimated rate constants of 8  10-4 s-1 and 4  10-4 s-1, respectively, whereas C2 
decreases in relative abundance with a rate constant of 2  10-3 s-1. (b) 
Formation of complexes D, C2, and C1 after 10, 30, 60 and 120 min incubation 
of siRNA in cytosolic HeLa cell extract. Samples were loaded onto a running 4% 
native polyacrylamide gel, leading to the indicated differences in migration. (c) 
Anti-Dicer antibody-based supershift of siRNA-containing complexes. Dicer 
containing complex D shifts in the presence of anti-Dicer antibody (lane 3: 0.8 µg; 
lane 4: 1.6 µg). Lanes 1, 5 and 6 indicate the mobility of the complexes in the 
absence of any antibody. Lanes 9-12 show negative controls where 0.8 µg or 1.6 
µg of anti-actin (lanes 9, 10) or anti-DsRed (lanes 11, 12) were added. (d) 
Quantification of the normalized fraction of siRNA bound in each complex, as 
derived from gels as in panel E. Fractions were normalized to the zero time point. 
(e) Formation of complexes after 2.5 h incubation of siRNA in cytosolic HeLa cell 
extract, and increasing concentrations of p19. (f) Quantification of the normalized 
fraction of siRNA bound in each complex, as derived from gels as in panel E, 
normalized as in D. (g) Formation of complexes D, C1, and C2 after 2 h 
incubation of siRNA in cytosolic HeLa cell extract, followed by the addition of 
increasing concentrations of p19 and further incubation for 30 min. Reprinted 









Figure 2.6. Non-denaturing western blot detection of Dicer.  (a) A scaled-up 
version of the non-denaturing time course gel in (Figure 4B), imaged for radio-
labeled siRNA, yields sufficient complexes for Western blot detection of Dicer. (b) 
Western blot of a similar non-denaturing gel to (a) probed with a rabbit primary 
antibody against Dicer, followed by a goat anti-rabbit secondary antibody, 
conjugated with horseradish peroxidase.  Samples were loaded onto a running 





complex D only (Fig. 2.6). Additionally, preliminary mass spectrometry analysis 
of the three siRNA containing complexes was performed to identify the proteins 
associated with these complexes and with the siRNA (Appendix C). Notably, 
adding increasing p19 concentrations to the cell extract prior to siRNA addition 
increasingly impairs the formation of all three siRNA-containing complexes, 
concomitant with an accumulation of the competing SP complex (Figs. 2.5d,e). 
When p19 is added to the RISC assembly assay after 2 h of pre-incubation with 
siRNA, the formation of particularly the Dicer-containing complex D is inhibited to 
a lesser extent (Figs. 2.5f,g). Similar results were obtained at higher HeLa cell 
extract concentrations and temperatures (Appendix A, Fig A.3). 
Modeling supports formation of a transient ternary siRNA:Dicer:p19 
complex. The mechanism of competition between p19 and human Dicer can be 
determined from mathematically modeling the two possible modes of competition 
for a two-protein-single-substrate system. First, competition may occur through a 
dissociative binding mode, where the higher affinity protein shifts the relative 
equilibrium of the system by binding all available substrate as it dissociates from 
the competitor, thus establishing a new equilibrium position (Fig. 2.4c). In the 
case of p19 and Dicer, siRNAs are pre-associated with Dicer at the onset, due to 
their cleavage from longer RNAs, making such dissociative binding by p19 
relatively fast only if spontaneous dissociation from Dicer is rapid. Second, 
competition may occur through formation of a ternary complex intermediate 
involving siRNA, Dicer, and p19 (Fig. 2.4c). Using the previously determined gel-
based apparent dissociation equilibrium constants for p19 (KP = 0.17 ± 0.02 nM) 
and Dicer (KD = 3.7 ± 0.4 nM), we can discriminate between these two possible 
modes of competition by calculating the resulting expected siRNA:Dicer and 
siRNA:p19 complex fractions and comparing them to experiments for a given set 
of equilibrium conditions.31 
 Assumption of the dissociative binding mechanism shows poor correlation 
with experiment, as evident from the facts that changes upon adding Dicer are 
consistently overestimated (Fig. 2.4a), while changes upon adding p19 are 
consistently underestimated (Fig. 2.4b). This poor correlation suggests that 
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ternary complex formation is needed to explain the observed efficient disruption 
of the siRNA:Dicer complex in the presence of p19. The inclusion of ternary 
complex formation into the mechanism creates a thermodynamic cycle that 
requires the ratio of KD/KSP to equal that of KP/KSD.
32 Rearranging and using the 
values of KD and KP we find that KSP/KSD = KD/KP = 21.6 and, therefore, KSP = 
21.6 KSD. This result suggests that the dissociation of the ternary complex into 
the binary siRNA:p19 complex is >20-fold more likely than dissociation into the 
siRNA:Dicer complex, indicating that siRNAs can indeed be effectively shuttled 
toward the p19 bound state by assuming transient formation of a ternary 
siRNA:Dicer:p19 complex. The resulting model correlates well with experiment 
and explains both the weak effect that Dicer addition has on the siRNA:p19 
complex and the large effect that p19 addition has on the siRNA:Dicer complex 
(Figs. 2.4a,b). A similar result is observed when p19 is placed in the context of 
the RNAi pathway, as follows.  
Modeling illustrates the benefits of reversible siRNA binding by p19. To 
further interpret and unify our results, we expanded a previously published, 
simplified steady-state kinetic model that encapsulates key features of the RNAi 
pathway, including RNA cleavage by Dicer, siRNA incorporation into RISC, and 
the resulting RISC-mediated RNA degradation.33 We included the experimentally 
observed competition of p19 with the siRNA:Dicer interaction and p19’s 
reversible interaction with siRNA. From this model the possibility of a multiple-
turnover “catch and release” mechanism emerges wherein p19 is effectively 
recycled after successfully competing with Dicer and dissociating again from the 
siRNA (Fig. 2.7a). We next sought to establish what impact, if any, such a 
mechanism has on the ability of p19 to suppress RNAi (for details of the model 
and its analysis see Appendix A).  
 Our model suggests that the intracellular steady-state load of viral proteins 
(and thus viral viability) is specified by three global parameters (Fig. 2.7a); the 
efficiencies of Dicer (A), RNAi in the specific host cell type (y), and p19 (v). 
These three global parameters are each composed of detailed mechanistic 






Figure 2.7. Steady-state kinetic modeling of p19 action in RNAi 
suppression. (a) Schematic of our expanded “catch and release” mathematical 
model. A, y, and v describe the efficiencies of Dicer, RNAi in the cell, and p19, 
respectively. n is the fraction of siRNAs that successfully reenters the RNAi 
pathway after release from p19. The mature human RISC (with single stranded 
siRNA bound) may or may not contain Dicer (dashed outline). (b) Enhancement 
of viral protein load over unsuppressed protein level, assuming reversible and 
irreversible p19 binding (Rev and Irr, respectively). The fraction of siRNA:p19 
complex over free p19, a, will increase as the efficiency of p19 (v) increases. The 
enhancement in the level of viral protein due to reversible p19 binding will 
therefore fall within the range (grey area) determined for a ranging from 0.1 
(upper bound) to 200 (lower bound). Reprinted with permission from Elsevier. 
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p19 to an siRNA (single turnover), the relative enhancement of the viral protein 
load in the presence over the absence of p19, ɸIrr, is then described by:
 
leading to a negligible dependence on the p19 suppression efficiency v (Fig. 
2.7b) when using a realistic parameter space (Table 2.1 and Materials and 
Methods). 
 In the case of a reversibly formed SP complex, as observed in our 
experimental work, two additional model parameters come into play (Fig. 2.7a), 
the fraction of siRNAs that successfully reenters the RNAi pathway after release 
from p19 (n) and the fraction of the total p19 that is bound to siRNA (a). Values of 
n close to zero lead to recycling of p19 protein without reincorporation of the 
released siRNA into RISC, whereas values of n close to unity effectively reduce 
the free concentration of p19 without changing the fate of the bound siRNA as an 
eventual guide for RISC. Previous studies have shown that Dicer substrates at 
sub-nanomolar concentrations are up to 100-fold more effective in gene 
knockdown than mature siRNAs,6,34 suggesting a low probability of n = 0.01 for 
reincorporation of free siRNA into the RNAi pathway especially at the low siRNA 
concentrations expected during early stages of viral infection. Previous 
experimental studies in Drosophila embryo lysate have shown that p19 is 
effective in preventing low nanomolar concentrations of siRNAs from 
incorporation into RISC but less effective in disrupting mature RISC,18,22 a feature 
also evident in our data (compare Fig. 2.5e,g), suggesting that indeed early 
stages of viral infection, where n is small, may be most effective for RNAi 
suppression by p19. The relative enhancement of viral protein load in the 
presence over the absence of p19 in our reversible binding model, ɸRev, is then 
described by: 
 
where koff is the dissociation constant of the SP complex and kcatD is the 
cleavage rate constant of Dicer. This model predicts a hyperbolic dependence of 
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ɸRev on the p19 efficiency v, with little dependence on a (Fig. 2.7b), which can be 
estimated from our experimental data in Fig. 2.4a,b to range between 0.1-200. 
Reversible siRNA binding by p19 is thus found to enhance viral protein 
production by up to ~2.2-fold over that observed for the irreversible binding 
model (Fig. 2.7b). Notably, even a value of n = 0.1 does not diminish this effect 
much due to a close-to-linear decrease of ɸRev toward unity with an increase of n 
toward unity (data not shown).  
 
2.4 Discussion 
 The small, positive-sense, single-stranded RNA genome of tombusviruses 
encodes p19, an RSS thought critical for symptom spread and cytotoxicity of this 
class of plant pathogens20,21,35,36 through its ability to bind and thus sequester 
Dicer-generated siRNAs.14,18 The proposed use of p19 in therapeutic and 
research applications including mammalian gene therapy,37 vaccine 
production,38,39 and as a human retroviral protein homolog40 motivates the study 
of p19 outside its natural host environment, across kingdom boundaries. We here 
have investigated binding of a generic siRNA by CIRV p19 through fluorescence 
quenching assays in combination with radioactive EMSAs. Noticeable 
dissociation of an siRNA from p19 (koff = 0.062  0.002 s
-1) is counterbalanced by 
fast association to yield a solution based dissociation equilibrium constant (KD = 
0.37 ± 0.08 nM; Fig. 2.3), within 2.2-fold of the high affinity previously deduced in 
EMSAs.15 The dissociation of siRNA from p19 is nearly three orders-of-
magnitude faster than that observed for many high-affinity nucleic acid-protein 
complexes with dissociation rate constants on the order of 10-4 s-1.24,25,41,42 
Strikingly, the rate and equilibrium constants for the siRNA:p19 complex 
resemble those of HIV-1 protein Rev for interaction with Rev Response Element 
(RRE) RNA (kon = 5.3 x10
8 M-1 s-1, koff = 0.14 s
-1), perhaps due to the similarly 
(primarily) non-sequence specific binding of a small protein to a (partially) base 
paired RNA duplex.43 
 The presence of even low concentrations of p19 dramatically weakens the 
interaction of recombinant human Dicer with its siRNA product (25- to >270-fold, 
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depending on the p19 concentration, Fig. 2.4a), in the absence of other 
detectable RISC components. Conversely, the presence of saturating 
concentrations of Dicer only slightly lowers (~4-fold) the affinity of p19 for siRNA 
(Fig. 2.4b), supporting the hypothesis that strong competition with the SD 
complex is an important mode of p19 action in vivo. Accordingly, assembly 
assays show that p19 also strongly disrupts RISC-related human siRNA-protein 
complexes observed in HeLa cell extract that we show to contain all core RISC-
loading complex components (Dicer, Ago2, and TRBP;5 Fig. 2.2d,e), suggesting 
that p19 is able to disrupt the SD complex even in the context of the full 
complement of RISC components (Fig. 2.5). Our experimental results inform 
mathematical modeling of the competition between Dicer and p19 for siRNA, as 
well as of the steady-state interactions between siRNA, Dicer, p19, RISC, and 
viral (m)RNA. We determine that the minimal model necessary to achieve the 
experimentally observed level of competition of p19 with Dicer for siRNA requires 
the postulation of a transient ternary complex that favors dissociation into the 
siRNA:p19 complex and free Dicer (Fig. 2.4). In addition, an expanded steady-
state kinetic model predicts a significant enhancement in viral protein load when 
the siRNA:p19 interaction is assumed to be reversible, as observed 
experimentally. Our results thus invoke a multiple-turnover “catch and release” 
mechanism wherein p19, unlike the released siRNA,6,34 is effectively recycled 
after successfully competing with Dicer (Fig. 2.7). Notably, if the dissociation rate 
constant of the siRNA:p19 complex were lower and thus closer to that of a slow-
release protein, p19 would be more efficient in competing with Dicer for siRNA, 
but also less efficient in releasing the siRNA to achieve multiple-turnover. It is 
tempting to speculate that evolution in this way has yielded a p19 with siRNA 
binding properties optimized for RNAi suppression. 
 As any mathematical model, ours relies on some assumptions, including 
an experimentally derived estimate for a low probability n of 1% for 
reincorporation of siRNA released from p19 into the RNAi pathway.6,34 The 
dependence of the predicted RNAi suppression has a relatively shallow 
dependence on n, and for any n < 1 predicts an enhancement of suppression 
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through the experimentally observed reversibility of the siRNA:p19 interaction. 
Strikingly, the estimated 2.2-fold enhancement in RNAi suppression through 
reversible siRNA:p19 complex formation is similar in magnitude to the typical 
RNAi effect that microRNAs have on the expression of cellular genes,9,44 
suggesting that even a modest change in gene expression level as predicted 
here can have profound biological consequences, in our case on the likelihood of 
survival of a virus in its host.  
 Several implications for the struggle between the virus and the cellular 
RNAi machinery arise from our work. First, in gene therapeutic applications p19 
will be required to be effective outside of its natural host environment, where a 
study of the protein’s potential interaction partners so far has been lacking. Here, 
we observe p19 in the context of human cellular components and find evidence 
for ternary complex formation between p19, an siRNA and human Dicer. Our 
experimental data suggest that the observed efficient competition of p19 with the 
siRNA:Dicer complex (Fig. 2.4) and the resulting Dicer-containing RISC 
assembly complexes (Fig. 2.5) targets a particularly critical step on the path to 
an activated RISC. Recent 3D reconstructions from negatively-stained electron 
microscopy images of human Dicer complexes depict it as a fist-like shape with a 
central flat surface that is thought to bind the siRNA.4,45,46 This architecture along 
with the known binding mode of p19 raises the possibility that p19 could bind the 
opposite face of the siRNA in a ternary complex with Dicer. Notably, crystal 
structures of several other viral suppressors also appear to bind only one face of 
the siRNA, leaving the opposite face open to potentially accommodate proteins 
such as Dicer.47 While we did not observe formation of a super-shifted band as 
indicative of such a ternary complex in our EMSAs with siRNA, p19, and human 
Dicer (Figs. 2.5d-g), the complex may simply be too short-lived or our EMSA too 
low in resolution for the complex to be detected.  
 Second, the previously proposed simple sequestration model would 
require stoichiometric p19 concentrations relative to all siRNA duplexes, native to 
CIRV or not, that are generated by Dicer, as well as all other small duplex RNAs 
bound by p19, including defective interfering RNAs,20 the siRNA amplification 
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products generated in plant and other cells by RNA-dependent RNA polymerase 
activity,2,48 and perhaps miRNA duplexes.19,49,50 We independently confirmed the 
ability of p19 to bind a human miRNA using the conserved, ubiquitous, and well-
studied let-7a miRNA, which has been implicated as a tumor suppressant.51 
Remarkably, we observed that p19 binds the partially mismatched, double-
stranded 22-nucleotide let-7a miRNA and our 21-nucleotide siRNA with equal 
affinities of 0.16 ± 0.02 nM and 0.17 ± 0.03 nM, respectively (Appendix A, Fig. 
A.6). Similar to our observations, a recent study used an affinity-capture 
approach to show that p19 from CIRV retains high affinity for let-7 miRNA, as 
well as a fluorophore labeled siRNA.50 These observations further underscore 
that p19 may face a large background of competitor RNAs while targeting its 
siRNA substrate, although the specific base pairing patterns of some plant 
miRNAs may disfavor their binding to p19.52 Our finding that formation of the 
high-affinity siRNA:p19 complex is readily reversible (Fig. 2.3) while still 
interfering with siRNA binding by Dicer and RISC-related assembly complexes in 
vitro (Figs. 2.4 and 2.5) raises the possibility that sub-stoichiometric p19 
concentrations may suffice in vivo to prevent siRNAs by multiple-turnover from 
assembling into RISC. In this fashion, the virus could keep pace with the 
amplified host response during systemic RNAi self-defense of the plant host 
against CIRV.53  
 Third, while our results have an immediate impact on our understanding of 
the physicochemical properties and biological function of p19, a more practical 
consideration also arises from our work. The future of RNAi based strategies 
may well be dependent on the ability to control and predict the relative 
intracellular expression levels of RISC components and potential 
therapeutics.37,54 Short hairpin RNAs (shRNA), for example, while shown in vivo 
to efficiently induce gene silencing, in long-term investigations have been found 
to cause dose-dependent liver injury and ultimately death in adult mice when 
sustained at high levels,54 and to cause dysregulation of microRNAs and 
increased tumorigenesis when marginally dosed.55 Co-expression with p19 could 
help ameliorate such toxic effects of shRNAs. In addition, CIRV p19 and other 
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RSS’s have been shown to aid in the transfection and difficult over-expression of 
alpha-, adeno-, and lentiviruses used in gene therapy and in plant based 
vaccines, through their ability to suppress the intracellular RNAi immune 
response.37 For such immunosuppression to be effective, dosing of the RSS is 
important, analogous to the use of immunosuppressants after organ transplant 
surgery. In fact, our observation that at least some miRNAs tightly bind to p19 
cautions that adverse developmental effects due to a sequestration of essential 
cellular RNAs has to be carefully avoided. Understanding and modeling relevant 
biophysical properties of RNAi processes in the presence of RSSs, as advanced 
here, is thus anticipated to become critical for a broader and safer use of RNAi 
therapeutics in human disease control.  
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Name Description (units) Determined 
From 
Value 
kcatD Catalytic Rate of Dicer (nM / h) Literature61  8.143 x 
106 
rdp Protein Degradation Rate Constant 
(h-1) 
Literature62 0.35 
rds siRNA Degradation Rate Constant  
(h-1) 
Literature62 0.029 
koff p19 Dissociation Rate Constant (h-1) Determined 
Experimentally 
223.2 
kon p19 Association Rate Constant          




n Fraction of siRNA that reenter the 
RNAi pathway 
Literature63 0.01 





1 - 100 
Cellular 
Volume 
Intracellular volume (L)  Literature62 1.4 x 10-12 
Grouped Parameters   
y RNAi Efficacy Parameter specific to 
HEK293 cells 
Literature33 1.22 
A Dicer Efficacy Parameter kcatD / rdp  2.33 x 107 
β RNAi Settling Time rds / rdp33 8.29 x10-2 
v p19 Efficacy Parameter Range 0 - 1 
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siRNA-like double-stranded RNAs are specifically protected against 




 RNA interference (RNAi), first described in the nematode C. elegans1, is a 
set of conserved post-transcriptional gene silencing pathways in eukaryotes. 
Following the first demonstration that RNAi is functional in human cells and 
receptive to using synthetic small interfering (si)RNA effector molecules2, 
significant progress has been made in harnessing the RNAi pathway for 
functional genomics and for therapies targeting previously “undruggable” genetic 
targets3, 4, 5, 6. Inside the cell, double-stranded siRNAs specifically interact with a 
number of proteins including the endoribonuclease Dicer that cleaves them from 
long precursor RNAs and steers incorporation of this product into a multiprotein 
complex referred to as the RNA-induced silencing complex (RISC). One strand of 
the siRNA duplex is retained in RISC and acts as a template for the sequence-
specific identification and site-specific cleavage of messenger (m)RNAs and 
concomitant reduction in gene expression.  
The inherent sensitivity of RNA molecules both inside and outside the cell 
towards degradation by ribonucleases motivated an immediate focus on 
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 Hoerter, J. A., Krishnan, V., Lionberger, T. A. and Walter, N. G. (2011). siRNA-like double-
stranded RNAs are specifically protected against degradation in human cell extract. PLoS One 
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and data analyses. Vishalakshi Krishnan performed Radioactivity-monitored gel electrophoretic 
analysis of RNA fragments and RISC-related RNA:protein complex formation assays (Fig 3.5). 
John A. H. Hoerter performed Nucleic acid labeling with fluorophores, Steady-state FRET assays 
of RNA degradation, RNase H1 inhibition assays and FRET-monitored gel electrophoretic 
analysis of RNA fragments (Fig 3.2, Fig 3.3, Fig 3.4, Fig 3.5). 
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development of chemically modified siRNAs that can withstand nucleolytic 
extracellular environments and reach the cellular milieu intact3. Investigationinto 
the determinants of siRNA stability have focused on extracellular stability, 
intracellular stability, and potency of silencing. First, to mimic the extracellular 
environment several groups have used blood serum and purified nucleases to 
determine the sensitivity of siRNAs to degradation. Chemical modifications were 
found to impart a considerable degree of nuclease resistance to siRNAs while 
retaining the ability to induce silencing through the RNAi pathway7, 8, 9, 10, 11, 12, 13, 
14, 15, 16, 17, 18. Furthermore, chemical modifications were found to be absolutely 
essential for systemic delivery of siRNA, both to mediate binding to serum 
proteins to increase circulating half-life and to block sites vulnerable to nuclease 
attack14,15. Only few exceptions to this tendency towards RNA-hostile 
extracellular environments exist19.  
The intracellular milieu, which is the functional environment of the siRNA, 
is the second environment to which the siRNA is exposed. By monitoring the 
expression of a target gene, several groups were able to assess the potency and 
duration of siRNA effects, including a number of studies that focused on 
determining whether chemically modified siRNAs are more potent than 
unmodified siRNAs7, 8, 9, 10, 11, 13, 16. A recent study has shown, however, that 
enhanced intracellular nucleolytic stability is not necessarily correlated with 
increased duration of the silencing effect8. In fact, the authors found that 
silencing in non-dividing cells persisted for up to one month from a single dose of 
an unmodified siRNA, suggesting that siRNAs may be quite stable inside the cell.  
Several groups have addressed questions of intracellular siRNA stability 
and localization by introducing fluorophore modified siRNAs into live cells and 
using various microscopy techniques20. siRNAs are actively exported from the 
nucleus21, except in cases where the RNA target is located in the nucleus22. 
Fluorescence fluctuation spectroscopy has been utilized in a separate study to 
assess the integrity of labeled intracellular RNAs, revealing that doubly-labeled 
RNA suitable for fluorescence resonance energy transfer (FRET) measurement 
between the fluorophores is relatively unstable in single-stranded form compared 
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to the corresponding siRNA duplex23. Intracellular FRET imaging of dsRNAs has 
also been employed to show that intact siRNA duplexes accumulate in cellular 
foci identified as P-bodies24, 25. We have used FRET labeled single-stranded 
RNAs to show that secondary structure in general attenuates degradation in 
human cell extracts26.  
The precise origin of the apparent intracellular protection of siRNAs is 
unclear. Long duration of silencing in non-dividing cells may be indicative of the 
stability of the single-stranded guide strand incorporated into RISC. Prior to RISC 
maturation, it can be assumed that some stability is derived from the decreased 
nuclease sensitivity of double-stranded RNA compared to single-stranded RNA 
23; 26. Previous intracellular fluorescence studies21, 22, 23, 24, 25 have focused, 
however, only on canonical 21-22 nucleotide (nt, per strand) siRNAs, while the 
observation that the RNAi pathway can utilize 21- to 27-nt double-stranded 
RNAs27 suggests that intracellular double-stranded RNAs are discriminated 
based on length.  
To better evaluate the potential of siRNAs in gene therapeutics, a real-
time characterization of their degradation kinetics under extracellular and 
intracellular conditions is necessary. Such an assay should include rapid and 
precise assessment of RNA stability as a function of bodily fluid, base paring 
partner, and RNA size and should eventually be amenable to high-throughput 
screening for optimizing siRNA drugs. To this end, we here have developed a 
generalizable series of RNAs modified for FRET measurements, where two 
uridines in positions 7 and 16 of the 21-nt guide strand were replaced with 
amino-modified deoxythymidines to introduce two fluorophores that undergo 
distance dependent FRET (Fig. 3.1). We varied the size of the labeled strand to 
generate double-stranded (ds)RNAs ranging from 18-24 nt per strand (while 
keeping the fluorophore distance constant, Fig. 3.1). We find that our dsRNA 
probes interact with enzymes in RNAi-active cytosolic extract from human HeLa 
cells, including RNase H1 (21-nt DNA/RNA hybrid) and Dicer (24-nt dsRNA). The 
DNA/RNA hybrid degradation by RNase H1 is quite efficient, with observed rate 
constants exceeding those for the single-stranded RNA, which is not expected to 
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be an RNase H1 substrate. Furthermore, our experimental design allows us to 
correlate the previously studied potency/size relationships for siRNAs27, 28 with a 
real-time readout of RNA stability. Our results demonstrate that 21- and 24-nt 
dsRNAs are protected in cell extract relative to the 18-nt dsRNA, potentially 
contributing to the longevity of intracellular RNAi effects. 
 
3.2 Materials and Methods 
Nucleic acid synthesis and labeling. All RNAs were synthesized by the HHMI 
Biopolymer/Keck Foundation Biotechnology Resource Laboratory at the Yale 
University School of Medicine, deprotected, TMR labeled (as necessary), and 
purified as previously described39, 40, 41. More specifically, the guide strand was 
labeled during synthesis with Fluorescein dT and Amino-Modifier C6 dT in the 
positions indicated in Fig. 3.1; the amino-modifier was subsequently coupled to 
TMR succinimidyl ester (Invitrogen), the RNA purified away from free dye by 
C18-reversed phase HPLC, and its purify checked by denaturing polyacrylamide 
gel electrophoresis39, 40, 41. Sequences are derived from the firefly luciferase gene 
and have been shown to be effective in RNAi-mediated target cleavage12, 28. All 
RNAs were purchased with a 5’ phosphate group, except for a second 
fluorophore-labeled 21-nt guide strand with a 5’ OH used for radiolabeling. The 
DNA oligonucleotides used in our studies (Sequence = VI-2, V-2, and S1-DNA)30 




Steady-state FRET assays of RNA degradation. A final concentration of 50 nM 
FL and TMR doubly-labeled RNAs was annealed either alone (single-stranded 
RNA) or with 100 nM (final concentration, in excess for saturation) of an 
appropriate DNA or RNA complement by heating to 70º C for 2 min and cooling 
to room temperature over 10 min in a standard buffer of 50 mM Tris-HOAc, pH 
7.4, 80 mM KCl, 20 mM NaCl, and 1 mM MgCl2 (chosen to mimic physiologic 
conditions). After the 10-min cooling period at room temperature, RNA solutions 
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were incubated in a circulating water bath at 37º C for 5 min before the samples 
were added to a fluorometer cuvette, also controlled at 37º C. After the initiation 
of collection of donor (F520) and acceptor fluorescence emission signal (F585) as 
described previously41, a baseline measurement was recorded for approximately 
50-100 seconds before a fraction of either HeLa S100 cytoplasmic cell extract (a 
gift from Danny Reinberg, Department of Biochemistry, Rutgers University, 
prepared and dialyzed following published protocols42), fetal bovine serum 
(Gibco), or purified Dicer (Stratagene, 2 Units) was added and the resulting 
signal evolution recorded. The FRET ratio Q (F585/(F585+F520)) was plotted over 
time t and fit where appropriate with either the single- or double-exponential form 
of the following expression to extract the observed rate constants kobs (please 
note that in case of a decreasing data curve the pre-exponential factor A is 
positive, otherwise negative): 
tktk obsobs eAeAyy 2,1, 210

  (Eq. 1) 
These assays were carried out over a range of 0-30% (v/v) HeLa cell extract and 
serum volume additions, equivalent to 0-2.5 mg/ml total HeLa protein 
(concentration measured by Bradford assay) and 0-11.1 mg/ml total serum 
protein (concentration provided by Gibco). The observed rate constants were 
plotted as a function of total protein content and fit with the following hyperbolic 









  (Eq. 2) 
In this equation, vmax is the maximal rate constant at saturation, and protein1/2 is 
the half-titration point.  
RNase H1 inhibition assays. Fluorometer assays to monitor RNase H1 
inhibition by DNA aptamers VI-2 and V-230 were conducted identically to the 
fluorometer assays described above with the following exceptions. The HeLa cell 
extract used in these assays was pre-incubated with a defined concentration of 
the pre-annealed DNA aptamer or the negative control DNA S1 for 30 min at 37º 
C before mixing with the DNA/RNA hybrid in the fluorometer. In addition, the 
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DNA/RNA hybrid was prepared in the presence of the respective aptamer or 
control DNA at a concentration equal to that in the HeLa cell extract. Again, the 
FRET Ratio Q for each trace was extracted and fit with a single-exponential 
expression as above, and the observed rate constants were plotted as a function 
of aptamer concentration and fit with the following hyperbolic binding equation 











  (Eq. 3) 
Here, vmin is the minimal rate constant reached at saturation and aptamer1/2 is the 
half-titration point.  
FRET-monitored gel electrophoretic analysis of RNA fragments. Denaturing 
gel electrophoresis was paired with FRET detection of the RNA to gain 
qualitative insight into the processing of the labeled RNAs by Dicer, cell extract, 
and serum. The doubly-labeled RNA strand was prepared at 500 nM final 
concentration in standard buffer, the complementary RNA or DNA as necessary 
added to 1 µM concentration and annealed as described above. After cooling, 
Dicer, cell extract, or serum was added as indicated and the samples were 
incubated at 37° C until the reactions were stopped by mixing with a final 
concentration of 10% (v/v) Contrad 70 at pH 9.3 (Decon Labs) as previously 
described26. For the samples of the FRET gel in Fig. 3.2C, serum was added to a 
final total protein concentration of 11.1 mg/ml for the DNA/RNA hybrid and 
dsRNA, but only 0.93 mg/ml for the ssRNA. Time points for these reactions were 
as follows: ssRNA, 1, 5, and 10 min; DNA/RNA hybrid and dsRNA, 0.5, 1 and 2.5 
h. For the samples of the FRET gel in Fig. 3.2G, HeLa cell extract was added 
throughout to a final total protein concentration of 2.49 mg/ml and time points 
were taken at 5, 10, and 20 min for the ssRNA and the DNA/RNA hybrid, while 
time points of 5, 20, and 60 min were taken for the dsRNA. The samples for the 
FRET gel in Fig. 3.4B were prepared by exposing each of the 18, 21, and 24-nt 
double-stranded RNAs to Dicer enzyme (1 unit), HeLa cell extract (2.49 mg/ml), 
or buffer alone for 200 min (3.3 h). The buffer for the HeLa and buffer only 
reactions was composed of our standard buffer supplemented with 10 mM DTT, 
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and the Dicer reactions contained the buffer supplied and recommended by the 
manufacturer whose final composition was 20 mM Tris-HCl, pH 8.0, 150 mM 
NaCl, and 2.5 mM MgCl2. The T1 and OH lanes in the gels refer to reference 
ladders using RNase T1 and alkali (OH-) digestion, respectively, prepared as 
described12 except that no carrier tRNA was added to the RNase T1 digest. For 
all reactions, 10 pmol/lane of labeled RNA was mixed with loading buffer for a 
final concentration of 1×TBE, 0.025% (w/v) bromophenol blue, and 40% (v/v) 
formamide, and the products were separated on a denaturing, 8 M urea, 20% 
(w/v) polyacrylamide gel. Fluorescence detection of the RNA was accomplished 
using a FluorImager SI fluorescence scanner with ImageQuant software 
(Molecular Dynamics) as previously described43, 44.  
Radioactivity-monitored gel electrophoretic analysis of RNA fragments and 
RISC-related RNA:protein complexes. The 21-nt non-phosphorylated, doubly-
fluorophore labeled RNA was 5’-32P labeled with T4 polynucleotide kinase (PNK) 
and -32P-ATP, mixed with loading buffer to give a final concentration of 1×TBE, 
0.025% (w/v) bromophenol blue, and 40% (v/v) formamide, and gel purified on a 
denaturing, 8 M urea, 20% (w/v) polyacrylamide gel. The radiolabeled full-length 
RNA was excised from the gel, diffusion eluted into 1 mM EDTA overnight, and 
ethanol precipitated. The dried RNA was dissolved in water.  
5’-32P labeled RNA (50,000 cpm/lane) was mixed with 50 nM non-
radiolabeled, but 5’ phosphorylated, doubly-fluorophore labeled RNA and 100 nM 
of the complementary 21-nt RNA strand, and annealed as described above in 
standard buffer. Degradation was initiated by the addition of a final total protein 
concentration of 2.49 mg/ml cell extract or 11.1 mg/ml serum at 37C. For the 
analysis in Fig. 3.5D, the assays were carried out over a range of 0-30% (v/v) 
HeLa cell extract. Time points were taken after 2, 5, 10, 20, 40, and 80 min for 
the cell extract sample and 5, 10, 20, 40, 80, 120, and 180 min for the serum 
sample. For the analysis in Fig. 3.5D, time points were instead taken 2, 5, 10, 20 
and 40 min after the addition of cell extract. All time points were quenched by 
mixing with a final concentration of 10% (v/v) Contrad 70 at pH 9.3 (Decon 
Labs)26. Loading buffer was added to a final concentration of 1×TBE, 0.025% 
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(w/v) bromophenol blue, 0.025% (w/v) xylene cyanol, and 40% (v/v) formamide, 
and the degradation products separated on a denaturing, 8 M urea, 20% (w/v) 
polyacrylamide gel. Individual bands were identified by comparison with 
sequencing ladders from partial digestion with G-specific RNase T1 and alkali as 
described45, quantified and normalized to the sum of all bands in a lane using a 
PhosphorImager Storm 840 with Image Quant software (Molecular Dynamics).  
Any error bars are derived from three independent determinations. 
For the radioactive dsRNA degradation data in Fig. 3.5D the normalized 
ratio of intact dsRNA over the sum of all bands in a lane was plotted over time t 
and fitted with a simple linear regression line to estimate the observed rate 
constant kobs: 
tkyy obs.0   (Eq. 4) 
These assays were carried out over a range of 0-30% (v/v) added HeLa 
cell extract, equivalent to 0-2.5 mg/ml total HeLa protein (concentration 
measured by Bradford assay). The observed rate constants were plotted as a 
function of total protein content and fitted as above with hyperbolic binding 
equation 2. 
The gel electrophoretic mobility shift assays of RISC-related RNA:protein 
complexes were initiated by the addition of a final total protein concentration of 
2.49 mg/ml cell extract to the annealed 5’-32P labeled RNA in standard buffer at 
4C. After 2 h incubation the reaction was stopped by mixing with non-denaturing 
loading buffer to a final concentration of 1×TBE, 0.025% (w/v) bromophenol blue 
and 0.025% (w/v) xylene cyanol and the RNA-associated complexes were 
separated by non-denaturing 4% (w/v) polyacrylamide gel electrophoresis at 4oC, 
quantified and normalized to the sum of all bands in a lane using a Typhoon 
9410 Variable Mode Imager with Image Quant software (GE Healthcare), 







We here have developed a set of fluorescein (FL) and 
tetramethylrhodamine (TMR) modified RNAs (or, more precisely, RNA-DNA 
chimeras with two 2’-deoxy modifications necessary for fluorophore labeling; Fig. 
3.1) for use in studies of intracellular and extracellular RNA stability by real-time 
FRET. To specifically address the question of how double-stranded RNAs are 
recognized as substrates by intra- and extracellular ribonucleases, we developed 
three dsRNAs (Fig. 3.1) of 18, 21, and 24 nt length that bracket the canonical 
human siRNA length and are derived from an siRNA previously developed and 
validated against the pp-luc luciferase gene12, 28. We fluorophore labeled the 
strand that dominantly acts as guide for the RNAi machinery and is antisense to 
the luciferase mRNA12, 28. We first sought to compare the degradation of these 
dsRNAs with those of the corresponding, relatively unstructured single-stranded 
RNA (ssRNA, Fig. 3.1) and its hybrid with a fully complementary DNA under our 
standard conditions of near-physiologic buffer (50 mM Tris-HOAc, pH 7.4, 80 mM 
KCl, 20 mM NaCl, and 1 mM MgCl2) at 37º C.  
Double-stranded RNA is stabilized in both cell extract and serum. To 
establish the relative degradation of a 21-nt dsRNA compared to a DNA/RNA 
hybrid and ssRNA, we applied our steady-state FRET assay to compare the 
degradation of these complexes upon the addition of 30% (v/v) of either fetal 
bovine serum (FBS) or HeLa S100 cytosolic cell extract, equivalent to 11.1 mg/ml 
total serum and 2.49 mg/ml total cellular protein, respectively. The blood serum 
contains a significant fraction of RNase A-like enzymes29, whereas the cell 
extract contains the protein components of the RNAi pathway and was previously 
tested as RNAi-active12.  
In general, a decrease in FRET ratio should be indicative of degradation of 
the labeled strand, as cleavage between the fluorophore labels is expected to 
lead to a decrease in FRET efficiency. Surprisingly, when the dsRNAs were 








Figure 3.1. Design of the single- and double-stranded RNAs used in this 
study. The sequences for the RNAs are derived from the pp-luc firefly luciferase 
gene and the corresponding siRNA previously reported12,28. The double-stranded 
RNAs consist of an identical central sequence and internal FL and TMR 
modifications, and the flanking sequences are derived from the luciferase gene. 
All dsRNAs are fully Watson-Crick base paired and contain the 2-nt 3’ overhangs 







Figure 3.2. Monitoring the degradation of ssRNAs and dsRNAs in fetal 
bovine serum and HeLa S100 cytosolic cell extract. (A) Degradation time 
course of the 21-nt dsRNA in 30% (v/v) serum, as monitored either in real-time 
by steady-state FRET (bottom) or discontinuously by radioactive labeling and 
denaturing gel electrophoretic analysis of time points (top). Solid lines represent 
double-exponential fits to both types of degradation data. In both cases the faster 
of the two rate constants are reported here and elsewhere and demonstrate good 
agreement between the FRET and radioactive assays. (B) Denaturing 
radioactive gel electrophoretic analysis corresponding to the data in panel A 
(top). RNase T1 (“T1”) and alkali (“OH”) ladders were run alongside varying time 
points of RNA degradation to identify the products. Arrows denote bands 
corresponding to positions 1, 2 (from the 5’ end), and PO4
3-. (C) Denaturing 
FRET gel revealing the serum degradation patterns of the indicated RNAs as a 
function of time, alongside RNase T1 (“T1”, leading to cleavage 3’ of G as 
indicated by arrows) and alkali (“OH”) ladders as well as a TMR-only labeled 
color calibration standard. The * denotes a double cut at both G13 and G3. (D) 
Observed degradation rate constants for the various RNAs as a function of total 
serum protein concentration, quantified from FRET time traces as exemplified in 
panel A (bottom). (E) Degradation time course of the 21-nt dsRNA in 30% (v/v) 
cell extract, as monitored either in real-time by steady-state FRET (bottom) or 
discontinuously by radioactive labeling and denaturing gel electrophoretic 
analysis of time points (top). Solid lines represent single-exponential fits to both 
types of degradation data with the respective rate constants shown, 
demonstrating good agreement between the FRET and radioactive assays. (F) 
Denaturing radioactive gel electrophoretic analysis corresponding to the data in 
panel E (top). RNase T1 (“T1”) and alkali (“OH”) ladders were run alongside 
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varying time points of RNA degradation to identify the products. Arrows denote 
bands corresponding to positions 1, 2 (from the 5’ end), and PO4
3-. (G) 
Denaturing FRET gel revealing the cell extract degradation patterns of the 
indicated RNAs as a function of time, alongside RNase T1 (“T1”, leading to 
cleavage 3’ of G as indicated by arrows) and alkali (“OH”) ladders. The * denotes 
a double cut at both G13 and G3. (H) Observed degradation rate constants for 
the various RNAs as a function of total cell extract protein concentration, 
quantified from FRET time traces as exemplified in panel E (bottom). Further 
details of the experiments are found in Materials and Methods. Reprinted with 
permission from PLOS.  
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FRET ratio, followed by a slow decrease (Fig. 3.2A). Assays using purified 
RNase A (the major type of ribonuclease present in serum) qualitatively 
reproduced this shape of the FRET ratio time trace (Appendix B, Fig. B.1). In 
cell extract, the fast phase(s) decreased significantly (Fig. 3.2E). To assess 
which phase and corresponding rate constant from the FRET traces reflect RNA 
degradation, we used 5’-32P radiolabeling of the 21-nt fluorophore-modified guide 
strand and denaturing gel electrophoretic analysis12 to determine the degradation 
rate constant independent of the real-time output of our FRET trace (Fig. 
3.2B,F). Gels were quantified for the fraction of the guide strand that was intact, 
therefore quantifying only primary cleavage events. The resulting data were 
plotted and fit with exponential functions (double-exponential increase for serum 
and single-exponential decrease for HeLa cell extract). Comparison with these 
data unambiguously identifies the relevant degradation rate constants from the 
FRET time traces as the dominant rise phases in serum and the dominant 
decrease phase in HeLa cell extract (Fig. 3.2A,E). We note that the curvatures 
and rates of the radioactively monitored decay time courses are well reflected in 
the real-time FRET time traces (despite the fact that the FRET trace in serum is 
inverted), attesting to the validity of using FRET to monitor the integrity of the 
guide strand over time. The increase in FRET particularly upon degradation in 
serum may be due to, for example, transient formation of doubly-labeled, 
(partially) single-stranded RNAs with shorter fluorophore distances. 
We next qualitatively showed by denaturing FRET gel analysis that serum 
manifests more efficient cleavage of the ssRNA compared to either the 
DNA/RNA or the dsRNA duplex (Fig. 3.2C). While the cleavage patterns of the 
DNA/RNA hybrid and dsRNA are quite similar, the cleavage pattern of the 
ssRNA is notably different. These differences include accumulation of a slight 
TMR-only band in the ssRNA sample (note the similar color to the reference 
TMR-only control lane), which indicates selective removal of the FL donor 
fluorophore. There is also significant accumulation of intermediate size (5-13 nt) 
products that are either singly TMR or FL labeled. By contrast, products smaller 
than 5 nt are almost absent from the ssRNA lanes, suggesting primarily 
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endonucleolytic, rather than 5’ exonucleolytic, decay (and/or very rapid 
degradation of smaller fragments). Some accumulation of short FL-only labeled 
products is seen upon degradation of the DNA/RNA hybrid and dsRNA, 
suggesting limited 5’ exonuclease activity.  
The degradation patterns in HeLa cell extract are markedly different (Fig. 
3.2G). Most notably, the DNA/RNA hybrid is more completely degraded in HeLa 
cell extract, whereas the ssRNA is more completely degraded in serum (compare 
with Fig. 3.2C). Another difference between serum and cell extract is the 
significant accumulation of short (<5 nt) products in the HeLa lanes, suggesting 
that these samples contain substantial detectable 5’ and 3’ exonucleolytic 
activities. The gel also shows that degradation of ssRNA by HeLa cell extract 
generates long (15-20 nt) exonucleolytic products that are not found for either the 
DNA/RNA hybrid or dsRNA (Fig. 3.2G). There is also a FL-only labeled, 
somewhat diffuse band found in all samples incubated with cell extract that co-
migrates with an ~15-nt RNA fragment (Fig. 3.2G). Given that the two 
fluorophores are attached only 8 nt apart (Fig. 3.1) this band may be evidence of 
a tight interaction of a component of the cell extract with a shorter, FL-only 
labeled fragment, leading to a band shift in the denaturing gel. 
Applying our real-time FRET degradation assay to the three fluorophore 
labeled RNA variants allowed us to determine their decay rate constants over a 
range of total protein concentrations from added serum or cell extract (Figs. 3.2 
D,H). Consistent with our qualitative observations by gel electrophoresis, the 
fastest observed rate constants are found for the decay of ssRNA in serum 
(maximum velocity at saturation, vmax= 2.7 min
-1; half-titration point FBS1/2= 0.14 
mg/ml; Fig. 3.2D). Degradation rate constants are significantly slower upon 
formation of secondary structure, as the dsRNA (vmax= 0.47 min
-1; FBS1/2= 7.7 
mg/ml) and particularly the DNA/RNA hybrid (vmax= 0.03 min
-1; FBS1/2= 0.46 
mg/ml) are less efficiently degraded. 
 The relative decay kinetics in HeLa cell extract (Fig. 3.2H) are significantly 
different from those in serum (compare with Fig. 3.2D). Here the DNA/RNA 
hybrid is most efficiently degraded (vmax= 7.4 min
-1; HeLa1/2= 7.6 mg/ml; Fig. 
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3.2H), while the ssRNA is relatively protected (vmax= 0.60 min
-1; HeLa1/2= 1.9 
mg/ml). We find that the secondary structured dsRNA is most strongly protected 
in cell extract, leading to only a slow decay (vmax= 0.02 min
-1; HeLa1/2= 0.18 
mg/ml). In both cell extract and blood serum, the formation of dsRNA thus 
protects ssRNA against nucleolytic degradation.  
 DNA/RNA hybrid is degraded by RNase H1 in HeLa cell extract. One of the 
most prominent features of our decay data is the fast degradation of the 
DNA/RNA hybrid in HeLa S100 cytosolic cell extract, contrasting with its strong 
protection in blood serum. We hypothesized that the efficient degradation of the 
DNA/RNA hybrid in cell extract results from the activity of human RNase H 
enzymes. RNase H activity degrades the RNA in a DNA/RNA hybrid and is 
important in nucleic acid processing in the cell, including in DNA replication. Two 
DNA aptamers have previously been in vitro selected for catalytic inhibition of 
human RNase H130, allowing us to specifically test for RNase H1 degradation of 
the fluorophore-labeled DNA/RNA hybrid. Fig. 3.3A shows the time evolution of 
the FRET ratio in several DNA/RNA hybrid degradation assays. In the absence 
of any added DNA or the presence of a negative control DNA, degradation is 
rapid. When the inhibitory RNase H1 aptamers VI-2 or V-2 were added, we 
observed a marked reduction in the observed decay rate constant, indicating 
specific inhibition of RNase H1 in the degradation of the fluorophore-labeled 
DNA/RNA hybrid. These experiments were repeated over a range of aptamer 
concentrations, and a dose dependent decrease in rate constant was observed 
for both aptamers (Fig. 3.3B; VI-2: initial rate constant v0= 1.35 min
-1, minimal 
rate constant at saturation vmin= 0.75 min
-1, half-titration point VI-21/2= 40 nM; V-
2: v0= 1.34 min
-1, vmin= 0.4 min
-1, V-21/2= 90 nM). These observations indicate 
that human RNAse H1 is (one of) the enzyme(s) responsible for degrading a 
DNA/RNA hybrid in HeLa cell extract. 
FRET labeled 24-nucleotide dsRNA is a Dicer substrate. Interaction with 
Dicer is one of the earliest and most crucial steps in RNAi, wherein larger 
dsRNAs are cleaved into 21-nt fragments that Dicer then loads into the RISC 







Figure 3.3. Inhibition of degradation of the doubly-labeled DNA/RNA hybrid 
in 30% (v/v) HeLa S100 cytosolic cell extract upon addition of DNA 
aptamers. (A) Steady-state FRET assays showing attenuation of degradation by 
RNase H1-specific DNA aptamers VI-2 (red) and V-2 (green) at 500 nM 
concentration. No such attenuation is observed in the absence of inhibitor 
(orange) or when 500 nM of the negative control S1-DNA is included (blue). Solid 
black lines represent single-exponential fits to the data to extract rate constants. 
(B) Rate constants of DNA/RNA degradation as a function of VI-2 or V-2 aptamer 
concentration. Solid lines are fits with a hyperbolic binding equation, revealing 
the nanomolar binding constants for the DNA aptamers reported in the text. 




Dicer, we employed both FRET assays and gel based analysis. First, we 
collected steady-state FRET time traces for our 18-, 21-, and 24-nt dsRNAs upon 
addition of purified human Dicer (Fig. 3.4A). While the traces for the 18- and 21-
nt dsRNAs hold steady over more than 30 min incubation time, the trace of the 
24-nt dsRNA significantly increases, suggestive of an interaction with Dicer (Fig. 
3.4A). Next, we incubated the three dsRNAs with either human Dicer or HeLa 
cell extract for 200 min and analyzed the degradation products on a denaturing 
FRET gel (Fig. 3.4B). As expected, the 24-nt dsRNA is processed by Dicer to the 
mature 21-nt siRNA. In HeLa cell extract, the 18-nt dsRNA exhibits a slightly 
stronger degradation band at ~7 nt length than either the 21- or 24-nt dsRNAs, 
but with that exception the lanes are quite similar. We only observed a weak 21-
nt Dicer-derived cleavage band in the 24-nt dsRNA lane, suggesting that 
processing by Dicer under these conditions in cell extract is slow, perhaps 
because the incorporation into Dicer containing protein complexes is modest for 
our fluorophore-labeled dsRNAs (see also Fig. 3.5E and corresponding 
discussion below). Overall, degradation is slow over the 200 min incubation and 
seems common to all dsRNAs in HeLa cell extract, generating the diffuse, FL-
only band that co-migrates with an ~15 nt RNA fragment and is also observed in 
Fig. 3.2G.  
21- and 24-nucleotide dsRNAs are protected in cell extract. Next, we 
employed our steady-state FRET assay to the 18-, 21-, and 24-nt dsRNAs and 
extracted the rate constants from the time traces that were identified in Fig. 3.2 
as reflective of the RNA degradation kinetics (the rising phase in fetal bovine 
serum and the decreasing phase in HeLa extract, Fig. 3.5). The results from 
serum (Fig. 3.5B) show that the degradation rate constants progressively 
decrease with length of the dsRNA (18-nt dsRNA: vmax= 1.2 min
-1, Serum1/2= 4.5 
mg/ml; 21-nt dsRNA: vmax= 0.47 min
-1, Serum1/2= 7.7 mg/ml; 24-nt dsRNA: vmax= 
0.09 min-1, Serum1/2= 1.7 mg/ml). This trend correlates with the increasing 
distance of the fluorophores from the ends as well as the higher thermodynamic 
stability of the longer duplexes (Fig. 3.1). By comparison, the decay rate 








Figure 3.4. Processing of doubly-labeled dsRNAs of varying length by HeLa 
S100 cytosolic cell extract and purified human Dicer. (A) Steady-state FRET 
time traces of 18-, 21-, and 24-nt dsRNAs as indicated upon Dicer addition; only 
the 24-nt dsRNA time trace slightly increases. (B) Denaturing FRET gel revealing 
the degradation patterns of the 18-, 21-, and 24-nt dsRNAs (from left to right in 
each triplet of bands) as a function of time, alongside RNase T1 (“T1”, leading to 
cleavage 3’ of G as indicated by arrows on the left) and alkali (“OH”) ladders. “-“ 
indicates incubation in buffer only, while the last two triplets of bands show 
samples incubated in HeLa cell extract and purified Dicer enzyme, respectively. 










Figure 3.5. Degradation kinetics of 18-, 21-, and 24-nt dsRNAs in fetal 
bovine serum and HeLa S100 cytosolic cell extract. (A) Steady-state FRET 
time traces upon degradation of 18-, 21-, and 24-nt dsRNAs (red, green, and 
blue respectively) in serum. The solid black lines represent double-exponential 
fits to the data, the fast rate constants of which are reported in panel B. (B) The 
resulting rate constants of degradation of the 18-, 21-, and 24-nt dsRNAs in 
serum plotted as a function of total serum protein concentration. Solid lines 
indicate fits with a hyperbolic binding equation. (C) Steady-state FRET time 
traces upon degradation of 18-, 21-, and 24-nt dsRNAs (red, green, and blue 
respectively) in cell extract. The solid black lines represent single-exponential fits 
to the data, the rate constant of which are reported in panel D. (D) The rate 
constants of degradation, derived from steady-state FRET (solid circles, left y-
axis) and radioactive assays (open circles, right y-axis) of the 18-, 21-, and 24-nt 
dsRNAs (red, green, and blue respectively) in cell extract and plotted as a 
function of total cell extract protein concentration. Solid lines indicate fits of the 
FRET-derived data with a hyperbolic binding equation. (E) Formation of 
complexes D, C2 and C1 after 2 h of incubation with radiolabeled 21-nt dsRNA 
with no modification (lane 1), 18-nt dsRNA (lane 2), 21-nt dsRNA (lane 3) and 
24-nt dsRNA (lane 4) in HeLa cytosolic extract. Lanes 5-8 represent the 
respective negative controls in the absence of cell extract with the dsRNAs in the 
same order from left to right. Normalized fractions in percent are indicated for 
each boxed band; * indicates an unknown complex. Reprinted with permission 
from PLOS. 
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  the FRET-based assays (filled circles in Fig. 3.5D, left y-axis) and even more so 
using 5’ 32P-labeled, fluorophore-labeled dsRNAs (open circles in Fig. 3.5D, right 
y-axis), measured in a less accurate, discontinuous radioactive assay where 
aliquots were taken periodically and decay products analyzed by denaturing gel 
electrophoresis as in Fig. 3.2. Steady-state FRET assays revealed that the 18-nt 
dsRNA is the most rapidly degraded of the three RNAs (vmax= 0.09 min
-1, 
HeLa1/2= 0.70 mg/ml). In contrast to the serum result, the 21- and 24-nt dsRNAs 
exhibit the same low vmax values, signifying that they are degraded at about the 
same rate in cell extract (21-nt dsRNA: vmax= 0.02 min
-1, HeLa1/2= 0.02 mg/ml; 
24-nt dsRNA: vmax= 0.02 min
-1, HeLa1/2= 0.17 mg/ml). The same trend was 
observed using the 5’ 32P-radiolabeled dsRNAs (18-nt dsRNA: vmax= 0.011 min
-1, 
HeLa1/2= 0.68 mg/ml; 21-nt dsRNA: vmax= 0.0031 min
-1, HeLa1/2= 0.3 mg/ml; 24-
nt dsRNA: vmax= 0.0032 min
-1, HeLa1/2= 0.29 mg/ml). These results suggest that 
the size dependence of the protection of dsRNA from decay in cell extract is 
distinct from that in serum. It should be noted that we also observed that the 
deoxythymidine and fluorophore modifications offered a general, modest 
protection to the RNAs, as may be expected (data not shown).  
Longer fluorophore labeled RNAs are more efficiently assembled into 
RISC-related complexes. To investigate the ability of the fluorophore labeled 
18-, 21-, and 24-nt dsRNAs to form protein complexes upon incubation with 
HeLa cell extract we performed gel electrophoretic mobility shift assays under 
non-denaturing conditions to identify such complexes based on a modified RISC 
assembly assay (Fig. 3.5E)35. Characteristic RISC-related RNA:protein 
complexes D (Retention factor, Rf: 0.2), C2 (0.4) and C3 (0.5) were observed, 
similar to those found previously using the unmodified 21-nt dsRNA35. Complex 
D in particular is known to contain Dicer35, 36. We observed that the fraction of the 
fluorophore-labeled 32P-labeled RNAs incorporated into Complex D is less than 
that of 32P-labeled 21-nt dsRNA devoid of any modification, consistent with the 
slow processing of 24-nt dsRNA by Dicer (Fig. 3.4B), whereas complexes C1 
and C2 are more highly populated (Fig. 3.5E). Importantly, the fraction of 18-mer 
dsRNA incorporated into any of these complexes is significantly less than those 
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of either the 21-mer or 24-mer dsRNA, which may explain the comparatively 
lesser protection of the 18-mer relative to the 21-mer and 24-mer dsRNAs in 
HeLa cell extract. 
 
3.4 Discussion 
Potent and specific induction of mRNA degradation by siRNAs is a key 
determinant for harnessing RNAi in reverse genetic studies and therapeutic 
applications. It remains unclear, however, just how stable siRNAs are inside the 
cell. We have previously shown the decreased nuclease sensitivity of dsRNA 
compared to ssRNA in human HeLa cytosolic cell extracts26, and recent work has 
employed FRET fluctuation spectroscopy to demonstrate this trend inside cells23. 
We here have established real-time assays to measure degradation profiles and 
kinetics for small, RNAi-related RNAs in both blood serum and RNAi-active 
cytosolic cell extract. We show that FRET-labeled RNAs interact with relevant 
cellular enzymes including RNase H1 and Dicer. A DNA/RNA hybrid is strongly 
protected in serum, but rapidly degraded by RNase H1 in cell extract. 21- and 24-
nt double-stranded RNAs are equivalently protected in HeLa cell extract, but 
degraded considerably faster in blood serum with their relative decay rate 
constants correlating with their relative lengths. Given that the 24-nt dsRNA is a 
substrate of human Dicer and the 21-nt dsRNA its product, these results suggest 
that RNAs that are involved in RNAi are specifically protected in the cellular 
milieu. Our observations may thus explain the relative longevity of intracellular 
RNAi effects induced even by chemically unmodified siRNAs8. 
As expected, dsRNAs are more stable against nucleases than the 
corresponding ssRNA in both HeLa cell extract and blood serum (Fig. 3.2). 
These results are consistent with the relative stiffness of the RNA duplex, 
stabilizing the phosphodiester and ribose torsion angles in conformations less 
amenable to the in-line attack conformation needed by ribonucleases such as the 
RNase A-like enzymes dominant in serum29, 37. Hybridization to a DNA further 
stabilizes the RNA component in blood serum, perhaps due to perturbation of the 
A-form helical structure or lack of 2’-OH functionality on an entire strand of the 
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duplex. By contrast, in cell extract the DNA/RNA hybrid is rapidly degraded by 
RNase H1, as shown by enzyme-specific inhibition by two in vitro selected DNA 
aptamers30 (Fig. 3.3). In human cells, a second, disparate, multi-subunit enzyme, 
termed RNase H2, has been characterized that degrades DNA/RNA hybrids38. 
This may be the enzyme that causes the residual DNA/RNA decay upon maximal 
inhibition of RNase H1 (Fig. 3.3). 
The size range of the dsRNAs we tested for their stability in serum and 
cell extract was chosen to bracket the specific 21-nt size of siRNAs in human 
cells. dsRNAs larger than ~21 nt are cleaved by human Dicer into siRNAs during 
the initial step of RNAi, as observed here for the 24-nt dsRNA, followed by 
incorporation into the RISC-loading complex (RLC), comprising the proteins 
Dicer, Ago2, and TRBP33, 34. Since cellular delivery of 21-nt siRNAs induces 
RNAi, albeit not as effectively as does delivery of Dicer substrates27, both types 
of dsRNAs must be interacting with the components of the RNAi machinery, in 
contrast to shorter dsRNAs. The similar protection of 21- and 24-nt dsRNAs in 
our assays relative to the corresponding 18-nt dsRNA (Fig. 3.5) is consistent with 
these findings. In addition, the fraction of 18-mer dsRNA incorporated into RISC-
related protein complexes is significantly less than those of either the 21-mer or 
24-mer dsRNAs (Fig. 3.5E).  This result suggests that the comparatively faster 
degradation rate of the 18-mer versus the 21-mer and 24-mer dsRNAs may be 
linked to the existence of protective RNA:protein complexes in HeLa cell extract 
preferably for the longer dsRNAs. By contrast, the efficiency of dsRNA 
degradation in blood serum monotonically decreases with increasing RNA size, 
that is, with distance of the FRET fluorophores from the ends and overall 
thermodynamic stability of the duplex (Fig. 3.5). These observations are in line 
with the known properties of RNase A, where the limiting step of enzyme action 
on dsRNA substrates is invasion of the duplex to access an in-line attack 
conformation and cleave the RNA backbone37.  
 In summary, our results are consistent with established steps in the RNAi 
pathway where dsRNAs of ~21 nucleotides per strand are bound by the RLC or 
other RNAi components and remain largely hidden from nucleolytic decay either 
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as the base-paired siRNA duplex or as the single guide strand processed into 
active RISC. The real-time in vitro FRET assays established here open up the 
possibility for future high-throughput screening of the nucleolytic stability of 
additional chemically modified RNAi effector molecules. 
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Compositional discrepancies in cell extracts facilitate different modes of 




 RNA interference (RNAi) and RNA silencing are a pair of key intracellular 
gene regulatory mechanism guided by small exogenous and endogenous 
ncRNAs known as short interfering RNAs (siRNAs) and microRNAs (miRNAs)1, 2, 
3, respectively. Exogenous siRNAs or long double-stranded RNAs (dsRNAs) are 
interpreted as invading gene elements by cells and trigger the cellular defense 
mechanism called RNAi4. Within the cell, these long dsRNAs are processed into 
mature siRNA duplexes by complexes containing the endoribonuclease Dicer 
(Dcr). These siRNA duplexes are subsequently loaded into an effector RNA 
Induced Silencing Complex5 (RISC) that contain RNase-H type Argonaute (Ago) 
proteins6; then, the two strands are unwound, and RISC is guided by the one 
retained RNA strand to cleave a complementary target RNAs in a sequence 
dependent manner2, 3.  
 Although it has been demonstrated that a minimal human RISC, 
containing just Dcr, TRBP (TAR RNA binding protein) and Ago2, mediates 
                                                          
5
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siRNA-guided RNA cleavage7, 8, several other Ago associated proteins have 
been shown to enhance RISC activities9. These proteins include Heat-shock 
protein 90 (Hsp90), GW182, RNA Helicase A (RHA) and Moloney leukemia virus 
10 (MOV10) protein. Hsp90 is a 90 kDa ubiquitous molecular chaperone that 
regulates the function or turnover of a specific subset of signaling proteins, cell 
cycle regulators, and apoptotic factors10. Hsp90 is required for Ago2 to bind the 
siRNA duplex; it has also been shown to be responsible for the transfer of siRNA 
duplexes from the RISC loading complex (RLC) to RISC and the unwinding of 
siRNA duplex to single-stranded siRNAs in Drosophila, possibly by mediating 
conformational rearrangement of the Ago2 protein11. In mammals, it was shown 
that Hsp90 binds the N-terminus of Ago2 and is needed for interaction between 
Ago2 and Dcr12, suggesting a potential role for Hsp90 in converting RLC into 
RISC. Additionally, Hsp90 activity has been shown to be essential for the stability 
of non-RNA bound Ago2 proteins, Processing bodies (P-bodies) and GW182 (P-
Body marker)13, as well as for the efficient targeting of Ago2 to P-bodies and 
stress granules14. Besides its role in siRNA loading and the efficient utilization of 
exogenous siRNA, Hsp90 also plays a significant role in miRNA loading13. It has 
been shown to affect the function of Ago2, and therefore RISC activity in both 
siRNA and miRNA mediated sequence-specific cleavage and gene regulation, 
respectively14. GW182, a 182-kDa core P-body component that is imperative for 
P-body integrity, is another protein that interacts with Ago and is required for both 
miRNA mediated translational repression of mRNAs15 and siRNA mediated 
mRNA decay16. GW182 interacts with the miRNA bound Ago2 through the N-
terminal GW repeats17 and the CCR4-NOT deadenylase complex through C-
terminal-conserved W motifs18, thereby linking the miRNA pathway to mRNA 
degradation. Recent studies have proposed a new role for GW182 in regulating 
stability of Ago-bound miRNAs where the interaction of the N-terminal region of 
GW182 with the miRNA-Ago complex inhibits the activity of an 3′–5′ 
exoribonuclease complex responsible for miRNA degradation19. 
 Ago has been observed to interact with a few helicases such as MOV1020 
and RHA21 whose role in the RNA silencing pathway is still under investigation. 
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MOV10 is a 130-kDa DExD-box helicase which, similar to Ago, was observed to 
localize to P-bodies20. MOV10 is an ortholog of Armitage, found in Drosophila 
melanogaster, which was suggested to be involved in the incorporation of single 
stranded siRNA into RISC22. The MOV10 protein is required for small RNA 
guided mRNA cleavage and has been shown to interact with mature-miRNA 
containing protein complexes functioning downstream of the Dicer cleavage step 
observed in Drosophila20. PAR-CLIP data, which capture transient interactions of 
RNAs with partner proteins, indicate that MOV10 mostly localizes to the 3' 
untranslated region of the mRNA and significantly overlaps with Ago2 binding 
sequences, suggesting that MOV10 and AGO2 bind to the same positions on the 
RNA23. It was also demonstrated that the interaction between MOV10 and Ago2 
is RNA dependent,23 however, the exact function of MOV10 in the RNA silencing 
pathway is still unclear. RHA is a 142 kDa DEAH-box protein that was found to 
interact specifically with active RISC21. RHA, similar to maleless, its ortholog in 
Drosophila24, is hypothesized to play an important role in transcriptional 
regulation of genes. RHA has been shown to be required for the recruitment of 
siRNAs into Ago2 (RISC loading) containing complexes and formation of active 
RISC, where it may function in RISC loading by inducing the remodeling of the 
RLC21. Although it was shown to have the ability to unwind RNA duplexes21, the 
specific protein(s) responsible for passenger strand removal remain a mystery.  
 Despite our expanding knowledge in this field, the full composition of RISC 
remains unknown.  Although active RISCs of varying sizes ranging from ~160-
500 kDa have all been shown to cleave mRNA targets7, 25, 26, it is still unknown if 
these complexes represent the complete RISC or if they just contain the core 
proteins responsible for the RNAi activity. Much of this complexity we believe 
arises from the lack of a standard system of study for understanding the RNAi 
pathway. The research present here describes the systematic differences 
observed in the RNAi pathway when using two different preparations of HeLa cell 
extract, i.e., S100 cytoplasmic extract27 and translationally active whole cell 
extract, both of which have been used interchangeably in the field as a model 
system to probe RNAi. Additionally, we found that MOV10 is required for the 
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RNA silencing machinery to utilize siRNA duplexes and mediate target mRNA 
cleavage.  
 
4.2 Materials and Methods 
Nucleic acid synthesis. siRNAs were synthesized by the HHMI 
Biopolymer/Keck Foundation Biotechnology Resource Laboratory at the Yale 
University School of Medicine, then deprotected and purified as previously 
described.28, 29 siRNA sequences were derived from the firefly luciferase gene30 
and were as follows: sense strand (21-mer) 5´-P-CGU ACG CGG AAU ACU 
UCG AAA-3´; antisense strand (21-mer) 5´-P-UCG AAG UAU UCC GCG UAC 
GUG-OH-3´; sense strand (32-mer) 5'-P- CAU CAC GUA CGC GGA AUA CUU 
CGA AAU GUC CG-OH-3'; antisense strand (32-mer) 5'-P- GAC AUU UCG AAG 
UAU UCC GCG UAC GUG AUG UU-OH-3', where P denotes a 5´-phosphate, 
and OH denotes a 3' hydroxyl. Both 5' phosphorylated and unphosphorylated 
versions of the 21-mer were purchased. 
P32 labeling of 21-mer and 32-mer RNAs. The non-phosphorylated, antisense 
strand was 5’-32P labeled with T4 polynucleotide kinase (PNK- NEB) and -32P-
ATP, mixed with loading buffer to give a final concentration of 1×TBE, 0.025% 
(w/v) bromophenol blue, and 40% (v/v) formamide, and gel purified on a 
denaturing, 8 M urea, 20% (w/v) polyacrylamide gel. The radiolabeled full-length 
RNA was excised from the gel, diffusion eluted into 1 mM EDTA overnight, and 
ethanol precipitated. The dried RNA was dissolved in water. For radiolabled 
siRNA duplexes, the non-phosphorylated antisense strand was first 5´-32P 
labeled with T4 polynucleotide kinase (PNK- NEB) and -32P-ATP. PNK was 
inactivated by heating to 65 C for 20 min, then the 5´ phosphorylated 
complementary strand was added in 1.5-fold molar excess and the reaction was 
heated to 90 C for 3 min and slowly cooled to room temperature ( or incubated 
37 C for 1 hr ) to anneal the two strands. The siRNA duplex was mixed with 
loading buffer to give a final concentration of 10% glycerol, 1×TBE and 0.025% 
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(w/v) bromophenol blue and further purified by nondenaturing, 20% (w/v) 
polyacrylamide gel electrophoresis. The duplex siRNA was cut out, eluted 
overnight into 1 mM EDTA at 4 oC, ethanol precipitated, and dissolved in RNase-
free water. Scintillation counting was done on a Beckman LS6500 Multipurpose 
Scintillation Counter. 
Target mRNA synthesis and labeling with P32. The target luciferase mRNA 
was synthesized as described31, but with the following modifications. PCR 
amplification of the pGEM-luc plasmid (Promega) using the Taq 2X Master Mix 
(NEB) and the following primers, Forward: GGCATAAAGAATTGAAGA and 
Reverse: GCGTAATACGACTCACTATAGGAACAATTGCTTTTACAG, resulted 
in a 181 bp PCR product containing an upstream T7 RNA polymerase promoter 
sequence for transcription. The PCR product was then in vitro transcribed using 
transcription reaction mixture containing 40 mM Tris-HCl (pH 7.5), 15 mM MgCl2, 
5 mM dithiothreitol (DTT), 2 mM spermidine, NTPs (4 mM each), 5 units/mL 
inorganic pyrophosphatase, and 0.1 mg/mL T7 RNA polymerase [purified in the 
His-tagged form from an overexpressing strain as described previously31] and 
incubated at 37 °C for 4 hrs. The 161 nt long full length transcript was mixed with 
loading buffer to give a final concentration of 1×TBE, 0.025% (w/v) bromophenol 
blue, and 40% (v/v) formamide, and extracted from a denaturing, 8 M urea, 20% 
(w/v) polyacrylamide gel electrophoresis by UV shadowing, diffusion elution of 
small gel slices into 1 mM EDTA, and ethanol precipitation. The dried RNA was 
dissolved in water and stored at -20 °C until further use. The purified target 
luciferase mRNA was 5'-cap P32 labeled using α-P32-GTP and 
guanylyltransferase enzyme (ScriptCap Capping enzyme from Epicenter) as 
recommended by the supplier. Cap labeled RNA was mixed with loading buffer to 
give a final concentration of 1×TBE, 0.025% (w/v) bromophenol blue, and 40% 
(v/v) formamide, and purified on a denaturing, 8 M urea, 15% (w/v) 
polyacrylamide gel. The RNA was excised, eluted into 1 mM EDTA at 4°C 
overnight, ethanol precipitated, and dissolved in water. 
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Cell Extracts. S100 cytosolic HeLa cell extract was obtained from Jena 
Biosciences, whereas translationally active HeLa whole cell lysate was obtained 
from ThermoScientific. Although the steps involved in the preparation of these 
extracts are different, in the final step of their preparation the extracts are 
dialyzed against buffers containing similar ionic strength, thus reducing the risk of 
ionic strength causing disparities in our comparative analysis. The S100 cytosolic 
HeLa cell extract contains 20 mM Tris-HCl, pH 7.9, 100 mM KCl, 0.2 mM EDTA, 
1 mM DTT, 20% glycerol and the HeLa whole cell lysate contains 20 mM Hepes–
KOH pH 7.5, 135 mM potassium acetate, 30 mM KCl, and 1.65 mM magnesium 
acetate. The ionic concentrations of these extract when used in the activity 
assays are comparable upon addition of the respective reaction buffers 
mentioned below.  
Western Blot Analysis. For denaturing Western blots, the S100 cytosolic HeLa 
cell extract and the HeLa whole cell lysate were run on a NuPAGE Novex 4-12% 
gradient Bis-Tris Gel in the presence of a molecular weight marker (ECL Plex 
Rainbow marker). The gel was then electroblotted in Tris-Glycine buffer (25 mM 
Tris, 192 mM Glycine, and 20% (v/v) Methanol) onto a Polyvinylidene Fluoride 
(PVDF) membrane (Immobilon-P Membrane, Millipore) over 75 min at 300 mA, 
using a Bio-Rad Trans-Blot SD semi-dry transfer cell per the manufacturer’s 
instructions. After transfer the membrane was probed with one of these 
antibodies: rabbit anti-Dicer (Santa Cruz Biotechnology), mouse anti-TRBP 
(Abnova), mouse anti-Ago2 (Abnova), mouse anti- GW182 (Santa Cruz 
Biotechnology), rabbit anti-MOV10 (Proteintech), rabbit anti-RHA (Vaxron), and 
mouse anti-Hsp90 (Enzo life sciences). Mouse anti-beta actin or rabbit anti-beta 
actin was used as a loading control for each of these westerns. The incubation 
with the primary antibody was followed by goat anti-Rabbit-Cy5 and goat anti-
mouse-Cy3 (both Amersham), respectively. The probed blots were visualized on 
a Typhoon 9410 Variable Mode Imager (GE Healthcare Life Sciences) and 
quantified using Image Quant software (Molecular Dynamics).  
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Dicing assay. Radiolabeled 32 nt long double stranded substrates(40000cpm, 
~300pM) was incubated with 40% (v/v) of either HeLa S100 extract or HeLa 
whole cell lysate, 25 mM creatine phosphate, 5 mM DTT, 10 mM HEPES, 150 
mM potassium acetate, 0.3 mg/mL Pefabloc SC, 20 ug/mL creatine kinase, 0.8 
U/uL RNasin and 10% (v/v) glycerol in a final volume of 10 uL. The reaction also 
contains 1mM ATP and 3 mM Magnesium Acetate unless otherwise stated. The 
entire reaction was incubated at 37 °C for 1 hr. The reaction was stopped by 
heating to 65 °C for 15 min and mixed with loading buffer to a final concentration 
of 1×TBE, 0.025% (w/v) bromophenol blue, and 40% (v/v) formamide, and 
analyzed on a denaturing, 8 M urea, 20% (w/v) polyacrylamide gel. Gels were 
then wrapped in plastic wrap and exposed to phosphor screens, which were 
scanned on a Typhoon 9410 Variable Mode Imager (GE Healthcare Life 
Sciences) and quantified using Image Quant software (Molecular Dynamics).  
Slicing assay and ATP depletion. For the slicing assays, 100 nM non 
radiolabeled siRNA duplex (21-mer) was preincubated with 40% (v/v) of either 
HeLa S100 extract or HeLa whole cell lysate, 25 mM creatine phosphate, 5 mM 
DTT, 10 mM HEPES, 150 mM potassium acetate, 0.3 mg/mL Pefabloc SC, 20 
ug/mL creatine kinase, 0.8 U/uL RNasin and 10% (v/v) glycerol in a final volume 
of 10 uL at 4 °C for 15 min. The reaction also contains 1mM ATP and 3 mM 
Magnesium Acetate unless otherwise stated. The reaction was then warmed to 
37 °C for 15 min, 40000cpm (~300pM) of radiolabeled target luciferase mRNA 
was added and the reaction was further incubated at 37 °C for 30 min. A time 
course of the slicing assay was performed to obtain the time at which target 
mRNA cleavage was maximal. The reaction was stopped by heating to 65 °C for 
15 min and mixed with loading buffer to a final concentration of 1×TBE, 0.025% 
(w/v) bromophenol blue, and 40% (v/v) formamide, and analyzed on a 
denaturing, 8 M urea, 20% (w/v) polyacrylamide gel. Gels were then wrapped in 
plastic wrap and exposed to phosphor screens, which were scanned on a 
Typhoon 9410 Variable Mode Imager (GE Healthcare Life Sciences) and 
quantified using Image Quant software (Molecular Dynamics). For ATP depletion 
experiments, ATP, creatine phosphate, and creatine kinase were omitted and 
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ATP in extract was depleted by incubating the extract with 25 mM glucose and 
0.5 units per μl hexokinase for 30 min at 15 °C. Lysis buffer instead of 
hexokinase was used for mock-treated samples. We substituted ATP with EDTA 
for the –ATP condition to normalize the free Mg2+ concentration and added 
equimolar concentration of Mg2+ for the excess ATP conditions.  
 
4.3 Results 
HeLa S100 cytosolic extract and HeLa whole cell lysate are viable for 
studying RNAi. We first confirmed that S100 cytosolic HeLa extract and HeLa 
whole cell lysate, as previously described30, 37, contain Dcr, TRBP and Ago2 (Fig. 
4.1a), the three protein components required for formation of minimal RISC. The 
process of cleaving (dicing) long RNA duplexes into mature siRNA/miRNA32, 33, 34 
and the cleavage (slicing) of target mRNA by RISC containing guide strand (the 
single-stranded guide also known as anti-sense strand)35, 36 are key established 
and characteristic steps of the RNAi pathway. We therefore showed that both 
S100 cytosolic HeLa extract and HeLa whole cell lysate can perform both dicing 
and slicing (Fig. 4.1b, c), by employing a segment of luciferase mRNA that has 
been used in previous studies30, thereby confirming that the core RISC 
components are functional. We also showed that the HeLa S100 cytosolic extract 
and HeLa whole cell lysate cleave a long dsRNA dicer substrate to the same 
extent to form a mature 21-nt long siRNA duplex, suggesting no difference in the 
dicing activity of both the extracts (Fig. 4.2).    
Single-stranded siRNAs are incorporated into RISC more efficiently than 
siRNA duplexes in HeLa S100 cytosolic extract, but the opposite is true for 
HeLa whole cell lysate. S100 cytosolic HeLa extract has been previously used 
to demonstrate the ability of single-stranded antisense siRNAs to guide target 
mRNA cleavage30. When we use similar conditions in our slicing assays with 
HeLa S100 cytosolic extract, we observed that target mRNA cleavage achieved 
with single stranded antisense guide strand was approximately 5- to 10-fold more 
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efficient than that obtained using siRNA duplexes (Fig. 4.3b). This is contrary to 
a report that single-stranded siRNAs are less effective and require 10- to 100-fold 
higher concentrations than siRNA duplexes27. Our results are in concordance 
with previous work, however, which reported that rabbit reticulocyte lysate also 
lacks the ability to load siRNA/miRNA duplexes into RISC/miRNP unless the 
si/miRNA is preheated and preannealed to the mRNA before addition to 
extract37. In contrast, slicing assays performed with HeLa whole cell lysate 
showed that the extent of target mRNA cleavage obtained using the duplex 
siRNA was ~10-fold greater than that seen with single-stranded antisense siRNA 
(Fig. 4.3a), supporting the notion that siRNA duplexes are required for formation 
of mature and active RISC32, 35, 36. We also observed that supplementing the 
slicing assays performed with HeLa S100 cytosolic extract with increasing 
amounts of HeLa whole cell lysate enhanced the ability of the HeLa S100 
cytosolic extract to utilize siRNA duplexes more efficiently to cleave 
complementary target mRNA (Fig 4.4). Thus, the inability of the HeLa S100 
cytosolic extract to utilize siRNA duplex may be due to the lack of potential RISC 
loading factor(s).  
MOV10 and RHA may have a potential role in loading siRNA duplexes into 
Ago. To address the question of why siRNA duplexes are utilized better in HeLa 
whole cell lysate compared to HeLa S100 cytosolic extract, we analyzed the 
protein of both extracts. In particular, we performed quantitative Western blot 
analyses of both cell extracts for known Ago2 interacting proteins that include 
Hsp90, GW182, RHA, MOV10, Dcr and TRBP with beta-actin as loading control 
(Fig. 4.5). Whereas the amount of Ago2, GW182 and TRBP present in both 
extracts are comparable, Dcr, RHA and MOV10 are significantly enriched in 
HeLa whole cell lysate compared to HeLa S100 cytosolic extract. More 
specifically, Dcr and RHA are present in 2- to 4-fold excess and MOV10 in >10-
fold excess in HeLa whole cell lysate compared to S100 cell extract. It is 
noteworthy that MOV10 and RHA are both helicases that have been previously 




Figure 4.1. HeLa whole cell lysate and HeLa S100 cytoplasmic extract are 
sutiable systems for studying RNAi. (a) Denaturing Western blot analyses of 
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extracts shows the presence of Dcr, Ago and TRBP in both HeLa whole cell 
lysate(W) and HeLa S100 cytoplasmic extract(S). (b) Dicing assay showing the 
ability of both W and S to cleave a 32 nt long radiolabeled RNA duplex to a 21 nt 
long mature siRNA duplex. The hyrodxyl (OH) ladder and the RNaseT1 (T1) 
ladder were prepared as described48. Lanes 3 and 4 show slicing activity with S 
and W respectively. Lane 5 is a control with no extract added to the reaction. (b) 
Slicing assay showing the ability of both W and S to cleave a 161 nt long 
radiolabeled target mRNA to a 52 nt long cleaved product. The RNaseT1 (T1) 
ladder were prepared as described48. Lanes 2 and 3 show slicing activity with S 








Figure 4.2. HeLa whole cell lysate and HeLa S100 cytoplasmic extract 
exhibit similar dicing activity. A graphical representation of the normalized and 
averaged fraction of cleaved 21-nt long RNA duplex over full length dsRNA 
substrate for dicing activity by HeLa whole cell lysate (HeLa W) and HeLa S100 





Figure 4.3. HeLa whole cell lysate and HeLa S100 cytoplasmic extract 
utilize single stranded antisense siRNA and siRNA duplexes to variable 
extents to mediate target mRNA cleavage. A graphical representation of the 
normalized and averaged fraction of cleaved target mRNA product over full 
length target mRNA for slicing activity by (A) HeLa whole cell lysate (HeLa W) 
and (B) HeLa S100 cytoplasmic extract (HeLa S). The gray and black bars 
indicate siRNA duplex (ds) and single stranded antisense siRNA (ss) mediated 








Figure 4.4. Addition of HeLa whole cell lysate enhances ds-siRNA mediated 
silencing activity in HeLa S100 cytoplasmic. A graphical representation of the 
normalized and averaged fraction of cleaved target mRNA product over full 
length target mRNA for slicing activity mediated by different ratios of HeLa whole 
cell lysate (HeLa W): HeLa S100 cytoplasmic extract (HeLa S) present in 








Figure 4.5. Quantitative Western blot analyses of Ago associated proteins 
in HeLa whole cell lysate and HeLa S100 cytoplasmic. (a) Denaturing 
Western blot analyses of extracts using antibodies against Dcr, Ago, TRBP, 
RHA, Hsp90, GW182 and MOV10 in both HeLa whole cell lysate(W) and HeLa 
S100 cytoplasmic extract(S). Beta- Actin was used as a loading control. (b). 
Graphical representation of the normalized and averaged ratio of protein of 
interest over beta-actin. The black and gray bars represent HeLa whole cell 




to have a potential role in strand unwinding and loading of siRNA duplex into 
Ago220, 21.  
ATP has an inhibitory effect on target mRNA cleavage mediated by single-
stranded antisense siRNA in HeLa S100 cytosolic extract. It has been 
previously reported that ATP drives RISC assembly and is required for efficient 
loading of small-RNA duplexes into AGO proteins but not for subsequent 
unwinding of siRNAs37. To investigate if addition of ATP had an effect on the 
ability of HeLa S100 cytosolic extract to utilize siRNA duplexes for RNAi, we 
performed slicing assays with extracts supplemented with ATP (Fig. 4.6a). 
Addition of ATP has an inhibitory effect on target mRNA cleavage mediated both 
by single-stranded antisense siRNA and siRNA duplex (Fig. 4.6a). Furthermore, 
completely depleting ATP from the extract led to enhanced cleavage activity (Fig. 
4.6b). This is contrary to previous reports that suggested that ATP-dependent 
RISC loading and helicase activities are required for subsequent ATP-
independent target mRNA cleavage39, 40.   
 
3.4 Discussion 
 The potential of the RNAi pathway to utilize exogenous genetic material to 
activate sequence specific regulation of gene expression has been exploited 
extensively in functional genomics and therapeutic applications. Although RNAi 
has found several applications, the mechanistic details of the pathway, 
composition of functional complexes and significance of protein role-players 
remain unclear. Enormous effort has focused on Drosophila, C. elegans and 
mammalian systems both in vivo (in live organisms and cultured cells) and in 
vitro (using cell extracts and purified proteins), to gain a better understanding of 
the pathway. In this study, we have employed seemingly well established 
preparations of HeLa cell extracts, in particular HeLa whole cell lysate and HeLa 
S100 cytosolic extract41, which have been previously used by several research 





Figure 4.6. Effect of ATP on single stranded antisense siRNA and siRNA 
duplexes to variable extents to mediate target mRNA cleavage in HeLa 
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S100 cytoplasmic. Graphical representation of the normalized and averaged 
fraction of cleaved target mRNA product over full length target mRNA for slicing 
activity HeLa S100 cytoplasmic extract. (a) The slicing assay was performed 
using 1 mM, 3.5 mM or 6 mM ATP as shown in the graph. The gray and black 
bars indicate siRNA duplex (ds) and single stranded antisense siRNA (ss) 
mediated target mRNA cleavage respectively. (b) The slicing assay was 
performed under the indicated ATP depletion conditions. ATP regeneration 
system: CK- Creatine Kinase, CP- Creatine Phosphate; G- glucose; H- 
Hexokinase. HeLa S100 cytosolic cell extracts were treated with glucose and 






Figure 4.7. MOV10/RHA have a potential role in RISC loading of siRNA 




Upon performing slicing assays, we found that HeLa whole cell lysate utilizes 
siRNA duplexes more efficiently than single-stranded antisense siRNAs, similar 
to intracellular observations32. However, the converse was true for HeLa S100 
cytosolic extract (Fig. 4.3), i.e., single-stranded antisense siRNAs elicited RNAi 
more robustly than siRNA duplexes. This observation is contrary to previous 
reports that have shown the S100 cytoplasmic extracts to bring about efficient 
mRNA cleavage with siRNA duplexes compared to single-stranded siRNAs30. 
One potential rationale for such contrasting results lies in the methods of extract 
preparation, where the S100 cytoplasmic extract lacks known RISC associated 
factors that localize to the nucleus42, 43, 44 and potential high molecular weight 
RISC associated proteins and complexes45 that may be removed during 
centrifugation steps used for enrichment of the cytoplasmic fraction. We also 
observed that supplementing HeLa S100 cytosolic extract with HeLa whole cell 
lysate in slicing assays increased the ability of the S100 extract to utilize siRNA 
duplex much more efficiently as shown in Fig 4.4. On the contrary dicing assays 
performed with these extracts showed that both the extracts can cleave a Dicer 
substrate with the same efficiency (Fig 4.2). The quantitative Western blot 
analyses of RNAi related and Ago interacting proteins presented in Fig. 4.3, 
together with previous reports44, 43, 42, 32,21 that these proteins localize to the 
nucleus, strongly support the above hypothesis. More specifically, MOV10, RHA 
and Dcr, which have been found to localize to the cell nucleus to significant 
extent44, 43, 42, 32, 21, were significantly more abundant in whole cell lysate than 
S100 cytosolic extract. This strongly suggests that the poor efficiency of siRNA 
duplexes to elicit RNAi in S100 extract is due to the loss of these nuclear 
localized RISC loading factors. Previous reports have also shown that the high-
molecular weight (~500 kDa) RLC complex containing Ago, Dcr and TRBP is 
formed prior to the encounter with pre-miRNAs or double-stranded siRNAs in 
humans46, thus increasing the likelihood of losing such complexes during the 
preparation of S100 cytoplasmic extracts. Additionally, MOV10 was found to be 
associated with ~2 MDa TRBP-containing complex that mediate miRNA 
silencing45. Put together, the results presented here suggest that a systematic 
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difference in extract preparation and abundance of the RNA helicases MOV10 
and RHA as potentially important cofactors involved in loading double-stranded 
siRNA duplexes into RISC may critically modulate RNAi efficiency. These 
helicases have been previously shown to associate with Ago and are required for 
formation of mature and active RISC, however, their exact roles in RISC still 
remain unknown20, 21. Additionally the fact that both these extracts have similar 
dicing activity suggests a role for MOV10 and RHA after the dicing step in the 
RNAi pathway as depicted in our model (Fig 4.7). 
 Another interesting observation from our results was the inhibitory effect of 
ATP on siRNA duplex and single-stranded antisense siRNA mediated target 
mRNA cleavage (Fig 4. 6). Although this observation needs further investigation, 
similar observations using Rabbit Reticulocyte extract suggested that these 
extracts lack miRNP or RISC loading activity and may employ an alternative 
mechanism to utilize the exogenous single-stranded antisense siRNA to mediate 
target mRNA cleavage38. Alternatively, as observed in the case of Dicer, where 
the deletion of the ATP-dependent helicase domain results in increased cleavage 
activity by the enzyme47, ATP may be mediating some yet-to-be-identified 
allosteric and/or structural changes in RISC that have an inhibitory effect on its 
target mRNA cleavage activity.  
 In summary, our results suggest a potentially critical role for MOV10 and 
RHA in RISC loading of mature siRNA duplexes. Although the use of different 
systems to study RNAi shed light on various mechanisms in RNAi and the roles 
for new Ago or RISC associated proteins, it also does add a layer of complexity 
to interpreting the pathway mechanism. Follow up studies on the inhibitory effect 
of ATP on single-stranded antisense siRNA mediated target mRNA cleavage 
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 RNAs and more specifically non-coding RNAs (ncRNAs) have gained 
immense popularity over the last decade, since the discovery that RNA plays key 
structural, functional and regulatory roles within the cell1. All of the research 
presented in this thesis has focused on understanding the role played by one 
such regulatory ncRNA called short interfering RNA (siRNA). siRNAs are mostly 
exogenous in origin and can be generated from long double-stranded (ds)RNA 
derived from trespassing RNA viruses, mobile genetic elements, self annealing 
transcripts or experimental transfection2. RNase III enzyme Dicer (Dcr) cleaves 
this long ds-RNA into ~21-28 nt siRNAs that are the functional triggers for the 
RNA interference (RNAi) pathway3. These mature siRNAs are then incorporated 
into a RNA Induced Silencing Complex (RISC) that mediates the sequence 
specific cleavage of a target mRNA with perfectly complementary sequence4, 5, 6. 
Synthetic mature siRNAs are also incorporated efficiently into RISC and can 
equally function as triggers for the RNAi pathway7. The inherent ability of the 
RNAi pathway to utilize synthetic siRNAs as triggers to mediate sequence 
specific target mRNA cleavage has been exploited in functional genomics and 
therapeutic applications.  
 The aspects of RNAi that have been studied as part of the work reported 
in this thesis include the investigation of: (1) the interactions of p19, a viral 
silencing suppressor protein, with siRNAs and RNAi pathway components; (2) 
the chemical stability of siRNA-like small RNAs in cell-like and blood-like 
environments; and (3) the process of RISC loading and activation in model cell 
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extracts that have demonstrated differential capacity for utilizing single-stranded 
versus double-stranded siRNAs. 
 
5.1 Kinetic characterization of RNA silencing suppressor protein, p19 
 The RNAi pathway is believed to have evolved to combat viral infections 
and to protect host cells from mobile genetic elements by inhibiting the replication 
of virus-derived transposons. As a countermeasure, viruses are thought to have 
evolved, in parallel, RNAi silencing suppressor (RSS) proteins8, 9, 10 to circumvent 
the RNAi mechanism. p19 is one such RSS protein, which has been shown to 
function as a homodimer in tombusviruses11. p19 binds mature siRNA duplexes, 
products of Dcr, in a caliper-like size specific, but sequence non-specific manner, 
thus making it unavailable for incorporation into mature RISC, thus inhibiting 
RNAi mediated virus RNA cleavage12, 13, 14. 
 The work presented in Chapter 2 of this thesis characterizes the 
interaction between p19 and components of the RNAi pathways using 
biochemical assays and computational modeling. A solution-based fluorescence 
quenching assay performed with p19 showed that it binds reversibly to siRNAs 
with fast association ((1.69 ± 0.07)  108 M-1s-1) and dissociation (0.062  0.002 
s-1) rate constants (Fig 2.3). It was observed that p19 binds to siRNA with a 
significantly higher affinity (KP,sol = 0.37 ± 0.08 nM) than Dcr (KD = 3.7 ± 0.4 nM) 
(Fig 2.4a). Competition of p19 with human Dicer for siRNA binding detected by 
EMSA showed that p19 efficiently competes with human Dcr, thereby disrupting 
the siRNA:Dcr complex (Fig 2.4a). This led to the hypothesis that p19 may be 
able to function to inhibit RNAi in humans by inhibiting the process by which 
Dicer hands off siRNA to RISC. Conversely, Dcr was unable to disrupt the 
p19:siRNA complex even when present at saturating concentrations, owing to 
the high affinity of p19 for siRNAs (Fig 2.4b). Additionally, from competition of 
p19 with human siRNA-containing complexes found in cytosolic HeLa cell extract 
we observed that adding p19 to the cell extract prior to siRNA addition 
increasingly impairs the formation of siRNA-containing complexes, concomitant 
with an accumulation of the competing siRNA:p19 complex (Fig  2.5d,e). 
120 
 
However, when p19 was added to fully mature siRNA containing complexes, the 
formation of particularly the Dicer-containing complex D was inhibited to a lesser 
extent (Fig 2.5f,g; Fig 2.6), suggesting that a tertiary interaction with the 
siRNA:Dcr complex is required for the interference of p19 with the RNAi pathway.  
Computational modeling informed by our experimental results and reports 
from the literature further support the formation of a ternary complex that favors 
dissociation into the siRNA:p19 complex and free Dicer (Fig 2.4c). Additionally, it 
predicts a significant enhancement in viral protein load when the siRNA:p19 
interaction is assumed to be reversible, as observed experimentally, thus 
invoking a multiple-turnover “catch and release” mechanism wherein p19, unlike 
the released siRNA, is effectively recycled after successfully competing with 
Dicer (Fig. 2.7). 
 RSS proteins play a key role in sustaining viral infection by combating the 
host anti-viral response posed by the RNAi pathway. RSS proteins may thus 
serve as ideal drug targets for shunting viral inhibitory effects. Thus, investigating 
RSS proteins as drug targets would facilitate restoring the host anti-viral 
mechanism during viral infection.  Additionally, the techniques presented in this 
chapter could be employed likewise to systematically characterize other RSS 
proteins both biochemically and biophysically, to understand better their 
interaction with the RNAi pathway components. Delineating their interaction 
kinetics and mechanism of action would further their potential as viable drug 
targets. For instance, competing non-specific RNAs of the appropriate size could 
be dosed as “bait” for p19 binding, thus suppressing p19’s inhibitory effect on 
RISC and ensuring robust antiviral response. It would also be interesting to 
investigate the role of Viral RSS proteins as potential immunosuppressors in viral 
gene therapy applications such as adenoviral gene therapy to suppress the host 
immune response against these viruses, very similar to the use of 






5.2 Stability of siRNAs and their implication in RNAi therapeutics 
 The ability of synthetic siRNAs to function as effector molecules of the 
RNAi pathway has significant implications in RNAi therapeutics15, 16. The major 
challenges that concern the use of siRNA duplexes for therapeutic applications 
are their delivery, stability, specificity and potency17. Much research has gone 
into modifying the pharmacokinetic properties of siRNAs to enhance their utility 
as therapeutic agents. The primary problem posed by nuclease sensitive RNA 
molecules is their low stability when exposed to the nuclease-rich cellular 
environment. Although chemical modifications have been shown to provide 
significant stability to siRNA in the cellular environment15, 18, questions regarding 
their utility within the cell persist.  
The work presented in Chapter 3 of this thesis establishes a real-time 
assay to measure degradation profiles and kinetics for small, RNAi-related RNAs 
in both blood serum and RNAi-active cytosolic cell extract. We observed that 
fluorophore labeled small siRNA-like single-stranded (ss)RNAs, dsRNAs and 
DNA/RNA hybrids interact with several cellular enzymes, including RNase H1 
and Dcr. It was observed that dsRNAs were more stable in both blood serum and 
RNAi-active cytosolic cell extract compared to ssRNA, although its hybridization 
to a DNA further stabilized the RNA component in blood serum (Fig 3.2). 
Additionally, the DNA/RNA hybrid that was strongly protected in serum, but 
rapidly degraded by RNase H1 in cell extract, which was confirmed by enzyme-
specific inhibition of RHase H1 by two in vitro selected DNA aptamers (Fig 3.2, 
Fig 3.3).  
We also observed a size specific protection of dsRNAs in both blood 
serum and RNAi-active cytosolic cell extract where 21- and 24-nt dsRNAs, but 
not 18-nt dsRNA, were equally protected in S100 cytosolic HeLa cell extract. 
However, in blood serum the relative decay rate constants correlated with their 
relative lengths, i.e., the rate of degradation decreased with increasing size of the 
dsRNA (Fig 3.5). We have shown that the 21- and 24-nt dsRNAs were 
incorporated in RISC related complexes (as seen in Chapter 2) to a greater 
extent than 18-nt dsRNAs, contributing to the faster decay rate of the 18-mer in 
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HeLa cell extract (Fig 3.5). The 24-nt dsRNA is a substrate of human Dicer (Fig 
3.4) and the 21-nt dsRNA Dicer’s product; coincidentally, these RNAs were 
protected specifically in the cellular milieu. Our results are consistent with 
established steps in the RNAi pathway where 21-nt dsRNAs are bound by the 
RISC loading complex (RLC) or other RNAi components and remain largely 
protected from nucleolytic decay, thus explaining the relative longevity of 
intracellular RNAi effects induced even by chemically unmodified siRNAs. 
 Although it has been hypothesized that the RLC or other RNAi associated 
proteins are responsible for binding to and protecting siRNA-like small RNAs 
upon entry into the cellular environment, the precise mechanism of this protection 
is still unclear. Future studies should focus on investigating what proteins or 
mechanisms are involved in rendering such protection to unmodified siRNA-like 
small RNAs. In addition to their localization and activity within the cell, there have 
been reports of miRNA in the bloodstream in a highly stable, extracellular form19. 
However, the mechanism underlying their remarkable stability in the RNase-rich 
environment of blood is still under debate. There has been evidence that these 
miRNAs are encapsulated in vesicles in the plasma, but it has also been shown 
that a significant portion of these miRNAs are associated with Ago2 complexes 
that may be responsible for the stability of plasma miRNAs19. Probing the 
mechanism behind the stability of these circulating miRNAs present in blood 
might give some insights into methods for delivery and improving the stability of 
exogenous siRNA introduced into the plasma for therapeutic purposes and can 
possibly function as signaling molecules as described 20.  
  
5.3 Differential modes of RISC loading and activation facilitated by cell 
extracts 
 Despite the wide application of RNAi in basic research and therapeutics it 
remains a poorly understood mechanism. Although Dcr, Ago and TRBP have 
been identified as core components of a siRNA-programmed RISC that mediates 
sequence specific cleavage of mRNA target21, 22, there have been conflicting 
ideas in the field about the potential role for other proteins that associate with 
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Ago2 or RISC23. Much of this complexity may arise from the lack of a standard 
system of study for understanding the RNAi pathway. 
 The work presented in Chapter 4 of this thesis describes the systematic 
differences observed in the RNAi pathway when using two different preparations 
of HeLa cell extract, i.e., S100 cytosolic cell extract and translationally active 
whole cell extract. We observed that despite demonstrating the ability to perform 
dicing and slicing activity (Fig 4.1), the extracts possess an inherent difference in 
their ability to utilize double- versus single-stranded siRNAs to mediate target 
mRNA cleavage. The HeLa whole cell extract accommodated siRNA duplexes 
more efficiently than single-stranded siRNAs to mediate target cleavage, as 
observed in previous reports. By contrast, the opposite was true for HeLa S100 
cytosolic extract, which lacks any nuclear components that might be involved in 
the RNAi pathway (Fig 4.2). Quantitative Western blot analysis of both extracts 
for Ago-associated proteins indicated that the HeLa S100 cytoplasmic extract 
had much lower concentrations of three proteins, MOV10, RHA and Dcr, which 
have been shown to be present in both the nuclear and cytosolic compartments 
of the cell and are required for mature RISC formation and activity (Fig 4.3). 
Additionally, we noticed that ATP in HeLa S100 cytosolic extract has an inhibitory 
effect on both siRNA duplex and single-stranded guide strand mediated target 
mRNA cleavage (Fig 4.4). Taken together, our results suggest a potential role for 
MOV10 and RHA in siRNA duplex loading of RISC. We also hypothesize that 
ATP may be mediating some yet-to-be-identified allosteric and/or structural 
change in RISC that has an inhibitory effect on its target mRNA cleavage activity. 
 Although MOV10 and RHA have been implicated in RISC loading and 
active RISC formation, the first step in confirming this observation would be to 
supplement HeLa S100 cytoplasmic extract with different molecular weight 
fractions of HeLa whole cell extract or purified recombinant MOV 10 or RHA and 
ask whether functional complementation is observed upon siRNA duplex loading 
into RISC. A reconstitution experiment with purified recombinant proteins of  
RISC would verify the implied role of MOV10 and RHA in RISC loading and 
active RISC formation. Additionally, follow up studies on the inhibitory effect of 
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ATP on single-stranded antisense siRNA mediated target mRNA cleavage would 
help in unraveling the mechanistic details of target degradation. Many conflicting 
ideas exist related to the role of RISC associated proteins, such as the presence 
of Dicer in the mature effector RISC, in the RNAi pathway, which could be 
attributed to the fact that most results reported thus far are from unsynchronized 
bulk assays. In order to gain deeper mechanistic insights into the role of siRNA-
containing complexes in RISC loading, unwinding of the siRNA duplexes, binding 
to the target mRNA and cleavage, in real-time, single-molecule fluorescence 
microscopy tools can be employed. Observing these processes at the single-
molecule level will shed light on the heterogeneity associated with these RNAi 
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Viral RNAi suppressor reversibly binds siRNA to outcompete Dicer and 






Figure A.1. Concentration dependence of siRNA:p19 dissociation kinetics. 
(a, b) Doubly-labeled siRNA (50 nM) after addition of Dicer (5 nM green dotted 
line) or Buffer (black dotted line) respectively, followed by addition of p19 (500 
 128 
nM, blue dotted line). (c) Doubly-labeled siRNA (50 nM) was bound by p19 (500 
nM, blue dotted line) after which excess unlabeled siRNA was added at 
concentrations of 500 nM (red), 750 nM (black), 1.5 µM (green), 3 µM (blue), 







Figure A.2. Competition between p19 and human Dicer for siRNA binding 
as shown by EMSAs.  siRNA (S) labeled with [γ_32P] ATP are bound to (a) 
Recombinant human Dicer (D) (Genlantis Inc.) where Dicer concentrations are 0, 
0.16, 0.25, 0.5, 2.5, 5, 10, 16, 50 ,100, 200 nM, respectively.  Samples were 
incubated for 30 min before loading onto a 12% nondenaturing polyacrylamide 
gel.  (b) siRNA pre-incubated with p19 at a concentration of 0.16 nM for 30 min 
followed by Dicer addition as described above.  (c) siRNA pre-incubated with p19 
at a concentration of 2.56 nM for 30 min followed by Dicer addition as described 
above. (d) p19 only (P) where p19 concentrations are 0, 0.02, 0.04, 0.08, 0.16, 
0.32, 0.64, 1.28, 2.56, 5.12 nM, respectively. Samples were incubated for 30 min 
before loading onto a 12% nondenaturing polyacrylamide gel.  (e) siRNA pre-
incubated with Dicer at a concentration of 140 nM for 30 min followed by p19 





Figure A.3.  Comparison of siRNA complex formation for different HeLa cell 
extract concentrations and temperatures. (a) (lanes 1-2) 15% or 75% (v/v) 
HeLa extract conditions incubated with siRNA for 1 h at 4 oC, (lanes 3-4) 
incubated at 25 oC, (lanes 5-8) incubated at 37 oC, and (lane 9) 93% (v/v) HeLa 
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cell extract in the absence of an ATP generating system and in supplied buffer 
(20 mM HEPES-Na pH 7.9, 42 mM ammonium sulfate, 0.2 mM EDTA, 0.5 mM 
DTT and 20% glycerol).  The effect of incubation temperature and HeLa extract 
concentration on complex formation was limited.  The same migration patterns 
are seen under all conditions.  (b) Formation of complexes D, C2, and C1 after 
10, 30, 60 and 120 min incubation of siRNA in 50% cytosolic HeLa cell extract. 
Samples were loaded onto a running 4% native polyacrylamide gel, leading to 
the indicated differences in migration. (c) Formation of complexes after 2.5 h 
incubation of siRNA in 50% (v/v) cytosolic HeLa cell extract, and increasing 
concentrations of p19. (d) Formation of complexes after 2 h incubation of siRNA 
in 50% (v/v) cytosolic HeLa cell extract, followed by the addition of increasing 
concentrations of p19 and further incubation for 30 min. Reprinted with 






Figure A.4. Gel-based dissociation chase assays. Duplicate gel chase 
experiments were done in standard buffer with (a) 70 nM recombinant Dicer or 
(b) 10 nM of p19 added to 5´-32P labeled siRNA before addition of 750 nM 




Figure A.5.  Size comparison of protein-siRNA binding complexes.  [γ_32P] 
ATP labeled siRNA incubated with: purified rDicer provided from the J. Doudna 
lab (lane 1); purified recombinant Ago2 protein provided from the J. Doudna lab 
(lane 2); rDicer (Genlantis Inc.; lane 3); purified p19 (lane 4); 15% (v/v) HeLa cell 
extract (lanes 5, 6).  All samples were incubated for 30 min before loading.  
Nondenaturing 4% (w/v) polyacrylamide gel electrophoresis was used to resolve 
these complexes as described above. Although Dicer is a larger protein (MW 218 
kDa) compared to Ago2 (MW 97 kDa), it has an isoelectric point of 5.47 
compared to 9.39 for Ago2.  This difference contributes to Ago2 running as an 
apparently slower migrating complex in buffer at pH 7.4. Reprinted with 





Figure A.6. Complex formation between p19 and miRNA let7a as shown by 
EMSAs. miRNA (M) labeled with [γ_32P] ATP is bound to p19 (P) to form the 
complex  (MP). (a) Representative EMSA.  (b) Analysis of binding by EMSA 






siRNA-like double-stranded RNAs are specifically protected against 







Figure B.1. FRET ratio time trace upon incubating doubly fluorophore labeled 
21-nt dsRNA with either serum (red) or 2 ng/ml of purified RNase A (black).  The 
real-time FRET traces for each of these conditions reveal that both serum and 
the purified nuclease manifest a significant initial increase in FRET ratio. 







Mass spectrometry analysis of siRNA associated protein complexes 





 Three distinct siRNA-containing complexes, complex D, C1 and C2,  were 
observed during the RISC assembly complex formation assay using cytosolic 
HeLa cell extract (Fig 2.5b). We confirmed the presence of Dicer in complex D 
using both native western blot analysis and supershift assays (Fig 2.6 and 2.5c). 
To further identify the proteins associated with these siRNA bound complexes we 
performed Mass spectrometry analysis.  
 
C.2 Materials and Method 
 The siRNA containing complexes, D, C1 and C2 were formed as 
described in Chapter 2 using unlabeled siRNAs and resolved on a non-
denaturing gel (Fig 2.5b). The portion of the gel containing these complexes was 
excised and the proteins were eluted by passive elution into a buffer containing 
100mM sodium acetate; 0.1% SDS; 100mM DTT. The eluted samples were run 
on a 10% NuPAGE Novex Bis-Tris Gel for about 1.5-2 cm into the gel, stained 
with Coomassie Brilliant Blue R-250 and destained before submitting it to 
NextGen Sciences for mass spectrometry analysis (Fig C.1). Each sample lane 
was excised into 10 equal segments using a grid. Each segment was digested 
using trypsin as described below. Gel digests were analyzed using LC/MS/MS 







Figure C.1. Denaturing electrophoresis of complexes D, C2 and C1. 
Denaturing electrophoresis of siRNA associated complexes on a 10% NuPAGE 
Novex Bis-Tris Gel for about 1.5-2 cm into the gel, stained with Coomassie 
Brilliant Blue R-250 and destained. Lane M indicates the protein size marker.  
  
M D C2 C1 
138 
 
1 h gradient on a LTQ Orbitrap XL mass spectrometer. Product ion data were 
searched against the concatenated forward and reverse IPI Human v3.46 
database using the Mascot search engine. The database was appended with 
commonly observed background proteins (cRAP) to prevent false assignment of 
peptides derived from those proteins. Mascot output files were parsed into the 
Scaffold program for collation into non-redundant lists per lane and filtering to 
assess false discovery rates and allow only correct protein identifications. 
Spectral counts per protein were output to the Excel summary, these are a semi-
quantitative measure of abundance across samples. Spectral count reflects the 
number of matched peptides and the number of times those peptides were 
observed. 
In-gel digestion 
Samples were subjected to proteolytic digestion on a ProGest (Genomic 
Solutions) workstation where they were reduced with DTT at 60 ºC, allowed to 
cool to room temperature, alkylated with iodoacetamide and incubated at 37 ºC 
for 4h in the presence trypsin. Formic acid was added to stop the reaction and 
the supernatant was analyzed directly. 
LC/MS/MS 
Samples were analyzed by nano LC/MS/MS on a ThermoFisher LTQ or LTQ 
Orbitrap XL. 30 μl of hydrolysate was loaded onto a 5 mm, 75 μm ID C12 (Jupiter 
Proteo, Phenomenex) vented column at a flow-rate of 10μL/min. Gradient elution 
was over a 15 cm, 75 μm ID C12 column at 300 nL/min. A 1h gradient was 
employed. The mass spectrometer was operated in data-dependent mode, the 
six most abundant ions were selected for MS/MS. The Orbitrap MS scan was 
performed at 60,000 FWHM resolution. MS/MS data were searched using a local 
copy of Mascot. The parameters for all LC/MS/MS searches were as follows: 
Type of search : MS/MS Ion Search, Enzyme : Trypsin, Fixed modifications : 
Carbamidomethyl (C), Variable modifications : Oxidation (M), Acetyl (N-term), 
Pyro-glu (N-term Q), Mass values : Monoisotopic, Protein Mass : Unrestricted, 
Peptide Mass Tolerance : ± 5 ppm (Orbitrap); ± 2.0 Da (LTQ), Fragment Mass 




Samples were processed in the Scaffold software using DAT files generated by 
Mascot. Parameters for LTQ data require a minimum of 3 peptides matching per 
protein with minimum probabilities of 90% at the protein level and 50-80% at the 
corresponding peptide level.  
 
C.3 Results 
 A combined total of 361 proteins were detected (with 2 or more unique 
peptides/protein) in these experiments (Table C.1, Table C.2). 
 
C.4 Conclusions 
 The mass spectrometry analysis identified 361 proteins from the samples 
obtained by eluting the siRNA associated complexes from a non-denaturing 
polyacrylamide gel. We identified few proteins which have been shown to be 
involved with the RNAi pathway, eg: Heat shock protein 90 (Hsp90), however 
further investigation is required to confirm the role of these proteins in siRNA 






 Parameters D C2 C1 
Total no. of proteins 105 116 210 
Total Spectral Count 6181 5668 5090 
Total Unique Peptides 805 976 1447 
Mean Spectral Count 58.9 48.9 24.2 
Median Spectral Count 25.5 17 9.5 
Mean Unique Peptides 7.7 8.4 6.9 
Median Unique Peptides 5 5 4 
No. of reverse hits 0 0 0 
% FDR 0 0 0 
 
































KRT1 Keratin, type II cytoskeletal 1 IPI00220327 (+1) 66 kDa 484 283 291 
KRT10 Keratin, type I cytoskeletal 10 IPI00009865 60 kDa 352 243 236 
sp_TRYP_PIG IPIsp_TRYP_PIG 24 kDa 220 265 233 
KRT2 Keratin, type II cytoskeletal 2 epidermal IPI00021304 (+1) 66 kDa 355 187 207 
HSPA8 Isoform 1 of Heat shock cognate 71 kDa protein IPI00003865 71 kDa 0 64 196 
VCL Isoform 1 of Vinculin IPI00291175 (+1) 117 kDa 0 0 141 
KRT9 Keratin, type I cytoskeletal 9 IPI00019359 (+1) 62 kDa 264 133 137 
HSPA1B;HSPA1A Heat shock 70 kDa protein 1 IPI00304925 70 kDa 0 0 137 
KRT5 Keratin, type II cytoskeletal 5 IPI00009867 62 kDa 227 117 114 
TPI1 Isoform 1 of Triosephosphate isomerase IPI00465028 31 kDa 0 0 114 
LDHB L-lactate dehydrogenase B chain IPI00219217 37 kDa 0 0 113 
KRT6B Keratin, type II cytoskeletal 6B IPI00293665 60 kDa 170 100 100 
KRT14 Keratin, type I cytoskeletal 14 IPI00384444 52 kDa 155 84 92 
NME2 Nucleoside diphosphate kinase IPI00604590 (+1) 33 kDa 0 16 83 
KRT16 Keratin, type I cytoskeletal 16 IPI00217963 51 kDa 118 0 80 
LDHA Isoform 1 of L-lactate dehydrogenase A chain IPI00217966 37 kDa 0 0 80 
PHGDH D-3-phosphoglycerate dehydrogenase IPI00011200 57 kDa 0 0 76 
ACTG1 Actin, cytoplasmic 2 IPI00021440 42 kDa 51 486 75 
IQGAP1 Ras GTPase-activating-like protein IQGAP1 IPI00009342 189 kDa 0 0 72 
S100A4 Protein S100-A4 IPI00032313 12 kDa 0 0 56 
M6PRBP1 Isoform B of Mannose-6-phosphate receptor-binding protein 1 IPI00303882 47 kDa 0 0 56 
EEF1A1 Elongation factor 1-alpha 1 IPI00396485 (+1) 50 kDa 14 14 49 
















NP CDNA FLJ25678 fis, clone TST04067, highly similar to PURINE 
NUCLEOSIDE PHOSPHORYLASE IPI00017672 (+1) 33 kDa 0 0 49 
TALDO1 Transaldolase IPI00744692 38 kDa 0 0 48 
ATIC Bifunctional purine biosynthesis protein PURH IPI00289499 65 kDa 0 0 48 
STIP1 Stress-induced-phosphoprotein 1 IPI00013894 (+1) 63 kDa 0 0 46 
TUBB Tubulin beta chain IPI00011654 (+1) 50 kDa 139 46 44 
VCP Transitional endoplasmic reticulum ATPase IPI00022774 89 kDa 0 0 44 
MDH1 Malate dehydrogenase, cytoplasmic IPI00291005 36 kDa 0 0 43 
TUBB2C Tubulin beta-2C chain IPI00007752 50 kDa 122 0 41 
PFN1 Profilin-1 IPI00216691 15 kDa 0 0 40 
KYNU Kynureninase IPI00003818 52 kDa 0 0 40 
G6PD Isoform Long of Glucose-6-phosphate 1-dehydrogenase IPI00216008 (+1) 64 kDa 0 0 40 
PRDX6 Peroxiredoxin-6 IPI00220301 25 kDa 0 0 39 
HPRT1 Hypoxanthine-guanine phosphoribosyltransferase IPI00218493 25 kDa 0 0 38 
sp_ALBU_BOVIN IPIsp_ALBU_BOVIN 69 kDa 67 37 37 
GOT1 Aspartate aminotransferase, cytoplasmic IPI00219029 46 kDa 0 0 36 
ACTN1 Alpha-actinin-1 IPI00013508 (+1) 103 kDa 0 0 35 
SERPINB1 Leukocyte elastase inhibitor IPI00027444 43 kDa 0 0 34 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase IPI00219018 36 kDa 9 0 33 
SRI Sorcin IPI00027175 (+1) 22 kDa 0 0 33 
GSTO1 Glutathione transferase omega-1 IPI00019755 28 kDa 0 0 33 
ALDH9A1 4-trimethylaminobutyraldehyde dehydrogenase IPI00873817 54 kDa 0 0 33 
TUBA1B Tubulin alpha-1B chain IPI00387144 (+1) 50 kDa 84 23 31 
EIF4A1 Eukaryotic initiation factor 4A-I IPI00025491 (+1) 46 kDa 0 136 31 
















MCM2 DNA replication licensing factor MCM2 IPI00184330 102 kDa 0 4 29 
PSMB6 Proteasome subunit beta type-6 precursor IPI00000811 (+1) 25 kDa 0 0 28 
IMPDH2 Inosine-5'-monophosphate dehydrogenase 2 IPI00291510 56 kDa 0 0 28 
KRT77 Keratin 77 IPI00376379 62 kDa 0 0 27 
CAND1 Isoform 1 of Cullin-associated NEDD8-dissociated protein 1 IPI00100160 (+1) 136 kDa 0 0 26 
MCM7 Isoform 1 of DNA replication licensing factor MCM7 IPI00299904 81 kDa 0 0 23 
CCT2 T-complex protein 1 subunit beta IPI00297779 57 kDa 0 0 22 
ACTN4 Alpha-actinin-4 IPI00013808 105 kDa 0 0 22 
HSP90AB1 Heat shock protein HSP 90-beta IPI00414676 83 kDa 76 450 21 
RUVBL2 RuvB-like 2 IPI00009104 51 kDa 0 0 20 
HSP90AA1 heat shock protein 90kDa alpha (cytosolic), class A member 1 
isoform 1 IPI00382470 (+1) 98 kDa 0 450 19 
STMN1 Stathmin IPI00479997 17 kDa 0 0 19 
PSMA6 Proteasome subunit alpha type-6 IPI00029623 27 kDa 0 0 19 
CAP1 Adenylyl cyclase-associated protein 1 IPI00008274 (+2) 52 kDa 0 0 19 
EEF2 Elongation factor 2 IPI00186290 95 kDa 0 0 18 
EEF1G Elongation factor 1-gamma IPI00000875 (+1) 50 kDa 0 0 18 
CAPG Macrophage-capping protein IPI00027341 (+1) 39 kDa 0 0 18 
GARS 85 kDa protein IPI00465260 (+1) 85 kDa 0 0 18 
TARS Threonyl-tRNA synthetase, cytoplasmic IPI00329633 83 kDa 0 0 18 
RNH1 Ribonuclease inhibitor IPI00550069 50 kDa 675 60 17 
HSPB1 Heat shock protein beta-1 IPI00025512 23 kDa 0 0 17 
DDT D-dopachrome decarboxylase IPI00293867 13 kDa 0 0 17 
PSME2 Uncharacterized protein PSME2 IPI00384051 (+1) 29 kDa 0 0 17 
















ACAT2 Acetyl-CoA acetyltransferase, cytosolic IPI00291419 41 kDa 0 0 16 
ARF1 ADP-ribosylation factor 1 IPI00215914 (+1) 21 kDa 0 0 16 
MCM3 DNA replication licensing factor MCM3 IPI00013214 91 kDa 0 3 15 
PGD 6-phosphogluconate dehydrogenase, decarboxylating IPI00219525 (+1) 53 kDa 0 0 15 
DUT Isoform DUT-M of Deoxyuridine 5'-triphosphate 
nucleotidohydrolase, mitochondrial precursor IPI00013679 (+3) 27 kDa 0 0 14 
GNPDA1 Glucosamine-6-phosphate isomerase 1 IPI00009305 33 kDa 0 0 14 
TXNRD1 Isoform 5 of Thioredoxin reductase 1, cytoplasmic IPI00554786 (+4) 55 kDa 0 0 14 
RPS27A;UBC;UBB ubiquitin and ribosomal protein S27a precursor IPI00179330 (+22) 18 kDa 11 7 13 
DCD Dermcidin precursor IPI00027547 (+1) 11 kDa 0 12 13 
ACP1 Isoform 1 of Low molecular weight phosphotyrosine protein 
phosphatase IPI00219861 (+2) 18 kDa 0 0 13 
PSMA3 Isoform 2 of Proteasome subunit alpha type-3 IPI00171199 (+1) 28 kDa 0 0 13 
USO1 Putative uncharacterized protein DKFZp451D234 IPI00031583 109 kDa 0 0 13 
TRIM28 Isoform 1 of Transcription intermediary factor 1-beta IPI00438229 (+1) 89 kDa 0 0 13 
USP9X ubiquitin specific protease 9, X-linked isoform 4 IPI00003964 (+1) 290 kDa 0 0 13 
ALB Isoform 1 of Serum albumin precursor IPI00745872 (+1) 69 kDa 27 17 12 
sp_CASK_BOVIN IPIsp_CASK_BOVIN 21 kDa 9 10 12 
#NAME? IPI00453476 (+1) 29 kDa 0 2 12 
MCM6 DNA replication licensing factor MCM6 IPI00031517 93 kDa 0 0 12 
PSMA1 Isoform Short of Proteasome subunit alpha type-1 IPI00016832 (+2) 30 kDa 0 0 12 
RUVBL1 Isoform 1 of RuvB-like 1 IPI00021187 (+1) 50 kDa 0 0 12 
PSME3 Isoform 1 of Proteasome activator complex subunit 3 IPI00030243 (+1) 30 kDa 0 0 11 
TMSB10 Thymosin beta-10 IPI00220827 5 kDa 0 0 11 
















MTHFD1 C-1-tetrahydrofolate synthase, cytoplasmic IPI00218342 (+1) 102 kDa 0 0 11 
GART Isoform Long of Trifunctional purine biosynthetic protein 
adenosine-3 IPI00025273 108 kDa 0 0 11 
KIAA0664 Putative eukaryotic translation initiation factor 3 subunit IPI00024425 147 kDa 0 0 11 
PDCD6 Programmed cell death protein 6 IPI00025277 22 kDa 0 0 10 
ADSL Isoform 1 of Adenylosuccinate lyase IPI00026904 (+1) 55 kDa 0 0 10 
- 22 kDa protein IPI00219910 (+1) 22 kDa 0 0 10 
CBR1 Carbonyl reductase [NADPH] 1 IPI00295386 30 kDa 0 0 10 
PRMT5 Protein arginine N-methyltransferase 5 IPI00441473 73 kDa 0 0 10 
PSME1 Proteasome activator complex subunit 1 IPI00479722 29 kDa 0 0 10 
MYL6;MYL6B Isoform Non-muscle of Myosin light polypeptide 6 IPI00335168 (+2) 17 kDa 0 0 10 
ARF4 ADP-ribosylation factor 4 IPI00215918 21 kDa 0 0 10 
CAPZA1 F-actin-capping protein subunit alpha-1 IPI00005969 (+1) 33 kDa 0 0 9 
TPD52L2 Isoform 2 of Tumor protein D54 IPI00221178 (+6) 20 kDa 0 0 9 
CAPZB Isoform 1 of F-actin-capping protein subunit beta IPI00026185 (+2) 31 kDa 0 0 9 
TPD52 tumor protein D52 isoform 2 IPI00619951 (+4) 22 kDa 0 0 9 
COTL1 Coactosin-like protein IPI00017704 16 kDa 0 0 9 
AHCY Adenosylhomocysteinase IPI00012007 48 kDa 0 0 9 
VPS35 Vacuolar protein sorting-associated protein 35 IPI00018931 92 kDa 0 0 9 
WARS Tryptophanyl-tRNA synthetase, cytoplasmic IPI00295400 (+1) 53 kDa 0 0 9 
MCM5 DNA replication licensing factor MCM5 IPI00018350 (+1) 82 kDa 0 0 9 
PIP Prolactin-inducible protein precursor IPI00022974 17 kDa 17 8 8 
sp_CASB_BOVIN IPIsp_CASB_BOVIN 25 kDa 0 0 8 
PSMD5 26S proteasome non-ATPase regulatory subunit 5 IPI00002134 56 kDa 0 0 8 
















IDH1 Isocitrate dehydrogenase [NADP] cytoplasmic IPI00027223 47 kDa 0 0 8 
DPYSL2 Dihydropyrimidinase-related protein 2 IPI00257508 62 kDa 0 0 8 
PSMA7 Isoform 1 of Proteasome subunit alpha type-7 IPI00024175 28 kDa 0 0 8 
PSMB5 29 kDa protein IPI00375704 (+1) 29 kDa 0 0 8 
MCM4 DNA replication licensing factor MCM4 IPI00018349 97 kDa 0 0 8 
LYZ Lysozyme C precursor IPI00019038 (+1) 17 kDa 23 0 7 
PSMA5 Proteasome subunit alpha type-5 IPI00291922 26 kDa 0 0 7 
RPLP0 60S acidic ribosomal protein P0 IPI00008530 (+2) 34 kDa 0 0 7 
PSMD11 Proteasome 26S non-ATPase subunit 11 variant (Fragment) IPI00105598 48 kDa 0 0 7 
FH Isoform Mitochondrial of Fumarate hydratase, mitochondrial 
precursor IPI00296053 (+1) 55 kDa 0 0 7 
PARK7 Protein DJ-1 IPI00298547 20 kDa 0 0 7 
STAT3 Isoform Del-701 of Signal transducer and activator of transcription 
3 IPI00306436 (+2) 88 kDa 0 0 7 
CKM Creatine kinase M-type IPI00027487 (+1) 43 kDa 0 0 7 
ESD S-formylglutathione hydrolase IPI00411706 (+1) 31 kDa 0 0 7 
NASP Isoform 1 of Nuclear autoantigenic sperm protein IPI00179953 (+1) 85 kDa 71 0 6 
sp_CAS2_BOVIN IPIsp_CAS2_BOVIN 26 kDa 11 9 6 
PGM1 Isoform 1 of Phosphoglucomutase-1 IPI00219526 (+1) 61 kDa 0 0 6 
COPS4 COP9 signalosome complex subunit 4 IPI00171844 46 kDa 0 0 6 
PSMA4 Proteasome subunit alpha type-4 IPI00299155 (+1) 29 kDa 0 0 6 
MAPK1 Mitogen-activated protein kinase 1 IPI00003479 41 kDa 0 0 6 
HINT1 Histidine triad nucleotide-binding protein 1 IPI00239077 14 kDa 0 0 6 
XPO7 Exportin-7 IPI00302458 (+2) 124 kDa 0 0 6 
















PSMA2 Proteasome subunit alpha type-2 IPI00219622 26 kDa 0 0 5 
AKR1B1 Aldose reductase IPI00413641 (+1) 36 kDa 0 0 5 
NUP93 Nuclear pore complex protein Nup93 IPI00397904 93 kDa 0 0 5 
CPNE3 Copine-3 IPI00024403 60 kDa 0 0 5 
CMBL Carboxymethylenebutenolidase homolog IPI00383046 28 kDa 0 0 5 
MAP2K1 Dual specificity mitogen-activated protein kinase kinase 1 IPI00219604 43 kDa 0 0 5 
FAM49B Protein FAM49B IPI00303318 (+1) 37 kDa 0 0 5 
MAPK3 Mitogen-activated protein kinase 3 IPI00018195 (+1) 43 kDa 0 0 5 
FLG2 Filaggrin-2 IPI00397801 248 kDa 7 0 4 
KPRP Keratinocyte proline-rich protein IPI00514908 64 kDa 0 0 4 
PGM2 Phosphoglucomutase-2 IPI00550364 68 kDa 0 0 4 
IMPA2 Isoform 1 of Inositol monophosphatase 2 IPI00023635 (+1) 31 kDa 0 0 4 
CARM1 Isoform 1 of Histone-arginine methyltransferase CARM1 IPI00412880 (+2) 63 kDa 0 0 4 
KIAA1598 Isoform 3 of Shootin-1 IPI00448751 (+4) 74 kDa 0 0 4 
PCBP2 poly(rC)-binding protein 2 isoform b IPI00012066 (+3) 38 kDa 0 0 4 
PFKM cDNA FLJ44241 fis, clone THYMU3008436, highly similar to 6- 
phosphofructokinase, muscle type IPI00465179 (+1) 93 kDa 0 0 4 
GPS1 G protein pathway suppressor 1 isoform 2 IPI00156282 (+1) 56 kDa 0 0 4 
GEMIN5 Gem-associated protein 5 IPI00291783 169 kDa 0 0 4 
DSP Isoform DPI of Desmoplakin IPI00013933 (+1) 332 kDa 3 0 3 
KPNB1 Importin subunit beta-1 IPI00001639 97 kDa 0 93 3 
STAT5A Signal transducer and activator of transcription 5A IPI00030783 (+1) 91 kDa 0 0 3 
CUL4A Isoform 1 of Cullin-4A IPI00419273 88 kDa 0 0 3 
ME1 NADP-dependent malic enzyme IPI00008215 64 kDa 0 0 3 
















NAMPT Isoform 1 of Nicotinamide phosphoribosyltransferase IPI00018873 (+1) 56 kDa 0 0 3 
ACOT7 Isoform 1 of Cytosolic acyl coenzyme A thioester hydrolase IPI00010415 (+6) 42 kDa 0 0 3 
ACO1 Cytoplasmic aconitate hydratase IPI00008485 98 kDa 0 0 3 
EFHD2 EF-hand domain-containing protein D2 IPI00060181 27 kDa 0 0 3 
NUDC Nuclear migration protein nudC IPI00550746 (+1) 38 kDa 0 0 3 
WDR1 Isoform 2 of WD repeat-containing protein 1 IPI00216256 (+3) 58 kDa 0 0 3 
PSMD2 26S proteasome non-ATPase regulatory subunit 2 IPI00012268 100 kDa 0 0 3 
COASY Bifunctional coenzyme A synthase IPI00184821 62 kDa 0 0 3 
SPAG9 145 kDa protein IPI00218097 (+6) 145 kDa 0 0 3 
PGP Phosphoglycolate phosphatase IPI00177008 34 kDa 0 0 3 
NAP1L1 Nucleosome assembly protein 1-like 1 IPI00023860 (+1) 45 kDa 30 0 2 
AARS Alanyl-tRNA synthetase, cytoplasmic IPI00027442 107 kDa 0 48 2 
C1orf68;LOC100129271 Skin-specific protein 32 IPI00023078 26 kDa 0 0 2 
SLK Isoform 1 of STE20-like serine/threonine-protein kinase IPI00022827 (+1) 143 kDa 0 0 2 
EEF1B2 Elongation factor 1-beta IPI00178440 (+1) 25 kDa 0 0 2 
MGEA5 Isoform 2 of Bifunctional protein NCOAT IPI00181391 (+2) 95 kDa 0 0 2 
HSPA4L Heat shock 70 kDa protein 4L IPI00295485 (+1) 94 kDa 0 0 2 
PSMB2 Proteasome subunit beta type-2 IPI00028006 (+1) 23 kDa 0 0 2 
NIT2 Nitrilase homolog 2 IPI00549467 (+1) 31 kDa 0 0 2 
NCDN Isoform 1 of Neurochondrin IPI00549543 (+2) 79 kDa 0 0 2 
COPS2 Isoform 2 of COP9 signalosome complex subunit 2 IPI00018813 (+1) 52 kDa 0 0 2 
PSMB4 Proteasome subunit beta type-4 precursor IPI00555956 29 kDa 0 0 2 
UMPS Isoform 1 of Uridine 5'-monophosphate synthase IPI00003923 52 kDa 0 0 2 
















ACLY ATP-citrate synthase IPI00021290 (+1) 121 kDa 0 0 2 
PRKAR1A cAMP-dependent protein kinase type I-alpha regulatory subunit IPI00021831 43 kDa 0 0 2 
BLVRA Biliverdin reductase A precursor IPI00294158 33 kDa 0 0 2 
NANS Sialic acid synthase IPI00147874 40 kDa 0 0 2 
AHCYL2 Putative adenosylhomocysteinase 3 IPI00101645 (+5) 67 kDa 0 0 2 
ATP6V1B2 Vacuolar ATP synthase subunit B, brain isoform IPI00007812 (+1) 57 kDa 0 0 2 
GALK1 Galactokinase IPI00019383 (+2) 42 kDa 0 0 2 
CPNE1 Copine-1 IPI00018452 (+8) 59 kDa 0 0 2 
ANKFY1 ankyrin repeat and FYVE domain containing 1 isoform 2 IPI00375301 55 kDa 0 0 2 
SPRR2G Small proline-rich protein 2G IPI00000849 (+4) 8 kDa 0 0 2 
STAT1 Isoform Alpha of Signal transducer and activator of transcription 1-
alpha/beta IPI00030781 (+2) 87 kDa 0 0 2 
PSMC3 26S protease regulatory subunit 6A IPI00018398 49 kDa 0 0 2 
USP14 Ubiquitin carboxyl-terminal hydrolase 14 IPI00219913 (+3) 56 kDa 0 0 2 
RELA Isoform 2 of Transcription factor p65 IPI00219084 (+4) 59 kDa 0 0 2 
IDI1 14 kDa protein IPI00645307 14 kDa 0 0 2 
APOA1 Apolipoprotein A1 IPI00853525 (+1) 28 kDa 0 0 2 
PDIA3 Protein disulfide-isomerase A3 precursor IPI00025252 57 kDa 0 0 2 
GSR Isoform Mitochondrial of Glutathione reductase, mitochondrial 
precursor IPI00016862 (+1) 56 kDa 0 0 2 
PITPNA Phosphatidylinositol transfer protein alpha isoform IPI00216048 32 kDa 0 0 2 
GRHPR Glyoxylate reductase/hydroxypyruvate reductase IPI00037448 (+2) 36 kDa 0 0 2 
PYGL Glycogen phosphorylase, liver form IPI00783313 97 kDa 0 0 2 
ANXA5 Annexin A5 IPI00329801 (+2) 36 kDa 151 0 0 
















KRT17 Keratin, type I cytoskeletal 17 IPI00450768 48 kDa 103 0 0 
PLA2G4A Cytosolic phospholipase A2 IPI00026108 85 kDa 91 0 0 
CLIC1 Chloride intracellular channel protein 1 IPI00010896 27 kDa 79 17 0 
NCL Isoform 1 of Nucleolin IPI00604620 (+1) 77 kDa 77 0 0 
GDA Guanine deaminase IPI00465184 (+1) 51 kDa 72 0 0 
KRT73 Isoform 1 of Keratin, type II cytoskeletal 73 IPI00174775 59 kDa 72 0 0 
NRD1 nardilysin (N-arginine dibasic convertase) isoform a IPI00243221 (+2) 139 kDa 67 0 0 
TPT1 Translationally-controlled tumor protein IPI00550900 20 kDa 65 0 0 
sp_K1M1_SHEEP IPIsp_K1M1_SHEEP 47 kDa 64 0 0 
KRT13 Isoform 1 of Keratin, type I cytoskeletal 13 IPI00009866 50 kDa 63 0 0 
BBS1;DPP3 Isoform 1 of Dipeptidyl-peptidase 3 IPI00020672 83 kDa 62 0 0 
APEH Acylamino-acid-releasing enzyme IPI00337741 81 kDa 54 0 0 
HAT1 Histone acetyltransferase type B catalytic subunit IPI00024719 50 kDa 49 0 0 
USP5 Isoform Long of Ubiquitin carboxyl-terminal hydrolase 5 IPI00024664 (+1) 96 kDa 49 0 0 
KRT71 Keratin, type II cytoskeletal 71 IPI00061200 57 kDa 48 0 0 
KRT83 Keratin type II cuticular Hb3 IPI00297795 (+2) 54 kDa 44 0 0 
CAPN2 Calpain-2 catalytic subunit precursor IPI00289758 (+1) 80 kDa 43 0 0 
TXN Thioredoxin IPI00216298 (+1) 12 kDa 42 0 0 
FDPS Farnesyl diphosphate synthase IPI00101405 48 kDa 40 0 0 
GLO1 Lactoylglutathione lyase IPI00220766 21 kDa 38 0 0 
CAPNS1 Calpain small subunit 1 IPI00025084 28 kDa 37 0 0 
CKB Creatine kinase B-type IPI00022977 43 kDa 36 0 0 
YWHAB Isoform Short of 14-3-3 protein beta/alpha IPI00759832 28 kDa 34 0 0 
















LOC389842 similar to RanBP1 IPI00399212 (+3) 23 kDa 32 0 0 
PPP2R1A Serine/threonine-protein phosphatase 2A 65 kDa regulatory 
subunit A alpha isoform IPI00554737 65 kDa 31 13 0 
RBBP7 Histone-binding protein RBBP7 IPI00395865 48 kDa 30 0 0 
SET Isoform 1 of Protein SET IPI00072377 (+4) 33 kDa 28 0 0 
NACA Nascent polypeptide-associated complex subunit alpha IPI00023748 (+2) 23 kDa 27 3 0 
IPO7 Importin-7 IPI00007402 120 kDa 26 51 0 
NUDT5 ADP-sugar pyrophosphatase IPI00296913 (+1) 24 kDa 25 0 0 
KRT27 Keratin, type I cytoskeletal 27 IPI00328103 50 kDa 25 0 0 
PBK Lymphokine-activated killer T-cell-originated protein kinase IPI00306708 36 kDa 23 0 0 
PUS7 Pseudouridylate synthase 7 homolog IPI00044761 75 kDa 23 0 0 
C6orf108 c-Myc-responsive protein Rcl IPI00007926 19 kDa 22 0 0 
LACRT Extracellular glycoprotein lacritin precursor IPI00020487 14 kDa 22 0 0 
S100A8 Protein S100-A8 IPI00007047 11 kDa 20 0 0 
GLRX3 Glutaredoxin-3 IPI00008552 37 kDa 19 0 0 
RAN GTP-binding nuclear protein Ran IPI00643041 (+1) 24 kDa 18 10 0 
SMS Isoform 1 of Spermine synthase IPI00005102 41 kDa 18 0 0 
YWHAQ 14-3-3 protein theta IPI00018146 28 kDa 18 0 0 
SSB Lupus La protein IPI00009032 47 kDa 17 0 0 
NAP1L4 Nucleosome assembly protein 1-like 4 IPI00017763 (+2) 43 kDa 17 0 0 
ASNA1 Arsenical pump-driving ATPase IPI00013466 39 kDa 16 0 0 
GSTM3 Glutathione S-transferase Mu 3 IPI00246975 27 kDa 16 0 0 
C12orf10 UPF0160 protein MYG1 IPI00029444 (+2) 42 kDa 16 0 0 
C7orf24 Uncharacterized protein C7orf24 IPI00031564 21 kDa 15 0 0 
















P4HB Protein disulfide-isomerase precursor IPI00010796 57 kDa 15 0 0 
YWHAZ 14-3-3 protein zeta/delta IPI00021263 28 kDa 14 0 0 
IGHV3OR16-13;IGHA1 IGHA1 protein IPI00061977 (+11) 54 kDa 13 0 0 
CUTA Isoform A of Protein CutA precursor IPI00034319 (+2) 21 kDa 11 0 0 
TGM2 Isoform 1 of Protein-glutamine gamma-glutamyltransferase 2 IPI00294578 (+1) 77 kDa 11 0 0 
COL1A1 Collagen alpha-1(I) chain precursor IPI00297646 139 kDa 11 0 0 
BTF3 Isoform 1 of Transcription factor BTF3 IPI00221035 (+1) 22 kDa 11 0 0 
YARS Tyrosyl-tRNA synthetase, cytoplasmic IPI00007074 59 kDa 10 23 0 
CHM Rab proteins geranylgeranyltransferase component A 1 IPI00028099 73 kDa 10 0 0 
TXNDC17 Thioredoxin domain-containing protein 17 IPI00646689 14 kDa 9 0 0 
PPM1G Protein phosphatase 1G IPI00006167 59 kDa 9 0 0 
TROVE2 Isoform Long of 60 kDa SS-A/Ro ribonucleoprotein IPI00019450 (+3) 61 kDa 9 0 0 
LCN1 Lipocalin-1 precursor IPI00009650 19 kDa 9 0 0 
LTF Growth-inhibiting protein 12 IPI00298860 (+3) 78 kDa 8 0 0 
STRAP Serine-threonine kinase receptor-associated protein IPI00294536 38 kDa 8 0 0 
HDGF Hepatoma-derived growth factor IPI00020956 27 kDa 8 0 0 
THUMPD1 THUMP domain-containing protein 1 IPI00550243 39 kDa 7 0 0 
SGTA Small glutamine-rich tetratricopeptide repeat-containing protein 
alpha IPI00013949 34 kDa 7 0 0 
TXNDC5;MUTED Thioredoxin domain-containing protein 5 precursor IPI00171438 (+1) 48 kDa 7 0 0 
DEFA1;LOC728358 Neutrophil defensin 1 precursor IPI00005721 (+1) 10 kDa 5 2 0 
BCCIP Isoform 1 of BRCA2 and CDKN1A-interacting protein IPI00002203 (+3) 36 kDa 5 0 0 
RAD23A UV excision repair protein RAD23 homolog A IPI00008219 40 kDa 4 0 0 
HDDC2 Isoform 2 of HD domain-containing protein 2 IPI00386751 (+3) 20 kDa 4 0 0 
















FTO Isoform 1 of Protein fatso IPI00028277 (+1) 58 kDa 2 0 0 
UBA1 Ubiquitin-like modifier-activating enzyme 1 IPI00645078 118 kDa 0 181 0 
CSE1L Isoform 1 of Exportin-2 IPI00022744 (+1) 110 kDa 0 171 0 
TPM3 Isoform 2 of Tropomyosin alpha-3 chain IPI00218319 29 kDa 0 167 0 
HSP90AB1 Heat shock protein beta IPI00411633 17 kDa 0 101 0 
IPO5 importin 5 IPI00793443 126 kDa 0 84 0 
TPM4 Isoform 1 of Tropomyosin alpha-4 chain IPI00010779 29 kDa 0 79 0 
CCT8 59 kDa protein IPI00302925 (+1) 59 kDa 0 70 0 
PFAS Phosphoribosylformylglycinamidine synthase IPI00004534 145 kDa 0 67 0 
TPM2 Tropomyosin 2 IPI00646748 33 kDa 0 65 0 
TNPO1 transportin 1 isoform 1 IPI00024364 (+1) 102 kDa 0 64 0 
RPSA 33 kDa protein IPI00413108 (+1) 33 kDa 0 59 0 
XPOT Exportin-T IPI00306290 110 kDa 0 50 0 
GSS Glutathione synthetase IPI00010706 52 kDa 0 48 0 
ANXA6 annexin VI isoform 2 IPI00002459 (+1) 75 kDa 0 42 0 
RNPEP Uncharacterized protein RNPEP IPI00647400 68 kDa 0 41 0 
HSP90B1 Endoplasmin precursor IPI00027230 92 kDa 0 38 0 
SERPINB6 Putative uncharacterized protein DKFZp686I04222 IPI00413451 (+1) 46 kDa 0 35 0 
SRM Spermidine synthase IPI00292020 34 kDa 0 32 0 
ANXA3 Annexin A3 IPI00024095 36 kDa 0 32 0 
MAT2A S-adenosylmethionine synthetase isoform type-2 IPI00010157 44 kDa 0 31 0 
ST13 Hsc70-interacting protein IPI00032826 (+3) 41 kDa 0 29 0 
CTPS CTP synthase 1 IPI00290142 67 kDa 0 28 0 
















ATP6V1A Vacuolar ATP synthase catalytic subunit A IPI00007682 68 kDa 0 27 0 
FKBP4 FK506-binding protein 4 IPI00219005 52 kDa 0 25 0 
PPA1 Inorganic pyrophosphatase IPI00015018 33 kDa 0 25 0 
THOP1 Thimet oligopeptidase IPI00549189 (+1) 79 kDa 0 24 0 
BAT1 Isoform 2 of Spliceosome RNA helicase BAT1 IPI00641829 (+1) 51 kDa 0 22 0 
NPEPPS Puromycin-sensitive aminopeptidase IPI00026216 103 kDa 0 21 0 
ABHD14B Isoform 1 of Abhydrolase domain-containing protein 14B IPI00063827 22 kDa 0 20 0 
GANAB Isoform 2 of Neutral alpha-glucosidase AB precursor IPI00011454 (+1) 109 kDa 0 20 0 
RPS21 40S ribosomal protein S21 IPI00017448 9 kDa 0 19 0 
IPO9 Importin-9 IPI00185146 116 kDa 0 18 0 
UAP1 Isoform AGX2 of UDP-N-acetylhexosamine pyrophosphorylase IPI00000684 (+3) 59 kDa 0 16 0 
HMGCS1 Hydroxymethylglutaryl-CoA synthase, cytoplasmic IPI00008475 57 kDa 0 16 0 
CDC37 Hsp90 co-chaperone Cdc37 IPI00013122 44 kDa 0 15 0 
HSPA5 HSPA5 protein IPI00003362 72 kDa 0 15 0 
IPO4 Isoform 1 of Importin-4 IPI00156374 (+1) 119 kDa 0 14 0 
HSPBP1 Isoform 1 of Hsp70-binding protein 1 IPI00100748 39 kDa 0 14 0 
BPNT1 Isoform 1 of 3'(2'),5'-bisphosphate nucleotidase 1 IPI00410214 33 kDa 0 13 0 
PRKCSH Glucosidase 2 subunit beta precursor IPI00026154 (+1) 59 kDa 0 13 0 
ARHGDIA Rho GDP-dissociation inhibitor 1 IPI00003815 (+3) 23 kDa 0 12 0 
S100A6 Protein S100-A6 IPI00027463 10 kDa 0 11 0 
UBA3 NEDD8-activating enzyme E1 catalytic subunit IPI00328154 52 kDa 0 11 0 
HNRNPF Heterogeneous nuclear ribonucleoprotein F IPI00003881 46 kDa 0 10 0 
TBCA Tubulin-specific chaperone A IPI00217236 (+1) 13 kDa 0 10 0 
















XRCC5 ATP-dependent DNA helicase 2 subunit 2 IPI00220834 (+1) 83 kDa 0 9 0 
ENO2 Gamma-enolase IPI00216171 47 kDa 0 8 0 
PRMT1 HMT1 hnRNP methyltransferase-like 2 isoform 1 IPI00018522 (+2) 42 kDa 0 8 0 
FAF1 Isoform Long of FAS-associated factor 1 IPI00070643 (+2) 74 kDa 0 8 0 
HK2 Hexokinase-2 IPI00102864 102 kDa 0 8 0 
APOD Apolipoprotein D precursor IPI00006662 21 kDa 0 7 0 
PFDN1 Prefoldin subunit 1 IPI00000051 14 kDa 0 7 0 
MGC3207 Isoform 1 of Translation initiation factor eIF-2B subunit 
alpha/beta/delta-like protein IPI00005948 (+1) 39 kDa 0 7 0 
GLOD4 Uncharacterized protein C17orf25 IPI00007102 (+2) 55 kDa 0 7 0 
PDXK Isoform 1 of Pyridoxal kinase IPI00013004 35 kDa 0 7 0 
RHOC Rho-related GTP-binding protein RhoC precursor IPI00027434 (+3) 22 kDa 0 6 0 
MAT2B Isoform 1 of Methionine adenosyltransferase 2 subunit beta IPI00002324 (+2) 38 kDa 0 6 0 
TBCD Isoform 4 of Tubulin-specific chaperone D IPI00030774 (+1) 139 kDa 0 6 0 
PDIA6 Isoform 2 of Protein disulfide-isomerase A6 precursor IPI00299571 (+1) 54 kDa 0 6 0 
GBE1 1,4-alpha-glucan-branching enzyme IPI00296635 80 kDa 0 5 0 
NDRG1 Protein NDRG1 IPI00022078 43 kDa 0 4 0 
USP47 Isoform 2 of Ubiquitin carboxyl-terminal hydrolase 47 IPI00165528 (+1) 147 kDa 0 3 0 
PEPD Xaa-Pro dipeptidase IPI00257882 (+2) 55 kDa 0 3 0 
HIST1H1C Histone H1.2 IPI00217465 (+2) 21 kDa 0 3 0 
NSFL1C Isoform 2 of NSFL1 cofactor p47 IPI00022830 (+3) 37 kDa 0 3 0 
UBA2 SUMO-activating enzyme subunit 2 IPI00023234 71 kDa 0 3 0 
XPO5 Isoform 1 of Exportin-5 IPI00640703 136 kDa 0 3 0 
POLR1C Isoform 1 of DNA-directed RNA polymerases I and III subunit 
















EIF2S1 Eukaryotic translation initiation factor 2 subunit 1 IPI00219678 36 kDa 0 2 0 
PPP2R2A Serine/threonine-protein phosphatase 2A 55 kDa regulatory 
subunit B alpha isoform IPI00332511 52 kDa 0 2 0 
GCLC Glutamate--cysteine ligase catalytic subunit IPI00215768 73 kDa 0 2 0 
PLS3 plastin 3 IPI00216694 71 kDa 0 2 0 
APOA1BP Isoform 1 of Apolipoprotein A-I-binding protein precursor IPI00168479 (+1) 32 kDa 0 2 0 
TNPO3 Isoform 2 of Transportin-3 IPI00395694 (+3) 104 kDa 0 2 0 
 






Visualizing the binding of target mRNA to siRNA-containing complexes and 





 In order to gain mechanistic insight into how the siRNA-containing 
complexes unwind siRNA duplexes, bind their target mRNA and cleave it, single-
molecule fluorescence microscopy was be used. Observing these processes at 
the single-molecule level will shed light on the heterogeneity associated with 
these RNAi processes and will delineate their kinetics. 
 
D.2 Materials and Method 
Nucleic acid synthesis. siRNAs were synthesized by the HHMI 
Biopolymer/Keck Foundation Biotechnology Resource Laboratory at the Yale 
University School of Medicine, having the same sequence as indicated in 
Section 4.2 with a 5’ phosphate (P) and a 3’ amino group on a C7 carbon linker. 
RNA was purified as described and the 3’ amine groups were labeled with Cy3 or 
Cy5 succinimidyl ester as described in Section 3.2. The target luciferase mRNA 
was synthesized as described in Section 4.2.  
Periodate Oxidation of the 3' Terminus of target mRNA and reaction with 
fluorophore or biotin. The reaction was performed as described in the 
Handbook of RNA Biochemistry. 20nmol of RNA  was incubated in a volume of 
400 uL containing 2.5 mM NaIO4, 100 mM NaOAc (pH 5.0) for 50 min on ice. 
The reaction was then ethanol precipitaed. For the coupling reaction with 
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fluorophore or biotin, the RNA was dissolved in 400 uL of 100 mM NaOAc (pH 
5.0) and 1 mM fluorophore or biotin mono-reactive hydrazide (10 mM stock 
solution in water) and incubated on ice overnight. The reaction was then ethanol-
precipitated and redissolved in 50 uL double distilled water and analyzed on 
denaturing polyacrylamide gel.  
Fluorophore/biotin lableling of the 5' end of target mRNA using EDC (1-
ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride). The reaction 
was performed as described by ThermoScientific. 7.5-15 nmol (~60-120 µg) RNA 
was dissolved in ~10 µl of water. Biotin or fluorophore hydrazide was dissolved to 
a final concentration of 0.25 M in 10 µl of 0.1 M imidazole. 1.25 mg (6.52 µmol) of 
EDC was weighed out and 7.5 µl of the prepared oligonucleotide was added to 
EDC. 5 µl of the hydrazide containing solution was added to it immediately and 
vortexed until contents were completely dissolved. An additional 20 µl of 0.1 M 
imidazole, pH 6, was added and the reaction was incubated overnight at room 
temperature. The non-reacted EDC was removed by purifying the sample using 
the bio-rad Micro Bio-Spin 30 Columns. The sample was eluted in 25 uL of water 
and analyzed on a denaturing polyacrylamide gel. 
Capping and Tailing of target mRNA with modified NTPs containing either 
biotin or fluorophore. The target mRNA was capped with 8[(6-Amino)Hexyl] 
Amino-GTP-Bio using the ScriptCap™ m7G capping system, from Epicentre 
Biotechnologies, as described by the manufacturers protocol. The RNA was 
purified using phenol-chloroform extraction followed by ethanol precipitation. The 
purified RNA was dissolved in water and tailed with fluorophore modified ATP 
using the Poly(A) Polymerase Tailing Kit, from Epicentre Biotechnologies, as 
described by the manufacturers protocol. The RNA was purified using phenol-
chloroform extraction followed by ethanol precipitation. The purified RNA was 
dissolved in water and analyzed on a denaturing polyacrylamide gel. 
Transcriptional priming of target mRNA with Bio- GG. The target mRNA 
sequence was designed to start with GG right after the T7 promoter sequence as 
depicted in Section 4.2. This facilitated the addition of Bio-GG at the 5'- end of 
the target mRNA transcript when the target mRNA was transcribed as described 
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in Section 4.2. Bio-GG was added to the transcription reaction in a 1:10 ratio 
with NTPs.  
Slicing assay observed using Single Molecule Total Internal Reflection 
Fluorescence Microscopy (sm-TIRFM). Single molecule experiments were 
performed on a custom-built microscope equipped for prism-type TIRF. 532 nm 
and 635 nm lasers were be used to excite Cy3 and Cy5 respectively. Appropriate 
filter sets were used to select for emission from each fluorophore. An ICCD 
camera (Princeton Instruments, I–Pentamax) was used for image acquisition at 
100 ms time resolution. First, the presence of tethered mRNA labeled with biotin 
and fluorophore was verified and then the slicing reaction containing the siRNA 
with the HeLa cell extract prepared as described in section 4.2 was flowed into 
the sample chamber and imaged. Data analysis was performed using custom-
made MATLAB routines. 
 
D.3 Results 
Target mRNAs were best labeled with fluorophores at the 3'-terminus using 
periodate oxidation and with biotin at the 5'-terminus using EDC coupling.   
Three different methods of target mRNA labeling was tested. We observed that 
the transcriptional priming of mRNA with biotin-GG yielded less than 10% 
biotinylated mRNA, and 5'- capping using modified GTP resulted in ~20% of 
biotinylated mRNA (Fig D.1).  Tailing of target mRNA with modified ATP yielded 
10-30%, however, there is limited control over the number of fluorophores being 
added to a single mRNA and hence we sought other labeling strategies as well. 
Incorporation of biotin using the EDC coupling method resulted in 30-60% 
labeling efficiency consistently (Fig D.2). The efficiency of biotinylation was 
tested by performing supershift assays with strepavidin or by estimating the bind 
efficiency of target mRNA to streptavidin coated beads. We also observed that 
periodate labeling of target mRNA with Alexa 488 hydrazide (Fig D.1) and 
Cy3/Cy5 hydrazide (Fig D.2) resulted in 10-20% labeling efficiency. We used 




Target mRNA cleavage at the single molecule level. Slicing assays performed 
at the single molecule level as shown in the schematic (Fig D.3) using mRNAs 
capped with 8[(6-Amino)Hexyl] Amino-GTP-Bio in the 5`end and Poly-A tailed 
with ATP-Cy3 at the 3`end in the presence and absence of siRNA ( cy5-guide 
strand) duplex showed target mRNA cleavage activity. However the rate of 
cleavage in the presence of specific siRNA was only ~1.5 fold faster than in the 
absence of siRNA (Fig D.4). Target mRNA cleavage assays performed with 
labeled with cy3 at the 3'-terminus using periodate oxidation and with biotin at the 
5'-terminus using EDC coupling showed ds- siRNA (unlabeled) specific cleavage 
with extent of cleavage being maximum at 30 min similar to that observed in bulk 
assays (Fig D.5). The initial lag observed during the cleavage assay at the single 
molecule level can be attributed to the time take for the reaction to equilibrate 
from 4oC to room temperature.  
 
D.4. Conclusion 
 Target mRNAs labeleling with fluorophores at the 3'-terminus using 
periodate oxidation and with biotin at the 5'-terminus using EDC coupling proved 
to be the most efficient method in our hands. We observe ds- siRNA specific 
cleavage activity at the single molecule level. Further investigation of target 


















               
Fig D. 1. Methods of labeling target mRNA with biotin and fluorophore. (A) 
Schematic of two methods used for labeling target luciferase mRNA. (B) SYBR 
gold stained non-denaturing polyacrylamide gel electrophoresis of mRNA labeled 
with BioGG in the 5'- end and supershifted in the presence of streptavidin (Left). 
Lanes: 1. mRNA plus Streptavidin, 2. mRNA-BioGG plus Streptavidin, 3. mRNA 
only control. 488 nm fluorescent scan of non-denaturing polyacrylamide gel 
electrophoresis of mRNA labeled with Bio-GG in the 5'- end and Alexa 488 at the 
3'-end (Right). Lanes: 1. Loading dye only control, 2. Alexa 488 only control, 3. 
mRNA with Alexa 488, mRNA- bio-GG- Alexa 488. (C) 532 nm (left) and 488 nm 
(SYBR Gold scan, right) fluorescent scan of denaturing polyacrylamide gel 
electrophoresis of mRNAs Poly-A tailed with ATP-Cy3. Lanes: 1. mRNA only, 2. 
mRNA – ATP, 3. mRNA – ATP cy3: ATP- 1:1, 4. mRNA – ATP cy3: ATP- 1:4, 5. 





         
 
 
Fig D. 2. Labeling target mRNA with biotin and fluorophore. (A) Schematic of labeling target luciferase mRNA. (B) 
532 nm fluorescent scan of denaturing polyacrylamide gel electrophoresis of mRNAs labeled with cy3 at the 3'-terminus 
using periodate oxidation and with biotin at the 5'-terminus using EDC coupling. The black arrow represents the supershift 






Fig D. 3. Schematic- Reaction setup for slicing assays performed at the 









Figure D.4. Target mRNA cleavage activity. (A) Representative images 
depicting the distribution of single-immobilized target mRNA molecules over the 
camera field of view at various time-points post HeLa cell extract +/- siRNA 
addition. (B) Representative intensity trajectory of an siRNA bound mRNA. The 
loss of signal from both the siRNA (Cy5/ red solid line) and mRNA (Cy3/ green 
solid line) simultaneously may depict a cleavage event. (C) Kinetics of cleavage. 
Grey dash line and squares represent fraction mRNA intact in the sample that 
was only treated with the extract. Black solid line and circles represents data 
points from the sample that was treated with both the siRNA and the extract. For 
these experiments mRNA was capped with 8[(6-Amino)Hexyl] Amino-GTP Bio in 
the 5`end and Poly-A tailed with ATP-Cy3 at the 3`end. mRNA was first 
immoblized on the PEG passivated streptavidin coated surface. Hela cell extract 





to the surface containing the immobilized mRNA. 30 continuous frames (at 10 
frames per second) were taken every 3mins. Three different areas on the slides 









Figure D.5. Target mRNA cleavage activity. (A) Representative intensity 
trajectory of mRNA cleavage using specific (SpsiRNA) and non-specific siRNA 
(NSpsiRNA). The loss of signal from mRNA (Cy3/ blue solid line) depicts a 
cleavage event. (C) Kinetics of cleavage. Orange line and round represent 
fraction mRNA intact in the sample that was treated with the extract containing 
SpsiRNA. Green line and squares represents data points from the sample that 
was treated with the NSpsiRNA and the extract. For these experiments mRNA 
was labeled with Cy3 at the 3'-terminus using periodate oxidation and with biotin 
at the 5'-terminus using EDC coupling. mRNA was first immoblized on the PEG 
passivated streptavidin coated surface. Hela cell extract was incubated with 
SpsiRNA or NSpsiRNA at 4 oC for 30 min and added to the surface containing 
the immobilized mRNA. 30 continuous frames (at 10 frames per second) were 
taken every min. The same area on the slide was imaged at every time-point.  
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